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ABSTRACT 
TOBACCO SMOKE EXPOSURES AND FERTILITY-RELATED OUTCOMES 
AMONG FEMALES SEEKING FERTILITY CARE, AND INTERACTION WITH N-
ACETYLTRANSFERASE 2 (NAT2) 
T’shura Ali 
April 16th, 2020 
Cigarette smoke contains thousands of harmful substances and is one of the 
leading preventable causes of mortality and morbidity in the United States. Past studies 
examining tobacco smoke exposures on fecundability and pregnancy outcomes are 
inconsistent. NAT2 is an important enzyme in the metabolism of xenobiotic substances 
found within tobacco smoke. This preconception cohort study examines associations 
between active smoking and secondhand smoke exposure (SHSe) on fecundability and 
spontaneous abortion (SA), and explores a possible interaction with NAT2 acetylator 
status. 
A total of 223 women seeking fertility care were followed for up to 2.3 years. 
Preconception tobacco smoke exposures were collected by questionnaires and verified by 
urinary cotinine. SHSe at home and work was measured using the questionnaire (never, 
rarely (once/week), often (1-6 times/week), daily for each location) and then combined 
and categorized as low or high SHSe. NAT2 was genotyped to determine acetylator 
status (rapid vs slow). Pregnancy outcomes (SA vs live birth) were collected on 72 
women. Cox proportional hazards regression was used to estimate fecundability ratios 
(FR) and 95% confidence intervals (CI), and logistic regression to estimate odds ratios 
(OR) and 95% CIs for the association of active smoking and SHSe on fecundability and 
vi 
SA, respectively. Full models were adjusted for age, BMI, assisted conception, gravidity, 
marital status, alcohol use and race. 
Overall, no significant effect of tobacco smoke exposure on fecundability was 
established. Though statistically insignificant, the effect of smoking on fecundability was 
stronger among slow NAT2 acetylators. Smokers (OR: 6.28; 95% CI 1.31, 37.9) and 
nonsmokers with high SHSe (OR: 3.20; 95% CI 0.87, 12.7) had increased odds of SA 
(ptrend= 0.02), compared to nonsmokers with low SHSe. Among nonsmokers, women 
with high SHSe had higher odds of SA (OR: 4.30; 95% CI 1.14, 19.1) than women to low 
SHSe. No significant interaction with NAT2 was reported. Despite wide CIs, results 
suggest that active smoking and high levels of SHSe may increase in the risk of SA 
among women seeking fertility care. This dissertation has clinical implications for patient 
care, and points to biological mechanisms by which tobacco smoke may affect fertility 
and pregnancy outcomes. 
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I. INTRODUCTION 
 Infertility is a growing health problem, in the United States (U.S.) and 
worldwide. In the last 10 years, the U.S. has experienced increases in infertility and 
impaired fecundity, along with a greater use of infertility services (1,2). Infertility is not 
just the absence of children; it is classified as a disease of the reproductive system and 
affects all aspects of health. The impact of infertility can start with undiagnosed health 
conditions and lead to severe financial, and emotional and psychological burdens (3). 
Infertility, defined as the inability to conceive after at least 12 months of trying, 
can affect both men and women (3,4). Approximately one third of all infertility cases are 
due to male factors and one third due to female factors; unexplained or “idiopathic” 
infertility, as well as both male and female factors account for the last third (5). The 
dissertation will focus primarily on female factors of infertility. There are several 
etiologies/factors of female infertility and which are grouped into ovarian, tubal, uterine, 
cervical and other factors such as autoimmune disorders (6). 
Infertility treatment depends on the type of infertility diagnosis. Treatments can 
range from education on changing lifestyle behaviors, to ovarian induction medications, 
to assisted reproductive therapies (ART). Medically assisted reproduction (MAR) is the 
term used for all therapies including ovulation induction (OI), intrauterine insemination 
(IUI), and ART, which in itself includes in vitro fertilization (IVF) with or without         
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intracytoplasmic sperm injection (ICSI).  In the U.S., approximately 1.7% of all infants 
born in 2017 were conceived through ART services (7). While infertility and the use of 
MAR services are increasing, the risk of adverse pregnancy outcomes has been shown to 
be higher among assisted compared to natural conceptions. Several studies have found 
significantly higher rates of spontaneous abortion (SA) among ART-assisted conceptions, 
compared to the general population (8). 
There are also several important risk factors that have been associated with 
infertility and/or SA. These include older age, genetic factors, menstrual cycle 
irregularities, sexually transmitted infections, extreme (very high and very low) levels  of 
stress, extreme levels of body mass index (BMI), extreme levels of exercise, diet, heavy 
caffeine use, heavy alcohol consumption and tobacco smoke exposure (9). Prior 
pregnancy loss and certain medication use are included with the previous list as risk 
factors for SA (10). 
Tobacco smoke exposure is one of the leading preventable causes of mortality and 
morbidity in the U.S. and has been found to be associated with longer time to conception, 
lower conception rates, and adverse pregnancy outcomes such as SA (11). While the U.S. 
Surgeon General report supported the association of active, current smoking on 
conception, it stated that there was less evidence of an association among women using 
MAR. The report also stated that there was suggestive but insufficient evidence to infer 
an association between current smoking and SA (12). In addition, studies examining the 
effect of secondhand smoke exposures on fertility and fertility-related outcomes are 
inconclusive and inconsistent. Many studies are subject to bias because of their 
retrospective design and reliance on self-reported information about smoking. In addition, 
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the majority of studies did not take all potential confounding factors into account. Finally, 
almost no studies explored possible gene-environmental interactions. 
N-acetyltransferase 2 is an enzyme used in the metabolism and detoxification of 
xenobiotic substances, including therapeutic drugs and exogenous chemicals such as the 
ones found in tobacco smoke (13). Genetic variation in the NAT2 gene results in 
different levels of acetylation, commonly grouped into rapid and slow acetylation 
phenotypes. NAT2 acetylator status may modify the metabolism of environmental toxins 
and therapeutic medicines. NAT2 acetylator status has also been associated with 
differences in cancer risk and may modify the effect of smoking on some cancers (14). 
Few studies have explored how NAT2 can modify the association of smoking and 
fertility. To date, only one study has found a significant interaction between NAT2 and 
smoking on female fertility (15), while two studies on idiopathic male infertility showed 
contradictory results (16,17). These studies have emphasized the importance of further 
exploring gene-environmental interactions on fertility outcomes. 
This dissertation explores the effects of active and secondhand tobacco smoke 
exposures on fertility-related outcomes and examines the interaction of NAT2 with 
tobacco smoke exposure among women seeking fertility counselling and treatment. 
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II. OBJECTIVE, SPECIFIC AIMS AND HYPOTHESES
The primary objective of the study was to assess the effect of active smoking (current 
and lifetime), secondhand smoke exposure (recent and in the past year) and the combined 
effect of both exposures on fecundability and probability of spontaneous abortion. Effect 
modification by NAT2 acetylator status on conception and spontaneous abortion was also 
examined. The potential for selection bias due to loss to follow-up was investigated. 
Analyses were done using (1) all women and their follow-up time, whether or not they 
used medically assisted reproduction (MAR); (2) MAR treatment cycles only; and (3) all 
other follow-up time, which is termed natural conception (NC) follow-up time, for the 
purposes of this dissertation. The populations are not mutually exclusive. 
The specific aims of the study are as follows: 
Specific Aim 1: Examine the association between tobacco smoke exposures (active and 
passive) and fecundability after fertility counselling among three populations: all follow-
up time; medically assisted reproduction (MAR) cycles; and natural conception (NC) 
follow-up time. 
a. Examine the effect of active smoking (current and lifetime) on
fecundability for all populations. Hypothesis: Active smoking (current and 
lifetime) is associated with reduced fecundability. 
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b. Examine the effect of secondhand smoke exposure (recent and in the
past year) on fecundability for all populations. Hypothesis: Secondhand 
smoke exposure (recent and past year) is associated with reduced 
fecundability. 
c. Examine the combined effect of active smoking with secondhand
smoke exposure on fecundability for all populations. Hypothesis: There is 
a dose-response relationship, in that smokers will have the lowest 
fecundability, and non-smokers with high SHS exposure will have reduced 
fecundability when compared with  non-smokers with low SHS exposure. 
d. Examine the interaction of active smoking with NAT2 acetylator status
for the measures estimated in aims 1a above. Hypothesis: There is a 
synergistic effect between active smoking and slow acetylation status, such 
that active smokers who are also slow acetylators will have markedly 
reduced fecundability. 
Specific Aim 2: Examine the association between tobacco smoke exposures (active and 
passive) and pregnancy outcomes among individuals who conceived, after fertility 
counseling. 
a. Examine the effect of active smoking (current and lifetime) on pregnancy
outcomes (spontaneous abortion vs live birth) among all conceptions. 
Hypothesis: Active smoking is associated with higher probability of 
spontaneous abortion. 
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b. Examine the effect of secondhand smoke exposure (recent and in the
past year) on pregnancy outcomes (spontaneous abortion vs live birth) 
among all conceptions. Hypothesis: Higher exposure to secondhand 
smoke exposure (recent and in the past year) is associated with a higher 
probability of spontaneous abortion. 
c. Examine the combined effect of active smoking with secondhand
smoke exposure on pregnancy outcomes (miscarriage vs live birth) after 
fertility counseling. Hypothesis: There is a dose-response relationship, in 
that smokers will have the highest probability of spontaneous abortion; 
non-smokers with high SHS exposure will have intermediate probability; 
and non-smokers with low SHS exposure will have the lowest probability 
of spontaneous abortion. 
d. Examine the interaction of active smoking with NAT2 acetylator status
for the measures estimated in aims 2a and 2b, above. Hypothesis: Active 
smokers who are also slow acetylators will have a markedly increased 
probability of spontaneous abortion (higher than expected when 
examining each risk factor alone). 
Specific Aim 3:   Evaluate the potential for selection bias due to loss to follow-up in the 
LOUSSI Study. 
a. Evaluate the potential for selection bias due to loss to follow-up by
comparing characteristics of participants lost to follow-up to participants 
7 
with complete follow-up. Hypothesis: Characteristics of those lost to 
follow-up are similar to those with complete follow-up. 
b. If there is evidence for selection bias due to loss to follow-up, apply
inverse probability weighting to adjust for selection bias. Hypothesis: 
If there is no selection bias due to loss to follow-up, there will be no 
differences in the odds/hazard ratio estimates when compared to the initial 
analysis. 
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III. BACKGROUND AND LITERATURE REVIEW
SECTION A - Infertility 
The World Health Organization’s International Committee for Monitoring 
Assisted Reproductive Technologies (WHO-ICMART), along with the Center for 
Disease Control and Prevention (CDC) describes infertility as a disease of the 
reproductive system defined by the inability to attain a clinical pregnancy after 12 months 
of regular, unprotected sexual intercourse or due to an impairment of a person's capacity 
to reproduce either as an individual or with his/her partner (3,4). Other fertility-related 
terms include subfertility, sterility, fecundity, impaired fecundity and fecundability. Most 
are used interchangeably, hence the need for more formal and universal definitions to 
accurately compare studies. 
In 2017, WHO-ICMART revised and expanded their 2009 edition of the 
International Glossary on Infertility and Fertility Care, from 87 to 283 terminologies (4). 
They define fertility as the capacity to establish a clinical pregnancy, sterility as a 
permanent state of infertility and state that subfertility should be used interchangeably 
with infertility. However, one article defined subfertility as any form of reduced fertility 
in couples unsuccessfully trying to get pregnant, not specifying a time period (18). 
Fecundity, on the other hand, is not just the capacity to conceive, but to also carry the 
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pregnancy to term, which is also known as the reproductive potential (19). The CDC 
states that infertility is specific only to married couples and deals only with issues getting 
pregnant; whereas impaired fecundity refers generally to all women regardless of marital 
or relationship status, and deals with problems with getting pregnant and carrying a baby 
to term (19). Time to pregnancy or conception (TTC) is the number of months or 
menstrual cycles taken to establish a pregnancy and fecundability is the probability of 
conception per month or menstrual cycle (4). 
Infertility is commonly classified into two main groups: primary infertility and 
secondary infertility, which can then be sub-divided by gender. Firstly, primary infertility 
for females is diagnosed if there has not been a clinical pregnancy and the infertility 
criteria is met. For males, primary infertility is defined when there was never initiation of 
a clinical pregnancy and by the infertility criteria (3). Female secondary infertility is 
defined by the inability to establish a clinical pregnancy following a previous pregnancy 
and similarly, male secondary infertility is the inability to initiate a clinical pregnancy 
after successfully initiating one before (4). 
The highest probability of conception among the general population occurs 2 days 
before ovulation of the first cycle of intercourse without contraception use and is 
approximately 30% (20). This probability decreases slightly over time/cycles; one article 
showed that the cumulative probability of conceiving within the first three cycles of 
unprotected intercourse is around 30%, then 75% within six cycles and almost 90% 
within 12 months (20). Highly fertile couples will conceive in the first cycles of attempt 
and others will still naturally conceive even after 12 months (20).  
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Epidemiology 
Infertility is known to be a global public health issue; however, global prevalence 
rates are very difficult and tedious to calculate due to the inconsistency within the 
literature. Studies use different definitions, for example the length of time actively trying 
to conceive using either 12 months, 24 months or 5 years. Also, the population included 
in the definition varies from including females, couples, individuals or married women. 
The lack of population-based studies and differences in definition and methodologies 
adds to the difficulty in estimating and comparing global infertility rates (21). However, 
in 2010 the WHO published a study on global infertility trends using 277 surveys from 
190 different countries. 
The prevalence of primary infertility among women aged 20 to 44 years was 
calculated at 1.9%; and secondary infertility, which was defined inability to have a 
second live birth, was calculated at 10.5% (22). They defined infertility as the inability to 
have a live birth over a 5-year period and was based on marriage/union status, desire for 
child and no contraception use. Worldwide, a small decrease from 1990 to 2010 in 
primary infertility (1.6% to 1.5%) and in secondary infertility (3.9% to 3.0%) was 
reported. The absolute number of couples impacted by infertility, though has increased 
from 42 million in 1990, to 48.5 million in 2010 due to accelerated population growth 
(22). The WHO stated that there was a significant increase to 121 million when the 
infertility time period was cut down to 2 years instead of 5. The overall global prevalence 
of infertility was calculated to range from 8% to 12% of couples (22). It was also noted 
that developing regions and countries such as sub-Saharan Africa, the Middle East, North 
Africa, South Asia, Central and South Asia, and Eastern Europe experienced 
11 
disproportionately higher infertility rates up to 30% (21). This may be due to higher 
secondary infertility rates which can result from infections from unsafe abortions and 
poor post-partum or maternity care (21). The global infertility prevalence from this study 
and other studies that definition of infertility only include married women are highly 
underestimated. 
Recently in December 2019, authors published estimates of the global burden of 
infertility, using results from a 2017 global burden of disease study among 195 countries. 
They found that worldwide, there had been a 0.37% increase annually in age-
standardized infertility prevalence rates for females and a slightly lower increase, 0.29% 
for males (23). These increases were maintained over all sociodemographic index 
countries. 
In the U.S., the National Center for Health Statistics used data from National 
Survey of Family Growth (NSFG) and showed that percentages of married women aged 
15 to 44 years with infertility were 7.4%, 6.0%, 6.7% and 8.8 % in 2002, 2006-2010, 
2011-2015 and 2015-2017, respectively (1,2). This increasing trend was retained after 
women were categorized into four age groups (15-29, 30-34, 35-39, 40-44) (1,2). A 
similar trend for impaired fecundity, which takes into account all women into account 
regardless of their marital status showed 11.8%, 10.9%, 12.1% and 13.1 % in 2002, 
2006-2010, 2011-2015 and 2015-2017, respectively (1,2). A similar increasing trend was 
shown with age. In 2013, one study estimated the prevalence of couple infertility from a 
male’s perspective using the 2002 NSFG data. Males estimated the prevalence of 
couple’s infertility at 12.0% (95% CI: 7.0, 23.2), which was found to be consistent with 
female reporting in prospective cohort studies (24). 
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Women and men can both endure emotional and psychological stress such as 
depression, discrimination and ostracism when dealing with infertility (21,22). The 
impact of infertility is all encompassing, ranging from the unexpected medical diagnoses 
to the financial burden of medical services and health disparities to access of care. 
Infertility has also been shown to be associated with adverse pregnancy outcomes, which 
can consequently affect the onset of adult diseases later in life and quality of life for the 
individuals (3).   
 
Causes, Risk Factors and Biological Mechanisms 
There are a number of well-defined risk factors that have been studied and found 
to increase the odds of being infertile among women (9). These factors can be non-
modifiable such as age (25–27), irregular menstrual cycles (28–31), and some genetic 
factors (32–34). Then there are several modifiable lifestyle factors that can affect fertility 
including diet (35–37), caffeine (38–40), alcohol consumption (29–31), body mass index 
(41–43), exercise (41,43,44), sexually transmitted infections (45,46), and stress and 
psychological state (47,48). Some of these important risk factors and causes, along with 
their biological mechanisms are outlined below. Tobacco smoke specifically, and its 
possible biological mechanisms on fertility are presented in the next section.  
Conception is a result of a multistep process that has to meet every criteria to be 
successful. Firstly, a woman must ovulate which means an egg is released from one of 
her ovaries and travels along the fallopian tube to the site of fertilization. A man’s sperm 
must also travel up the uterus to fertilize the egg. After successful fertilization, the 
fertilized egg known as the zygote then travels down the fallopian tube to the uterus. The 
13 
zygote will proliferate into an embryo, which develops into a blastocyte and will then 
implant itself into the uterus lining. Disruptions at any stage can lead to infertility issues 
(5). 
Among all infertility cases, female factors account for approximately 35% and 
male factors account for 35% (5,49). The majority of the remaining 30% of cases do not 
meet the criteria for any known causes of infertility and are diagnosed with unexplained 
infertility (5). Female infertility has several etiologies that can be grouped into categories: 
ovulation dysfunction, tubal obstruction, uterine abnormalities, cervical factors and other 
factors such as autoimmune disorders and genetic factors (6). The different 
categorizations of etiologies also help to differentiate the specific type of infertility 
diagnosis. 
Ovulatory Dysfunction 
Ovulatory dysfunction is one of the common causes of female infertility, 
accounting for over 30% of cases (49). It can manifest in a variety of forms including 
anovulation (absence of ovulation), oligoovulation (irregular ovulation), ovarian aging 
and diminished ovarian reserve (DOR) (5). Ovarian reserve is the quantity and quality of 
the oocytes within the ovaries and is highly correlated to reproductive potential (5). The 
main causes of DOR are aging, obesity, cigarette smoking, genetic abnormalities (Fragile 
X and other X chromosome abnormalities), aggressive treatments (radiation) and ovarian 
surgery (for endometriosis). Other causes of DOR are unknown and are termed idiopathic 
(50). Some women with low ovarian reserve may respond to ovarian stimulation with a 
poor follicular development and may need more aggressive management; however, some 
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women with higher ovarian reserve may experience ovarian hyperstimulation syndrome 
(OHSS) that can also lead to adverse fertility outcomes (5,50). One retrospective cohort 
study in 2015 showed a significant increase in DOR from 19% in 2004 to 26% in 2011 
(51). However, few studies have reported that DOR is not an accurate predictor of poor 
ovarian response (51). 
Ovarian aging is a term used to describe the natural decline in the quantity and 
quality of eggs due to normal aging (5,49). The biological mechanisms behind ovarian 
aging are not fully understood, however, it is established that as the follicle pool 
diminishes with age, the odds of chromosomal abnormalities increases (49). While 
ovarian aging is a natural process, DOR can also affect younger women. Ovarian aging 
and DOR are quantified through Antral Follicle Count (AFC) and different reproductive 
hormones such as Follicle-Stimulating Hormone (FSH), Antimüllerian Hormone (AMH), 
luteinizing hormone (LH) and estradiol (49). One prospective fecundability study showed 
the percentage of infertility increased with woman’s age: 8% among 19 through 26-year-
olds, 13%-14% for 27 through 34-year-olds and 18% among 35 through 39-year-olds 
(26). Lower fecundability rates have also been seen among aging follicles with linear 
decline in fecundability and increasing female age (27). Primary Ovary Insufficiency 
(POI) is another disorder, where the ovaries stop producing hormones and releasing eggs, 
and experience either anovulation or oligoovulation (52). It is a common condition that 
increases with age and can induce premature or early menopause (53). One study showed 
a 10-fold increase every decade for the prevalence of POI, from 0.01% among women 
younger than 20 years to 0.1% in women under 30 years of age and 1% among women 
younger than 40 years (54). 
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Amenorrhea (absence of bleeding) and oligomenorrhea (irregular or extended 
menstrual cycle bleeding) are also related factors in anovulation infertility (49). The 
menstrual cycle includes several stages that prepare the body for conception. 
Irregularities or disruption at any stage can lead to infertility. Two recent studies have 
shown that any deviation from normal or the average menstrual cycle characteristics such 
as longer or shorter menstrual cycle lengths, later or earlier onset of menarche and shorter 
or longer bleeding duration have been associated with reduced fecundability (30,31). 
Other diseases associated with anovulation include thyroid disease, and 
hypothalamic and pituitary dysfunction which controls the production of hormones 
(5,49). Functional hypothalamic amenorrhea (FHA) is one the most common causes of 
secondary amenorrhea and is associated with chronic stress and psychiatric disorders like 
depression (55). Studies done both in the general and infertile population have shown that 
psychological distress including chronic stress have been shown to increase odds of 
DOR, affect menstrual cycle characteristics, lower conception rates and increase adverse 
pregnancy outcomes (47,48,56). 
Polycystic Ovary Syndrome 
Polycystic ovary syndrome (PCOS) is the most common cause of anovulation and 
affect 6 to 12% (~ 5 million) of reproductive aged women in the U.S. (57). Among 
anovulatory infertility, PCOS accounts for 80% to 90% of cases (58). It is characterized 
by oligomenorrhea, obesity, insulin-resistance and an overproduction of androgen, which 
increases LH and lowers FSH. Hormonal imbalances have been shown to obstruct the 
development and maturation of follicles and ovulation, leading to issues with fertility and 
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fertility treatments (5). PCOS can also arise from endocrine, genetic, lifestyle and 
environmental factors. 
 Anovulation infertility is commonly found in both overweight (BMI ≥ 30 kg/m2) 
and severely underweight women (BMI < 17 kg/m2) (49). One case-control study 
compared cases of anovulatory infertility to fertile controls and found that overweight 
women had 3.1 times the odds of anovulatory infertility, and severely underweight 
women also had increased odds compared to women with a normal BMI (59). Proper 
diet, healthy exercise and weight loss management have been shown in studies to help 
treat PCOS, increase fecundability and increase odds of natural conception by facilitating 
spontaneous ovulation (49). However, a bad “fertility” diet from one study included 
higher intake of trans fats and animal protein, lower intake of high-fiber, plant-based iron 
and multivitamin use showed to increase the risk of anovulatory infertility (35,36). While 
vigorous exercise can improve fertility among overweight and obese women, women 
with normal BMI that exercise vigorously everyday including cycling, running and 
swimming have increased odds of anovulatory infertility (43,60). Though the research 
examining infertility and alcohol consumption is inconsistent and needs to be further 
elucidated, heavy alcohol use has been shown to increase estrogen levels through a 
decrease in FSH secretion which can then lead to ovulatory dysfunction (9,61). 
Caffeine’s association with infertility is also not well-defined, with some studies showing 
an increased risk for higher levels of consumption and others showing no association. 
The biological mechanisms are unclear; however, some studies theorized that caffeine 
may affect ovulation through disruptions in glucose metabolism and insulin production 
(9,62,63). 
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Structural Dysfunction 
Structural or anatomical dysfunction within the fallopian tubes, uterus and cervix 
can all obstruct the sperm from joining the egg, block transport of zygote to uterus and 
impair implantation of embryo into the endometrium. Tubal factor infertility accounts for 
the majority of the structural abnormalities, affecting approximately 30% of female 
infertility cases (5,49). Some of the main causes of tubal disease include sexually 
transmitted diseases (STD) such as untreated gonorrhea and chlamydia; which can lead to 
pelvic inflammatory disease (PID), prior tubal or pelvic surgery, septic abortion and 
appendicitis (5,49). One large study showed that women with tubal factor infertility had 
higher odds of chlamydia trachomatis antibodies compared to infertile women who did 
not have tubal blockage (46). Another study showed that a recurrent PID infection was 
significantly associated with twice the odds of tubal infertility (45). In most developed 
countries such as North America and Europe, infections affecting tubal infertility mostly 
include chlamydia and PID, however, in developing countries like India and Nepal, 
tuberculosis is the more common source of infection. Previous history of a ruptured 
appendix was also significantly associated with tubal factor infertility, but not 
appendicitis (64). 
Congenital malformations, cervical trauma, chronic infections of the cervix and 
surgical treatments such as loop electrosurgical excision (LEEP) procedure used for 
human papillomavirus (HPV) associated cervical lesions can lead to cervical factor 
infertility (5,65). Most of these factors impair fertility by affecting the quality and 
quantity of cervical mucus (65). The cervical mucus helps to protect the sperm within the 
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acidic environment of the vagina and improve motility to cervix (5). One meta-analysis 
reviewed six clinical studies and found a significant association between high risk-HPV 
infection and female infertility (66). 
Uterine Abnormalities 
Uterine factor infertility is the term used for abnormalities of the uterus that can 
lead to infertility. It includes uterine fibroids, uterine polyps, uterine scarring or 
adhesions and endometriosis (5,49). Uterine polyps are formed within the endometrial 
lining and can impair the function of the uterus. They typically are noncancerous and can 
regress over time. Fibroids, on the other hand, are made up of thick muscle tissue and are 
more common, occurring in up to 60% of women. Higher rates of uterine fibroids are 
found among older women and women of African American race (43). While most 
women with fibroids can get pregnant, uterine fibroids contribute to 5 to 10% of all 
female infertility cases (5). They can be found at various locations: within the uterus, 
endometrium and around the cervix (67). The fibroids that grow within the uterine cavity 
have the most potential to cause infertility by either obstructing the fallopian tubes, 
impairing blood supply, altering the shape of the uterus or altering position of the cervix 
(5,67,68). Pelvic adhesions also known as scarring are bands of fibrous (scar) tissue that 
form within the uterus from a previous surgery, an injury or an infection (5). They can 
physically block sperm from traveling to fertilize an egg, as well as, impair blood supply 
to the uterus consequently affecting implantation (5,67). 
Endometriosis is a disease characterized by the growth of uterine tissue outside 
the uterus. Approximately 10 to 15% of reproductive women are diagnosed with 
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endometriosis, however, the prevalence rates among infertile women are much higher 
ranging from 25% to 50% (5,69). The biological mechanisms behind this association are 
still unknown and controversial but there are proposed theories. They include infertility 
through pelvic adhesions or scarring which can impair egg release, excessive fluid within 
the peritoneum which can disrupt the functions of the sperm, eggs and tubes, and lastly, 
chemical changes within the endometriosis which can lead to implantation failure (5,69). 
Treatment Options 
Evaluation of female infertility starts with extensive medical and reproductive 
history and physical examination, along with vital laboratory and imaging tests (6). 
Treatment options depend on the evaluation and the type of infertility diagnosed. 
Treating the underlying cause of infertility is the first step. This can be as simple as 
lifestyle changes such as stopping tobacco use, maintaining a healthy BMI and proper 
diet, reducing stress, caffeine and alcohol intake and increasing frequency and proper 
timing of intercourse (5,6). Women with anovulatory infertility can use medications to 
stimulate ovulation known as ovulation induction (OI). Medications include letrozole, 
clomiphene or clomiphene citrate, human chorionic gonatropin (hCG) and gonadotropins 
such as FSH (5,6,49). Infertile women with thyroid disease can also take medications to 
regulate their hormones and increases chances of conception. Surgery is more effective 
for tubal and uterine factor infertility. Blockages can be removed from fallopian tubes 
and tubes can be repaired, however, there is a low success rate and high risk of ectopic 
pregnancies (5). Uterine scarring from endometriosis, polyps and fibroids can also be 
surgically removed to increase the odds of pregnancy. 
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Intrauterine insemination (IUI) is a technique involving the preparation of a 
semen specimen which is then inserted into the uterus via a catheter (4,5). It is commonly 
used among uterine, cervical or male factor infertility. IUIs can also be used in 
combination with OI to increase the odds of conception (5,65). The next line of treatment 
is ART which per the 2017 International Glossary of Infertility and Fertility Care, does 
not include OIs and IUIs that involves the handling of only one gamete (4). The glossary 
uses the term MAR to define any and all technologies to treat different types of infertility 
diagnoses, including OIs IUI and ART (4). If ART using one’s own eggs or a partner’s 
sperm is unsuccessful, couples can use donors, as well as embryo donors, surrogates and 
gestational carriers (70). 
 
Assisted Reproductive Technology (ART) 
Assisted Reproductive Technology is a medical treatment for infertility that 
handles both sperm and egg for conception and do not include treatments such as IUI or 
OI (4). ART include but are not limited to include in-vitro fertilization (IVF), IVF with 
embryo transfer and IVF with intracytoplasmic sperm injection (IVF-ICSI) (7,71). IVF is 
the main form of ART and involves retrieving a woman’s eggs usually after OI, 
fertilizing the eggs with a semen specimen in a laboratory, then implanting the most 
optimal embryo(s) into the woman’s uterus or a gestational carrier (71). For couples with 
a diagnosis of male factor infertility, ICSI is incorporated and involves a single sperm 
being injected into the egg for fertilization (72). In the U.S. approximately 60% of IVF 
procedures use ICSI (72).  
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ART success rates can depend on patients’ characteristics such age, infertility 
diagnosis, parity/gravidity, previous miscarriages, lifestyle choices and others factors (7). 
These include the number and quality of embryos transferred, the type and numbers of 
ART cycles and use of ICSI also affect success rates. There are different ways to measure 
ART success rates. The most commonly used rate reported is the percentage of IVF 
cycles or embryo transfers that resulted in a live birth (7). IVF success rate can also be 
measured as the percentages of IVF cycles or embryo transfers that resulted in a 
pregnancy (72). 
Epidemiology of MAR 
One global report done by the ICMART used a retrospective cross-sectional study 
to investigate trends over time during 2011. The study involved both women and men 
undergoing ART from 65 different countries, which is around two thirds of global ART 
activity (73). Data was imputed for clinics that did not report ART information. There 
was a reported total of 1,643,912 cycles that resulted in more than 394,662 live born 
infants (73). There was also an increase in the proportion of women aged 40 years and 
older undergoing ART from 23.2% in 2010 to 24.0% in 2011 and a slight drop in ICSI 
percentages from 67.4% in 2010 to 66.5% in 2011 (73). From 2010 to 2011, results also 
showed an increase in cumulative delivery rates per cycle, a decrease in perinatal 
mortality rate after fresh IVF/ISCI cycle and even lower drop among perinatal mortality 
rates after frozen ET (FET) (73). 
In the U.S. the CDC released the 2017 Fertility Clinic Success Rates Report and 
estimated that there were 284,385 ART cycles which had increased from 231,936 in 
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2015. This resulted in 68,908 live births in 2017, an increase from 60,778 live births in 
2015 (7). In the U.S., 1.7% of all infants born in 2017 were conceived through ART 
services (7). One article published estimates of trends for infertility services, using the 
NSFG data from 1982 to 2010. They found 12% (7.3 million) of 15 to 44-year-old 
women reported ever using infertility services from 2006 through 2010 (74). They also 
found that women who ever used infertility services were older, nulliparous, of non-
Hispanic white race, had infertility issues, and were more likely to have higher income 
and education (74). Additionally, a recent survey in 2019 using NSFG data, showed an 
increase in ever use of infertility services with 12.7% for 15 to 49-year-old women (24). 
SECTION B - Adverse Pregnancy Outcomes 
Early pregnancy loss (EPL) of an intrauterine pregnancy prior to 20 weeks’ 
gestation, without the use of elective medical or surgical means to terminate the 
pregnancy is known as a spontaneous abortion (SA) or miscarriage (10,75). However, the 
2017 International Glossary of Infertility and Fertility Care uses 22 weeks of gestational 
age to define SA (4). Previous nomenclature also included blighted ovum and missed 
abortion. Spontaneous abortions can be subdivided into several categories such as 
incomplete abortion, complete abortion, threatened abortion, inevitable abortion, missed 
abortion, septic abortion and recurrent spontaneous abortion (10). These inconsistencies 
in the definition and length of gestation make it difficult to compare studies. Early 
pregnancy loss is a public health burden in that it can be a traumatic experience for many 
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and is shown to have adverse physical and mental effects including anxiety, depression 
and grief (10). 
Epidemiology of Early Pregnancy Loss 
The incidence of EPL is difficult to calculate as many go unrecognized. Most 
women are unaware of the onset of pregnancy and may misinterpret a SA for a late or 
heavy menstrual cycle (10,75). Early pregnancy losses can occur either between post-
implantation and pre-clinical detection or post medical recognition (75). After four to six 
weeks of gestational age, the rate of EPL ranges from 10% to 15% and decreases as 
gestational age increases (76). An early study found that approximately 20% of all 
clinically detected pregnancies resulted in an early loss (77). However, that number 
increased to 31%, when women with a biomarker measurement (e.g. hCG) were followed 
up (77). A recent study in the U.S. analyzed trends in the risk of EPL and found a rate of 
13.5% during 1990 through 2000, with a 1% increase per year adjusted for maternal and 
pregnancy factors (78). Spontaneous abortion rates among ART-assisted conceptions 
were significantly higher with rates ranging from 8% to 30% compared to the general 
population (8). One retrospective cohort study found a significant 20% increased risk of 
SA among ART-assisted pregnancies compared to natural conceptions (8). However, 
these number may be biased in that ART procedures allow for earlier and more effective 
detection of losses, as well as the characteristics of infertile women may also predispose 
their risk. 
Predictors of Spontaneous Abortion 
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There are many common risk factors that can predispose women to have an 
increased risk of SA including maternal age, prior pregnancy loss, certain medical 
conditions, substance and specific medication use, some lifestyle factors and 
environmental exposures (10,79). Etiologies of SAs can be grouped into endocrine 
dysfunction, immunological causes, infectious diseases, abnormalities in implantation, 
structural dysfunction of the uterus and most commonly, genetic factors (75,79). The 
causes and risk factors are discussed below, along with their biological mechanisms. 
Up to 90% of EPLs are caused by both numerical and structural chromosomal 
abnormalities (10). Aneuploidies are numerical chromosomal mutations that result in less 
or more than the usual number of chromosomes such as in Turner’s syndrome. 
Polyploidy, on the other hand, is defined as having an extra complete set of chromosomes 
(10,79). The risk of aneuploidies increases with advancing age, along with the risk of SA. 
One study showed that the risk of EPL varied based on maternal age, for women under 
25 years the risk of EPL was around 8.9%, and up to almost 75% among women older 
than 45 years of age (80). Another more recent study done in Norway, also showed that 
the risk was lowest for women under 25 years but gradually started increasing after the 
age of 30, with 53% risk of SA among women older than 45 years (81). 
A prior miscarriage is an important risk factor for subsequent losses, after 
controlling for maternal age (10). The previously mentioned study also examined the risk 
of SA recurrence and found that after adjusting for age, the odds of having another SA 
was 60% higher after one prior SA, more than twice the odds after 2 previous SAs and 
almost four times the odds after 3 prior SAs (81). Medical conditions specifically viral 
and bacterial infections account for over 15% of all cases and include cytomegalovirus 
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(CMV), human parvovirus B19, herpes simplex virus, varicella zoster virus and many 
other infections (10,79). One study showed that the odds of the presence of CMV 
antibodies were 2.5 times higher among SA compared to normal live births (82). Other 
maternal diseases such as thyroid dysfunction, PCOS, endometriosis, diabetes, celiac 
disease and other autoimmune diseases have also been associated with SA (75,79,83). 
Characteristics of PCOS such as obesity, high levels of LH and insulin resistance have 
also shown to increase the risk of SA, independent of PCOS (75,83). 
One way that immunological factors can cause miscarriage involves the foreign 
paternal genes inherited within the zygote (75,79). Certain immunological characteristics 
of the maternal environmental helps to prevent attack or rejection of the inherited 
paternal genes, thus promoting successful fertilization, implantation and development 
(75,83). Lack of expression of antiphospholipid antibodies (APA), human leukocyte 
antigens (HLA), antisperm antibodies (ASA), leukemia inhibitory factor (LIF), integrins, 
endometrial adhesion factors, cytokines and uterine natural killer cells have all been 
associated with both infertility and SA (79). 
Uterine abnormalities are not as common but include uterine or pelvic adhesions, 
uterine polyps and uterine fibroids (10). Congenital uterine malformations, such as a 
septate uterus, have shown to significantly increase the risk of first trimester miscarriage 
by almost 3-fold (84). Certain medications such as misoprostol (Cytotec), retinoids, 
methotrexate and nonsteroidal anti-inflammatory drugs including ibuprofen have also 
been found to increase EPL risk (10). The severity of the risk depends on the drug, the 
exposure window and the dose or concentration. Environmental exposures such as 
arsenic, lead, carbon disulfide, heavy metals and organic solvents may also increase the 
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risk of EPL through apoptosis, impairment of tissue development, or disruptions within 
cell division and other processes (75,79). Lastly, lifestyle factors that may increase the 
risk of EPLs include moderate alcohol consumption, heavy caffeine use, substance abuse 
with methamphetamines, marijuana and cocaine and cigarette smoking, through a dose-
response effect (10,75). 
SECTION C - Smoking and Secondhand Smoke Exposure 
The WHO reported in May 2017 that over 6 million people die yearly as a direct 
result of tobacco use and over 890,000 people solely from exposure to secondhand smoke 
(85). Secondhand tobacco smoke (SHS) also known as environmental tobacco smoke 
(ETS) is a combination of the smoke produced from the burning of tobacco products such 
as cigarettes, cigars, pipes or bidis and the smoke exhaled by the person smoking a 
tobacco product (85). There is no safe level of SHS exposure and almost everyone is at 
risk (85). Globally the prevalence of smoking and  is decreasing; however, the absolute 
number of smokers remains significantly high due to accelerated population growth and 
an increase in the amount and variety of tobacco products on the market (85). 
Epidemiology of Tobacco Use 
In 2012, a worldwide study reported that approximately 1 billion men and 250 
million women smoked every day, and the prevalence of smoking among women alone 
was estimated to increase from 12% in 2010 to 20% in 2025 (86). The CDC reported in 
2018 that the prevalence of current cigarette smoking among adults aged 18 years and 
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older in the U.S. is 13.7%, equivalent to 34.2 million adults (87). In the same year, the 
U.S. reported that 12% of adult females in the U.S. were current smokers (87). A study 
using the Pregnancy Risk Assessment and Monitoring Survey (PRAMS) data from 27 
different sites estimated the prevalence of smoking before pregnancy in 2010. They 
showed approximately 23% of women reported smoking 3 months before pregnancy, 
with trends from 2000 through 2010 unchanged for 20% of the women (88). Another 
study examined the prevalence of self-reported smoking along with intensity of smoking 
three months before pregnancy in 2016. They found that the overall rate of low-intensity 
smoking (< 10 cigs/day) was 9.4% and 6.3% for high-intensity smoking (≥ 10 cigs/day) 
(89). 
While there have been significant decreases in current cigarette smoking rates, the 
level of SHS exposure over the past 30 years remains high. The CDC reported over 58 
million non-smokers were exposed to SHS in the U.S. during 2011 to 2012 (90). The 
total U.S. economic burden directly attributable to smoking for both direct medical care 
for adults and lost productivity due to deaths and SHS exposure was over $300 billion a 
year (91). In 2018, the CDC reported from the Behavior Risk Factor Surveillance System 
(BRFSS) that the percentage of current cigarette use among adults in Kentucky was 
23.4%, compared to the national percentage of 16.1% (92). They also reported that the 
percentage of women aged 18 to 44 years, who reported smoking at least 100 cigarettes 
in their lifetime and currently smoke every or some days was 23.3% (92). 
Types of Tobacco Smoke Exposures 
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There are several ways to be exposed to tobacco smoke. Mainstream smoke is the 
smoke that is inhaled then exhaled by a smoker, while sidestream smoke is the smoke 
emitted into the surrounding environment directly from the burning end of the cigarette, 
pipe, or cigar (93). The differences in the chemical compositions between mainstream 
smoke and sidestream smoke depends on the burning conditions. During inhalation, the 
cigarette burns at a higher temperature allowing for complete combustion in mainstream 
smoke (93). However, the incomplete combustion from sidestream smoke produces 
undiluted chemicals that are more concentrated with harmful and carcinogenic chemicals 
compared to mainstream smoke (93). SHS is a mixture of two forms of smoke from 
burning tobacco: the exhaled mainstream smoke and sidestream smoke (93). People are 
also exposed to SHS in their homes, workplaces, public spaces and cars.   
Recently, thirdhand smoke has been recognized as another type of tobacco smoke 
exposure and is the result of residual tobacco smoke chemicals accumulating and 
attaching to hair, surfaces, clothing, furniture and dusts in the environment (94). These 
toxins remain settled for months long after the SHS is cleared and over time can become 
increasingly more dangerous (94,95). One study in 2014 examined the effects of 
thirdhand smoke using animal models under similar conditions that simulate human 
exposures. They found that the mice exposed to thirdhand smoke showed changes in 
multiple organ systems, specifically the liver, lung and skin (95). They found higher lipid 
levels and non-alcoholic fatty liver disease within the livers of thirdhand smoke exposed 
mice. In the lung, there were an excess of collagen and inflammatory cytokines and 
lastly, poor healing of wounded skin on mice exposed to thirdhand smoke (95).  
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Tobacco Smoke Composition 
 There are over 7,000 chemicals in tobacco smoke, of which at least 250 are 
known to be harmful and over 70 that are carcinogenic (96). Some known human 
carcinogens in SHS are benzene, 2-napthylamine, 4-aminobiphenyl, nickel and 
polonium-201. Probable human carcinogens in SHS include formaldehyde, hydrazine, 
1,3-butadiene, benzo[a]pyrene and cadmium. Some of the toxic substances include 
carbon monoxide, acrolein, ammonia and nitrogen gases (93,97). Smoking tobacco can 
potentially harm every organ within the human body and there are a plethora of studies 
associating tobacco smoke, both active smoking and SHS exposure to a multitude of 
diseases and illnesses. Some health effects of tobacco smoke include cardiovascular 
disease such as coronary disease and stroke; respiratory disease such as chronic 
obstructive pulmonary disease and asthma; several types of cancers such as lung, bladder, 
cervix and liver; and infertility and adverse pregnancy outcomes (11).   
Measures of Tobacco Smoke Exposures 
There are a few methods to assess and measure tobacco smoke exposure, with 
varying levels of validity and reliability. The two most commonly used methods are self-
report and biomarkers (97). Self-reported exposures can easily be assessed and measured 
through questionnaires or interviews. Questionnaires are the most convenient and 
inexpensive method especially for larger observational studies. Unfortunately, there are 
limitations with self-reported data such as lack of standardized measurements, 
misclassifications, recall bias and under-reporting (98). However, meta-analyses have 
showed that self-reported smoking measures can be validated with biochemical 
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measurements (99). Some examples of questions asked to assess smoking, for both active 
and passive smoking include “Do you currently smoke tobacco on a daily basis, less than 
daily, or not at all?”, “Have you smoked tobacco in the past?”, “How many cigarettes or 
packs (or list of other tobacco products) do you smoke a day/week?”, “Have you ever 
smoked more than 100 cigarettes?”, “How often does anyone smoke inside you home?” 
and “Did anyone smoke at your work during the past 30 days?” (100).  
A more objective and reliable measurement of tobacco smoke exposure is the use 
of biomarkers. The two most widely used are nicotine and cotinine (101). Nicotine is the 
primary addictive and major component of tobacco smoke. Its half-life is between 2 and 
3 hours within the blood and it is then later excreted through urine (101). However, only 
5 to 10 percent of nicotine is excreted in the urine and among the remaining, 
approximately 80 percent is metabolized to cotinine in the liver (101). The limitations to 
using nicotine include its short half-life, which limits it from assessing long-term 
exposures, as well as, the assay used to measure nicotine is costly and must be highly 
specific due to low levels present (101). Cotinine is a metabolite of nicotine and is the 
preferred biomarker for tobacco exposure (102). Its half-life ranges from 15 to 20 hours 
and depend on the type of specimen it is being measured from (102). Cotinine can be 
measure from blood, urine, saliva and hair follicles. Published cutoff values by exposure 
levels are different for plasma, urine and saliva. For urinary cotinine, levels less than 10 
ng/mL to indicate unexposed non-smoker, 10-200 ng/mL for a passive smoker and above 
200 ng/mL indicates an active smoker (103). Another example differentiated active 
smokers with cotinine levels >14ng/mL, SHS exposed from 0.5-13.9 ng/mL and 
nonsmokers a <0.5ng/mL (104). One recent study used urinary cotinine levels >30ng/mL 
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to identify current smoking with 94% sensitivity and 98% specificity (105). There are 
limitations using biomarkers such as differences in uptake, metabolism and excretion 
rates, which can increase inter-subject variation. It is also very difficult to differentiate 
SHS exposures because of lower levels of cotinine. 
Zenzes and associates examined cotinine levels in follicular fluid among infertile 
women by smoking status (106). They enrolled 111 infertile women from a hospital IVF 
program and classified them into active, passive and non-smokers, using self-reported 
number of cigarettes smoked for both females and their husbands (106). Cotinine was 
measured in follicular fluid and was strongly correlated in a dose-dependent manner with 
the number of cigarettes smoked per day for both active and passive smokers. The 
authors discussed that there were a lot of inter-variation between cases that reported 
similar number of cigarettes smoked but suggested it may be due to difference in nicotine 
metabolism, unreliability of self-reported data and time before last cigarette smoked 
given cotinine’s half-life (106). This was one of the first studies to examine cotinine 
levels in passive smokers. Cotinine was also detected in all active smokers, most of the 
passive smokers and some nonsmokers, which they deemed as environmentally exposed 
passive smokers. 
Smoking and Biological Mechanisms 
Several mechanisms have been proposed to explain how tobacco smoke exposure 
(particularly before conception) may be harmful for reproductive function. Scientists 
have used both animal models and clinical data to develop and support these theories. 
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Folliculogenesis and Steroidogenesis 
Follicular fluid is secreted during folliculogenesis and maintains a healthy 
environment to promote granulosa cell and oocyte development (107). Cigarette smoke is 
theorized to be associated with folliculogenesis and ovarian steroidogenesis impairment 
(107,108). Harmful tobacco smoke constituents can build up within the ovaries resulting 
in a deleterious follicle environment, causing increased oxidative stress, abnormal 
intercellular crosstalk, meiosis impairment and activation of cell death pathways (107–
111). Chemicals found in tobacco smoke such as cadmium and benzo(A)pyrene (BaP) 
can act as endocrine disrupting chemicals and lead to impairment of production of 
estradiol and progesterone (107,108). Cigarette smoke components such as nicotine and 
cotinine can also inhibit the expansion of the cumulus-oocyte complex (COC) (107,108). 
The structural and functional processes involved in the expansion of COC is important in 
oocyte maturation, fertilization and embryo development (107,108). 
Oxidative stress is the term used to characterize uncontrolled reactive oxygen 
species (ROS) production, which is a by-product of oxygen metabolism, or an imbalance 
between free radicals (pro-oxidants) and antioxidants (109). Heavy metals and other 
harmful substances within tobacco smoke promote oxidative stress, which can lead to 
harmful effects on cell membranes, DNA and proteins (107,110). DNA damage can lead 
to aneuploidies which in turn adversely affect fertilization and pregnancy outcomes 
(109,110). Studies have shown that tobacco smoke contains over 1015 ROS per puff (112) 
and that higher levels of ROS were associated with lower oocyte yield (113). Higher 
levels of ROS have also been shown to produce immature and poorer quality embryos in 
women who were not successful with IVF (114). Khan and associates used a mouse 
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model to show that SHS exposure is associated with adverse fertility outcomes in female 
mice, which was not prevented by antioxidant use (115). Mai and colleagues examined 
cigarette smoke extract on ovulation, oocyte morphology and ovarian gene expression 
using an animal mode. They found cigarette smoke exposure to be associated with poorer 
quality of oocytes and a shrink size which they believe is due to oxidative stress (116).  
Tobacco smoke has been associated with depletion of the follicle pool and earlier 
menopause either through apoptosis of maturing follicles or autophagy of primordial 
follicles (107,109). Apoptosis is the term used for programmed cell death and may be the 
main cause for smoke-induced loss of primordial follicles. Gannon and colleagues 
showed that mice that were exposed to cigarette smoke twice a day had a reduction in 
primordial follicle pool as well as, a higher number of autophagosomes in granulosa cells 
(117).  Several studies have also shown accumulation of cotinine and carcinogens within 
follicular fluid and granulosa cells, which can induce apoptosis and potentially affect 
ovarian function by directly depleting oocytes (118,119). In 2009, Tuttle and associates 
tested whether cigarette smoke exposures, representative of human exposure levels would 
decrease ovarian follicles by apoptosis using mice (120). They found a significant 
reduction in the number of ovarian follicles via an increase in a pro-survival B-cell 
lymphoma 2(Bcl 2) marker, which inhibits apoptosis (120). Plante and colleagues studied 
the impact of smoking on AMH levels and found that active smoking (not former or 
passive smoking) was associated with lower AMH levels, inferring that tobacco smoke 
directly affected the antral follicles and not the primordial follicles (121).  
 
Fallopian Tube, Uterine and Placental Effects 
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Tobacco smoke components have been shown to impair fertility through fallopian 
tube and uterine effects (108,111). Cigarettes smoke targets the oviduct leading to an 
increased number of ectopic pregnancies after exposure and with a dose-response effect 
(108,111). Toxins in cigarette smoke can also cause tubal dysfunction through decreased 
quality and quantity of ciliary cell activity, abnormal ciliary beat frequency and 
infundibular smooth muscle contraction, along with lower oocyte retrieval due to 
excessive adhesions between the COC and tubal lining that is responsible for transport of 
the COC and embryo along the tubes to the uterus lining (73,108). 
 A healthy and prepared uterus and uterine lining is necessary for successful 
embryo implantation. Several studies have shown lower rates of implantation for smokers 
compared to nonsmokers among ART users (122–124). The mechanisms behind tobacco 
smoke’s effects on the endometrium are still being elucidated. However, several animal  
studies have shown that chemicals in cigarette smoke (mostly nicotine, cadmium and 
BaP) can decrease the weight of the uterus, suppress the uterine response to 
decidualization, decrease mobility of endothelial cells, and inhibit cell proliferation (108). 
Early placentation involves growth, differentiation, transport and invasion of the 
trophoblast (108,111). Few studies using human trophoblastic cells have shown that 
cigarette smoke chemicals--particularly cadmium, which is a known placental toxin, BaP, 
and nicotine-- can disrupt proliferation, differentiation and migration (108,111). These 
effects are also directly related to the increased risk of SA. 
SECTION D - Epidemiological Studies 
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Active Smoking and Fertility 
There have been many studies investigating whether active current smoking is 
associated with TTC or fecundability (26, 117–119), infertility (128–130) and conception 
outcomes for both natural conceptions (131) and MAR (132,133). Findings have been 
inconsistent, with some studies showing significant associations and some showing no 
association (134,135). The following section describes past research on active smoking 
by different types of fertility outcomes. These studies are summarized in Table 1. 
Fecundability 
In 1997, Curtis and colleagues examined the effects of active smoking and other 
risk factors on fecundability, using a retrospective cohort study. Couples from the Ontario 
Farm Family Health study who were planning to conceive, completed detailed 
questionnaires self-reporting the number of pregnancies, TTC, detailed exposure 
information and other important covariates (38). The final sample size included 1277 
couples that contributed 2607 pregnancies. After adjusting for spouse's smoking, recent 
oral contraceptive use, and woman's age, women who smoked had significantly reduced 
fecundability compared to nonsmokers (adjusted fecundability ratio (aFR): 0.90; 95% 
confidence intervals (CI): 0.82, 0.98). There was also a significant a dose-response effect 
for the number of cigarettes per day (aFR: 0.74; 95% Cl: 0.59, 0.92 for >20 cigarettes per 
day) (38). Limitations of the study above include the lack of generalizability given the 
specific population, the results may be not be generalizable to the general population. 
Effects may be overestimated, as smokers who are highly fertile may have been 
excluded, given that they are more likely to have unplanned pregnancies (38). Also, data 
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was only collected on couples who did conceive, which excluded potentially infertile, 
sterile or less fecund couples. And because smoking has been shown to be associated 
with infertility and fecundability, the estimates may be biased towards a null association. 
In 2014, Radin and colleagues used a prospective cohort study to assess active 
smoking on fecundability also using women planning to conceive (126). Current and past 
smoking history along with important covariates were collected by questionnaire at 
baseline. Outcome data were self-reported twice a month using follow-up questionnaires. 
Confirmation of pregnancy by either a home pregnancy test or physician was collected, 
along with TTC and last menstrual cycle. The final sample size included 3773 women 
who contributed 15,774 cycles with 2,578 confirmed pregnancies (126). After adjusting 
for cycle number at risk, age, partner smoking, and passive smoking, women who were 
current smokers had lower fecundability than never smokers, but the estimate was not 
significant (aFR:0.89; 95% CI: 0.77, 1.03) (126). The authors also found that women who 
were regular smokers for ten years and more had a significantly reduced fecundability 
than never smokers (aFR:0.85; 95% CI: 0.71, 1.00) (126). No significant dose-response 
effect was established. As detailed as the exposure assessment was, heavy smokers have 
been shown to under-report their smoking intensity, leading to exposure misclassification 
which can lead to a downward bias. The authors also mentioned unmeasured 
confounding and overestimated effects, if the smokers who that were more likely to be 
lost to follow-up, were also more likely to conceive (126). Similar to the previous study 
described, excluding unplanned pregnancies can also lead to an upward bias. 
A more recent study in 2019 examined the extent to which cigarette smoking 
affected fecundability using a North American internet-based cohort of pregnancy 
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planners. Among 5,473 females, active and passive smoking exposures were self-
reported at baseline, then followed up bi-monthly to collect current smoking history for 
the prior month (135). Conception outcomes were also self-reported and collected at each 
follow-up, along with TTC measured in cycles. Smoking intensity using number of 
cigarettes smoked per day and duration were analyzed individually and then jointly 
among female current smokers. The authors used proportional probabilities regression to 
estimate FRs and 95% CIs, adjusted for important covariates (135). 
Results showed minor insignificant reductions in fecundability for current, female 
smokers (aFR: 0.90; 95% CI: 0.77, 1.07), current occasional smokers (aFR: 0.88; 95% 
CI: 0.73, 1.06), and former smokers (aFR: 0.89; 95% CI: 0.81, 0.98) (135). Females who 
smoked ≥10 cigarettes/day for ≥10 years had stronger associations with reduced 
fecundability, though still not statistically significant (aFR: 0.77; 95% CI: 0.53, 1.10) 
(82). The results of this study supported past studies that revealed current smoking is 
associated with reduced fecundability; however, this study also had a few limitations. 
Firstly, all smoking exposures were self-reported, which are commonly under-reported 
and can lead to non-differential misclassification and a downward bias. Results also 
showed low agreement between female and male reporting of smoking intensity which 
could be further evidence of under-reporting (135). An objective biomarker such as 
cotinine could have increased the validity of the estimates and reduce bias. The study 
excluded women who had been trying to conceive for 6 or more months prior to 
enrollment and restricted the sample to couples planning a pregnancy. It has been 
theorized that smokers are more likely to have unplanned pregnancies either because of 
contraceptive use or risky behaviors, so in theory, less fertile smokers would be enrolled, 
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which would bias the estimate in an upward direction (135). Lastly, the authors stated 
that results from additional analyses showed female current smokers were more likely to 
be lost to follow-up, which can lead to an upward bias, if female smokers who did not 
conceive were disproportionately lost to follow-up. 
Infertility 
In 1998, Augood and colleagues conducted a systematic review and meta-analysis 
on active smoking and female infertility. Twelve studies were used after meeting the 
stringent criteria of the meta-analysis. There were 4 case-control studies and 8 cohort 
studies: one prospective and seven retrospective (130). The results overall showed a 
significant 60% increased odds of infertility among current cigarette smokers when 
compared to non-smokers (OR: 1.60; 95% CI: 1.34, 1.91) (130). This statistically 
significant result was also seen when the results were stratified by study designs; for 
case-control studies (OR:2.27; 95% CI: 1.28, 4.02) and cohort studies (OR:1.42; 95% CI: 
1.12, 1.91) (130). Regardless of the limitations of this meta-analysis, the overall precision 
and consistency of effects across the different study designs, outcomes, and sample sizes 
like past studies, supported the negative effect of smoking on female fertility (130). 
However, while some of the individual studies within the meta-analysis were adjusted for 
important confounders, the overall estimates were not. 
Laurent and colleagues used a retrospective case-control study to investigate the 
effect of active smoking on female infertility. Women used in this study were among the 
controls of a cancer and steroid hormone study (128). They recruited 482 cases and 2231 
controls. Cases of primary female infertility were defined as having 24 months of actively 
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trying to get pregnancy (unprotected intercourse) without pregnancy. And controls were 
defined as women who did not meet the criteria for a case, and also had documented 
fertility (128). Exposure data was self-reported during an interview-administered 
questionnaire. After adjusting for age at infertility/conception, age at first intercourse, 
education level, race, and history of benign ovarian disease, the odds of primary 
infertility were 36% higher for women who smoked a pack a day compared to 
nonsmokers (adjusted odds ratio (aOR):1.36; 95% CI: 1.14, 1.36) (128). However, there 
were many limitations including the retrospective study design which cannot assess 
temporality of the effect to outcome. Also, women who were categorized as infertile may 
over-report exposures because of known associations with infertility and lastly, smoking 
behaviors can change over time, leading to misclassification and can lead to 
overestimated effects. The authors also stated that contraceptive use and treatment of 
infertility were important confounders that were not adjusted for and can ultimately bias 
the estimates in an upward direction (128). 
In 2016, Hyland and others cross-sectionally examined a large prospective cohort 
to assess tobacco smoke exposure with infertility. All information including tobacco 
smoke exposures, infertility history and other relevant variables were extracted from 
questionnaire used in the Women’s Health Initiative observational study (129). Among 
the 88,732 women, active smokers overall had significant increased odds of infertility 
compared to never smokers (aOR: 1.14; 95% CI: 1.03, 1.26) after adjusting for several 
confounders (129). However, there were a few limitations to this study. Firstly, cross-
sectional studies are a weak design to infer causality, because it does not allow for 
temporality, especially given that many women change their smoking behaviors. 
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Exposures and outcome data were self-reported which can be subjected to recall bias or 
under-reported leading to misclassification and a downward bias. The authors also stated 
that there maybe be bias from the lack of adjustment for important confounders such as 
alcohol use, contraceptive use, infertility treatment and male factor infertility (129). 
Clinical Outcomes of Medically Assisted Reproduction 
With the emergence of MAR, study designs have improved to allow for more 
efficient methods in assessing exposures on conception outcomes among infertile women 
and couples. Several meta-analyses and more recent studies have examined the effect of 
active smoking on MAR outcomes (131,136–138). Feichtinger and colleagues conducted 
a meta-analysis to examine the relationship between the clinical pregnancy rate of female 
smokers after the first IVF-ET cycle (136). The authors used seven articles and one of 
their own studies to calculate pooled odds ratios and 95% CI. Among a total of 2314 first 
IVF-ET cycles, it was found that almost twice as many IVF-ET treatment cycles were 
needed for smokers to conceive compared to non-smokers (OR:1.79, 95%CI: 1.24, 2.59) 
(136). Given the weak methodological designs of the studies used in this meta-analysis, 
the authors warned that the accuracy of overall effect estimate should be taken with 
careful consideration. 
Waylen and colleagues also conducted a meta-analysis examining the clinical 
outcomes ART and smoking at the time of treatment. Among the 18 studies used for the 
clinical pregnancy rate per cycle outcome, there were 1284 smokers and 3959 matched 
controls (137). The results showed a significant decrease in clinical pregnancy rate per 
cycle for women smoking at the time of ART treatment compared to women who did not 
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(OR: 0.56; 95% CI: 0.43, 0.73) (137). Budani and colleagues updated the above meta-
analysis in 2016 to include three additional studies and found similar results for the 
clinical pregnancy rate per cycle (OR: 0.53; 95% CI: 0.41, 0.68) (138). Similar 
limitations were mentioned for both, including that the results are more likely to be 
confounded by age or male smoking status and the lack of external validity (137,138). 
Also, most of the studies included in both meta-analyses only took into account self-
reported smoking status by questionnaire, while only a few used an objective marker. 
Summary 
Although there are inconsistencies across studies, the body of literature as a whole 
suggests that current smoking may be associated with reduced fecundability, increased 
odds of infertility, and lower the odds of both natural and MAR conceptions (Table 1). 
The associations are weaker, however, among the larger studies. Of the seven cohort 
studies analyzed, three were of prospective designs and of those, two did not find a 
significant association. There were only two studies that found significant dose-response 
effects with the number of cigarettes. Also, cross-sectional analyses, case-control or even 
retrospective study designs are more susceptible to bias which limits inferences on 
causality. Lastly, almost all of these studies used self-reported smoking exposures which 
can lead to misclassification and underestimated associations because of under-reporting. 
Few studies used an objective biomarker to verify smoking status which can help to 
increase accuracy of the estimates and reduce bias. 
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Table 1.  Studies on Active Smoking Exposures and Fertility 
Study 
Design 
N  ART Exposure Outcome Esti
mate 
95% 
CI 
Baird & 
Wilcox, 
1985 
(125) 
TTC 678 
women 
No Self-
reported 
Time to 
conception 
0.72a 0.59 - 
0.87 
Hull 
et al., 
2000 
(134) 
CS of 
PCS 
8515 
women 
No Self-
reported 
Delayed 
conception 
1.23a 0.98 - 
1.49 
Curtis 
et al., 
1997 
(38) 
RCS 1277 
women 
No Self-
reported 
Fecundability 0.90b 0.82 - 
0.98 
Radin et 
al., 2014 
(126) 
PCS 3773 
women 
No Self-
reported 
Fecundability 0.85b 0.72 - 
1.00 
Sapra et 
al., 2016 
(127) 
PCS 501 
women 
No Self-
reported 
Fecundability 0.53b 0.33 - 
0.85 
Wesseli
nk et al., 
2019 
(135) 
PCS 2962 
women 
No Self-
reported 
Fecundability 0.90b 0.77 - 
1.07 
Laurent 
et al., 
1992 
(128) 
CACO 
482 
cases, 
2231 
controls 
No Self-
reported 
Infertility 1.36a 1.14 - 
1.61 
Hyland 
et al., 
2016 
(129) 
CS of 
PCS 
88 732 
women 
No Self-
reported 
Infertility 1.14a 1.03 - 
1.26 
Van 
Voorhis 
et al., 
RCS 499 
women 
Yes Self-
reported 
Ongoing 
pregnancy 
rate 
0.32a 0.13 - 
0.79 
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1996 
(132) 
Freour 
et al,. 
2008 
(133) 
RCS 111 
women 
Yes Self-
reported 
Clinical 
pregnancy 
rate 
% 
differ
ence 
NA (p 
value < 
0.05)  
Hughes 
& 
Brennan
, 1996 
(131) 
MA 13 
studies 
No Mostly 
self-
reported, 
few used 
biomarkers  
Natural 
conception 
0.33 
to 1.0 
* 
NA 
7 
studies 
Yes Conceptions 
per cycle 
0.57c 
* 
0.42 - 
0.78  
Augood 
et al., 
1998 
(130) 
MA 12 
studies 
No Self-
reported 
Infertility 1.60c 
* 
1.34 - 
1.91 
Feichtin
ger et 
al.,1997 
(136) 
MA 8 
studies 
Yes Self-
reported 
Clinical 
pregnancy 
rate  
1.79c 
* 
1.24 - 
2.59 
 
9 
studies 
Yes Self-
reported 
Pregnancies 
per IVF-
treated cycles 
0.66c 
* 
0.49 - 
0.88 
Waylen 
et al., 
2009 
(137) 
MA 18 
studies 
Yes Self-
reported 
and 
biomarkers  
Clinical 
pregnancy per 
cycle 
0.56c 
* 
0.43 - 
0.73 
Budani 
et al., 
2018 
(138) 
MA 21 
studies 
Yes 
Self-
reported 
and 
biomarkers 
Clinical 
pregnancy 
rate per cycle 
0.53c 
* 
0.41 - 
0.68 
TTC - Time to conception, CS - Cross-sectional, RCS - Retrospective cohort study, PCS 
- Prospective cohort study, CACO - Case-control, MA - Meta-analysis 
a - Adjusted Odds Ratio, b - Adjusted Fecundability Ratio, c - Pooled OR/RR 
* - Some individual studies adjusted for confounders
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Secondhand Smoke Exposure and Fertility 
Research on SHS exposure with fertility outcomes such as TTC or fecundability 
(127,134), infertility (129) and natural or assisted conception outcomes (122,124) are few 
and limited with mostly inconclusive or inconsistent results (126,139,140). The following 
section describes past research on SHS exposures by different types of fertility outcomes. 
These studies are summarized in Table 2. 
Fecundability 
  In 2000, Hull and colleagues investigated passive smoking on TTC by 
retrospectively analyzing a prospective cohort study. Using the Avon Longitudinal Study 
of Pregnancy and Childhood, exposures, outcome and other relevant variables were self-
reported by questionnaire (134). Pregnancies were enrolled at 18 weeks of gestation and 
both unplanned pregnancies and planned pregnancies that did not reach 24 weeks of 
gestation were excluded. The final sample included 8,515 women who contributed 9,065 
pregnancies (134). After adjusting for confounders, passive smoke exposure was found to 
significantly delay 6-month conception (aOR: 1.17; 95%CI: 1.02, 1.37) compared to no 
SHS exposure (134). Possible limitations to this study included the lack of 
generalizability, unmeasured confounders, the study population which was limited to 
only fecund women and under-reporting of smoking behaviors, which can lead to 
misclassification and null associations. This study also did not use an objective biomarker 
to verify current passive or active smoke exposures. 
However, as previously described in 2014, Radin and coauthors used a 
prospective cohort study to examine passive smoking on fecundability among women 
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planning to get pregnant. Among 2,346 never smokers, passive smoking was associated 
with reduced fecundability but was not statistically significant (aFR: 0.92; 95% CI: 0.83, 
1.03), after adjusting for confounders (126). The authors stated that as of 2014, their 
study was the largest prospective study to examine passive smoking and fecundability. 
Infertility 
Also described earlier, Hyland and colleagues assessed lifetime tobacco smoke 
exposure on infertility using a cross-sectional design. After adjusting for age, race, 
education, alcohol use, insecticide exposure, oral contraceptive use, BMI, and exercise, 
never-smoking women with the highest levels of lifetime SHS exposure had significantly 
increased odds of infertility compared to nonsmoking women with no SHS exposure 
(aOR:1.18; 95% CI:1.02, 1.35) (129). Some strengths of this study included its large size 
which increased statistical power, adjustment of several confounders and thorough 
assessment the impact of lifetime tobacco exposure (129). However, limitations included 
the cross-sectional study design which limited causality, recall bias as women were all 
past reproductive age, social-desirability bias, and not accounting for male factor 
infertility. 
Clinical Outcomes of Medically Assisted Reproduction 
Neal and associates conducted a retrospective study to measure cigarette smoke 
effect from mainstream (MS) and sidestream (SS) smoke-exposed women undergoing 
IVF on fertility outcomes compared to non-smoking (NS) women (124). Smoking status 
was self-reported and categorized into three categories as stated above. The fertility 
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outcomes included embryo quality, implantation rates and pregnancy rates. Among 225 
women, results showed a significant difference in implantation rate (MS=12.0%, 
SS=12.6%, and NS=25.0%, p<0.001) and pregnancy rate per embryo transfer 
(MS=19.4%, SS=20.0%, and NS=48.3%, p<0.001), but showed no difference in embryo 
quality between the three smoking groups (124). Misclassification errors and recall bias 
may have limited the accuracy of the effect, in that women under-reported exposures 
which can lead to a downward bias. Other limitations include the lack of an objective 
marker for smoking exposure and residual confounding. 
In 2007, Meeker and colleagues conducted two retrospective analyses of a 
prospective cohort study to analyze SHS exposure on pregnancy outcomes among 
women undergoing MAR. The first study used a retrospective cohort study to investigate 
adverse pregnancy outcomes and maternal exposure to SHS (139). Adverse pregnancy 
outcomes were collected from medical records and included failure of fertilization, failed 
implantation and SA. Maternal exposure to SHS was self-reported on questionnaires and 
urinary cotinine levels adjusted for creatinine were measured at the time of ART 
treatment. After adjusted for confounders, urinary cotinine levels above the median were 
not associated with failed implantation (aOR: 0.98; 95% CI: 0.70, 1.37)(139). The second 
study was done to analyze women with childhood SHS exposure from their parents and 
SA, with self-reported exposure data. Using a larger sample of 1449 non-smoking 
women, no significant association was also found between any current self-reported SHS 
exposures and failed implantation (aOR: 1.43; 95% CI: 0.97, 2.09)(140). 
In 2011, Benedict and associates carried out a retrospective analysis of a 
prospective cohort study to assess the association between SHS exposure and 
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implantation failure among non-smoking women already in IVF treatment (122). The 
study enrolled 1909 couples with 3270 total IVF cycles. Medical and lifestyle histories 
were self-reported. SHS exposure status was self-reported and then verified by measuring 
cotinine in follicular fluid. After adjusting for confounders, the authors found a 
significant increase in risk of failed implantations among SHS exposed women compared 
to unexposed women (aOR = 1.52; 95% CI = 1.20, 1.92; adjusted risk ratio (aRR) = 1.17; 
95% CI = 1.10, 1.25) (122). They claimed to have the largest study of SHS exposure 
using cotinine on fertility outcomes among IVF patients. Some strengths of this study 
included the use of odds and risk ratios; both statistically significant indicating a robust 
model, adjustment for several potential confounders and use of an objective marker to 
verify SHS exposure status. However, the generalizability of the study is limited because 
the study population only included couples in IVF treatment, which is a very specific 
demographic. The outcome of implantation failure is usually not observed outside MAR 
population and choosing the best embryos in a laboratory is not an option in the general 
population (122). 
Summary 
There are only a few studies examining the association of SHS exposure and 
conception outcomes and some are summarized in Table 2. However, the available 
studies are inconsistent and do not have strong associations. Most of the studies were 
cross-sectional in design rather than the ideal prospective cohort, which would allow for 
temporality to infer causality. Only one of three cohort studies found significant results, 
however, that study was relatively smaller compared to the others. Furthermore, three of 
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the eight studies used a biomarker to measure and verify SHS exposure, the others relied 
on self-reporting which has been shown to result in null association. Lastly, adjustment of 
important confounders and the use of biomarkers such as cotinine are necessary to reduce 
bias in the association of SHS exposure on conception. 
Table 2: Studies on Secondhand Smoke Exposures and Fertility 
Study 
Design 
N ART Exposure Outcome Estim
ate 
95% CI 
Hull et 
al., 2000 
(134) 
CS 8515 
women 
No Self-
reported 
Delayed 
conception 
1.17b 1.02 - 
1.37 
Radin et 
al., 2014 
(126) 
PCS 3773 
women 
No Self-
reported 
Fecundability 0.92c 0.82–
1.03 
Sapra et 
al., 2016 
(127) 
PCS 501 
women 
No Serum 
cotinine 
Fecundability 0.64c 0.41 - 
0.98 
Wesseli
nk et. 
al., 2019 
(135) 
PCS 2962 
women 
No Self-
reported 
Fecundability 0.93c 0.70 - 
1.25 
Hyland 
et al., 
2016 
(129) 
CS 
of 
PCS 
88 732 
women 
No Self-
reported 
Infertility 1.18b 1.02 - 
1.35 
Neal et 
al., 2005 
(124) 
RCS 225 
women 
Yes Self-
reported 
Implantation 
rate 
Differ
ence 
in rate 
 p-value 
<0.01 
Meeker 
et al., 
2007a 
(139) 
CS 
of 
PCS 
921 
women 
Yes Urinary 
cotinine 
Implantation 
failure 
0.98b 0.70–
1.37 
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Meeker 
et al., 
2007b 
(140) 
CS 
of 
PCS 
1449 
women 
No Self-
reported 
Implantation 
failure 
1.43b 0.97–
2.09 
Benedict
 et al., 
2011 
(122) 
CS 
of 
PCS 
1909 
women 
Yes Follicular 
fluid 
cotinine 
Implantation 
failure 
1.17a, 
1.52b 
1.20–
1.92, 
1.10–
1.25 
TTC - Time to conception, CS - Cross-sectional, RCS - Retrospective cohort study, PCS 
- Prospective cohort study, CACO - Case-control, MA - Meta-analysis 
a - Adjusted risk ratio 
b - Adjusted odds ratio 
c - Adjusted Fecundability Ratio 
d - Pooled OR/RR 
* - Some individual studies adjusted for confounders
Active Smoking on Spontaneous Abortion 
Past studies have shown that active smoking affects early pregnancy loss for both 
natural (141–145) and assisted conception (123,146). However, most of these studies 
measured tobacco use during pregnancy and only a few took into account exposures 
before conception or before MAR procedures (144,147). In 1999, Ness and colleagues 
examined active smoking on SA among pregnant adolescents and women aged 14 to 40 
years who visited the emergency department at the University of Pennsylvania Hospital 
(142). Tobacco use after conception, during the pregnancy was self-reported and verified 
by urinary cotinine. Women with urinary cotinine levels great than 500 ng/mL were 
defined as heavy smokers. Four hundred pregnant subjects had a SA either within 3 days 
of enrollment or during follow-up and 570 women (controls) remained pregnant past 22 
weeks of gestation (142). Results showed that heavy smoking was independently 
associated with an 80% increased risk in SA (aOR: 1.8 (95%CI: 1.3, 2.6) (142). 
However, the authors discussed several limitations including residual confounding from 
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unmeasured factors, recall and misclassification bias and urinary cotinine’s half-life 
which only measured recent tobacco use.(142). 
One study that examined tobacco exposures prior to pregnancy on SA was 
conducted in 2006 by Nielsen and associates. Using a nested case-control study from a 
population-based cohort comprising of 20 to 29-year-old women established from 1991 
to 1993. The authors recruited 343 cases of SA and 1578 women who had live births 
(144). Detailed pre-conception tobacco smoke exposures were self-reported during an 
interview-administered questionnaire at enrollment. After adjusting for age, marital 
status, previous SA, use of oral contraceptives, use of intrauterine devices, current 
smoking status, cigarette smoked per day, duration of smoking, and time since quit 
smoking; pre-conception smoking was significantly associated with SA (aOR: 1.64; 95% 
CI: 1.07, 2.50) (144). A significant dose-response effect was also found among the 
number of cigarettes smoked per day and SA (aOR: 1.20; 95% CI: 1.04, 1.39). However, 
no association was for duration of smoking (144). While this study warranted the need 
for further investigation of pre-pregnancy smoking habits on SA and had many strengths, 
there were a few limitations. 
The study suggested that pre-conception smoking may be a proxy for smoking 
during pregnancy. It has been shown that heavy pre-conception smokers may have a 
harder time quitting during pregnancy, which can be relevant in predicting smoking 
during pregnancy (144). However, because data on smoking during pregnancy was not 
collected, this assumption was not tested which limited the study effect estimates. As it 
was unclear whether the effect estimates were truly a result of pre-conception smoking or 
if pre-conception smoking acted as a proxy for smoking during pregnancy (144). Other 
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limitations included recall bias, unmeasured factors such as SHS exposure from spouse or 
work and the lack of differentiation between early and late SA. 
Spontaneous Abortion after Medically Assisted Reproduction 
The relationship between active smoking and clinical outcomes within MAR 
helps to add and improve the research among the specific population, by allowing for 
earlier and efficient detection of pregnancy losses. One study done in 2005 assessed the 
effects on smoking with the IVF success rates among infertile couples. The authors 
retrospectively analyzed data from a large prospective cohort study and used 8457 
eligible women with first IVF cycles (146). Exposures, outcome and relevant information 
were either extracted from the medical record or self-reported through a mailed 
questionnaire. Smokers were defined as having smoked more than one cigarette a day, for 
one year or more, at the time of oocyte retrieval. After adjusting for age, BMI, different 
infertility diagnoses and duration of subfertility, current smoking was found to 
significantly lower of odds of live birth per IVF cycle compared to nonsmokers (aOR: 
0.72; 95% CI: 0.61, 0.84) (146). The authors conducted non-responder analysis which 
showed that women with live births were more likely to respond and participate than 
women with unfavorable outcomes. This may have caused an overestimation of IVF-
assisted birth rates which can result in biased estimates in upward direction, if non-
response was associated with the smoking exposure (146). 
In  2019, Rockhill and colleagues used a retrospective cohort in the U.S. to 
estimate the proportion of ART cycles with self-reported smoking, and its association 
with ART related outcomes (147). Women who self-reported any smoking 3 months 
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before the treatment cycle were defined as smokers. Using national data from 2009 
through 2013, outcome data was collected for every ART cycle and included 
cancellations of ART cycles for all cycles, cycles before egg retrieval and cycles before 
ET/FET (147). Pregnancy outcomes such as SA, stillbirth and live birth among cycles 
with at least one ET were also collected and examined. Logistic regression was used to 
estimate ORs and 95% CIs, taking into account clustering by state, clinic and patient for 
smoking and intensity of smoking with the previously mentioned outcomes (147).  
Results showed that smoking was reported in over 12,000 (1.9%) ART cycles and 
that smokers were more likely to be younger, multiparous, of non-Hispanic White race 
and be diagnosed with tubal and male factor infertility (147). Smokers had lowered odds 
of implantation, IUP and live birth, along with an increase in the odds of SA, however, all 
estimates were not statistically significant (147). While this study incorporated a large, 
nationally representative sample and found results consistent with past studies, 
limitations included recall bias and misclassification, as exposure status was not verified 
with a biomarker. The authors also stated that women undergoing ART treatment tend to 
under-report their smoking habits, which can lead to exposure misclassification and 
consequently, bias estimates toward the null. The study did not address partners’ smoking 
history or SHS exposure, which have shown to be important risk factors. 
 
Summary 
 The 2020 U.S. Surgeon General report stated that there is suggestive but 
insufficient evidence of a causal relationship between maternal smoking and SA (12). 
However, a number of studies examining the association were not used in the report. As 
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shown in Table 3, there is a lack of prospective cohort studies in this area. The majority 
are cross sectional, case-control or retrospective designs which are susceptible to 
misclassification, and cannot assess temporality, which threaten inferential causality. 
There is also a paucity of studies examining pre-conception smoking and among past 
smokers. Exploring smoking at different time periods such as before and during 
pregnancy, can help further elucidate potential mechanisms. 
Table 3: Studies on Active Smoking and Spontaneous Abortion 
Study 
Design 
N ART Exposure Outcome Esti
mate 
95% 
CI 
Armstron
g et al., 
1992 
(141) 
CS ~56000 
women 
No Self-
reported 
SA 1.68a 1.57 - 
1.79 
Ness et 
al., 1999 
(142) 
CACO 400 cases, 
570 controls  
No Urinary 
Cotinine 
SA 1.80a 1.3 - 
2.6 
Mishra et 
al., 2000 
(143) 
CS 2617 women  No Self-
reported 
SA 2.00a 1.50 - 
2.80 
Winter et 
al., 2002 
(123) 
RCS 1196 
pregnancies 
Yes Self-
reported 
EPL 2.00a 1.27 - 
3.15 
Linsten et 
al., 2005 
(146) 
CS of 
PCS 
8457 women 
w/ 1st IVF 
cycle  
Yes Self-
reported 
Live birth 
rate after 
IVF 
0.72a 0.61 - 
0.84 
Nielsen 
et al., 
2006 
(144) 
Nested 
CACO 
343 cases, 
1578 controls 
No Self-
reported 
(pre-
conception) 
SA 1.20a 1.04 - 
1.39 
Hyland et 
al., 2015 
CS 77 805 
women 
No Self-
reported  
SA 1.16a 1.08 - 
1.26 
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(145) 
Rockhill 
et al., 
2019 
(147) 
RCS 175885 ART 
cycles 
Yes Self-
reported 
(pre-ART)  
SA 1.05a 0.96 - 
1.15 
Hughes 
and 
Brennan, 
1996 
(131) 
MA 7 studies No Mostly 
self-
reported, 
few 
biomarkers 
SA 0.83 - 
1.8* 
NA 
Waylen 
et al., 
2009 
(137) 
MA 4 studies 
(100 to 6903 
cycles) 
Yes Self-
reported 
and 
biomarkers 
Live birth 
per cycle 
0.54b
* 
0.30 - 
0.99 
7 studies 
(211 
smokers, 
3959 
matched 
controls) 
Yes Self-
reported 
and 
biomarkers 
SA 2.65b
* 
1.33 - 
5.30 
Pineles et 
al., 2014 
(148)  
MA 50 studies Both Self-
reported 
and 
biomarkers  
SA 1.23b
* 
1.16 - 
1.30 
Budani et 
al., 2018 
(138) 
MA 7 studies 
(3407 
smokers, 738 
nonsmokers) 
No Self-
reported 
and 
biomarkers 
Live birth 
rate per 
cycle 
0.59b
* 
0.44 - 
0.79 
8 studies 
(226 
smokers, 
1796 
nonsmokers) 
Yes Self-
reported 
and 
biomarker 
SA rate 
per 
clinical 
pregnancy 
2.22b
* 
1.10 - 
4.48 
CS - Cross-sectional, RCS - Retrospective cohort study, PCS - Prospective cohort study, 
CACO - Case-control, MA - Meta-analysis 
a - Adjusted odds ratio 
b - Pooled OR/RR 
* - Some individual studies adjusted for confounders
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Secondhand Smoke Exposure and Spontaneous Abortion 
 Several individual studies have examined SHS exposure and SA (122,145,149–
151), however, studies are limited and results are inconsistent (139,140,152). Hyland and 
colleagues used a large cross-sectional study to examine the effect of lifetime SHS 
exposure among 40,850 never-smoking women from the Women’s Health Initiative 
observational study. Exposures, outcome and relevant covariate data were self-reported 
via questionnaire (145). Nonsmoking women with the highest levels of lifetime SHS 
exposure, including childhood SHS exposure greater than 10 years; adult home SHS 
exposure greater than 20 years and adult work SHS exposure for more than 10 years, had 
a significantly increased odds of SA compared to nonsmoking women with no SHS 
exposure (aOR: 1.17; 95% CI: 1.05, 1.30) after adjusting for age, BMI, gravidity, oral 
contraceptive use, race, education and alcohol use (145). A significant dose-response 
effect was also established among SHS exposure and SA (p value = 0.01) (145). 
Limitations included the cross-sectional study design which is a weaker design to infer 
causation and under-reporting of tobacco smoke exposures which can lead to 
misclassification and a downward bias. The authors stated that home pregnancy tests 
were not readily available which limited the outcome to be recognized by the patient or 
by physician and could have also driven estimates toward the null (145).  
A large clinical prospective cohort study was done in 1991 by Ahlborg and Bodin, 
examined passive smoke exposure during pregnancy on pregnancy outcomes. The study 
enrolled 4,787 women attending prenatal care centers in Sweden (149). The authors 
defined pregnancy outcome as either SA or stillbirth and relied on self-reported exposure 
data. The only significant results found were among first-trimester intrauterine deaths, 
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which showed an increased risk for passively exposed women at work (aRR:2.16; 95% 
CI:1.23, 3.81) (149). They also showed that active smoking was associated with 
intrauterine deaths, but not passive smoke exposure in the home. While this was a large 
prospective study, results may be biased because of self-reported data and lack of 
adjustment of important confounders. The authors also stated that more quantitative 
measures of exposure at different time points were another limitation to their study. 
In 1992, Windham and colleagues used a large case-control study to examine 
maternal SHS exposure during pregnancy and SA (150). Cases were defined as women 
who had a SA recorded at local hospitals and exposure information were self-reported via 
a telephone interview. Results showed that pregnant women exposed to SHS for an hour 
or more a day had significantly increased of odds of SA (aOR:1.5; 95% CI: 1.2, 1.9) 
compared to women who reported no SHS exposure (150). However, the same authors 
conducted a similar study using a large prospective cohort of 5000 women in 1999 and 
found no significant results (aOR1.01; 95% CI: 0.80, 1.27) between maternal SHS 
exposure and SA (152). This latter study differentiated SHS exposure from home, work 
or either compared to the previous study in 1992. While the prospective cohort was a 
larger sample, the authors reported that similar limitations such as reporting bias, 
misclassification, unidentified confounders and lack of more objective, quantitative 
exposure measure such as cotinine to accurately measure SHS exposure (150,152). These 
contradicting results further add to the inconsistencies among estimates from studies 
analyzing SHS exposure and SA. 
In 2006, George and colleagues used a population-based case-control study to 
examine the relationship of SA with SHS exposure using plasma cotinine concentrations 
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(151). The authors claimed to have conducted the first study assessing SHS exposure 
using plasma cotinine levels and SA. Cases were defined as having a SA at 6 or 12 weeks 
of gestation and exposure information was self-reported weekly before and after 
conception (151). Plasma cotinine was measured from blood samples taken at time of 
miscarriage. Active smokers were defined as having cotinine levels greater than 15 
ng/mL and SHS exposure between 0.1 and 15 ng/mL (151). Nonsmokers had plasma 
cotinine levels less than 0.1 ng/mL. The results after adjusting for relevant confounders, 
showed significant increases in the odds of SA for SHS exposed women (aOR:1.67; 95% 
CI: 1.17, 2.38) compared to nonsmokers (151). Some possible limitations included the 
study design, using a case-control study does not allow for temporality to be established, 
and the authors did not examine dose-response relationships which is also important in 
assessing causality. 
Meta-analyses conducted have also shown contradicting results (148,153,154). In 
2011, Leonardi-Bee and others conducted a systematic review and meta-analysis of 19 
studies to assess the risk of adverse fetal outcomes among nonsmoking pregnant women 
with SHS exposure (154). They looked at several outcomes including SA which was 
defined as death before 20 weeks’ gestation and stillbirth, defined as death between 20 
weeks’ gestation and birth. SHS exposures were assessed either through self-report or a 
biochemical measure. The authors did not find a significant association among SHS 
exposure and SA from 6 studies (pooled OR: 1.17; 95% CI: 0.88, 1.54) (154). The 
authors conducted sensitivity analyses with similar findings and reported low 
heterogeneity between studies. Also, most of the studies relied on self-ported exposures 
and pooled ORs were not adjusted for important confounders. Another significant 
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limitation of all the previously mentioned studies is a lack of assessment of infertility 
within the association of SHS exposure and SA. As stated before, there is a significant 
increased prevalence of SA among the in infertile population and how it may modify the 
association is essential in accurately estimating an unbiased effect. 
Spontaneous Abortion after Medically Assisted Reproduction 
Conception and pregnancy outcome studies can be designed to better explore risk 
factors since the emergence of MAR. As previously described, Meeker and colleagues 
analyzed adverse pregnancy outcomes and maternal exposure to SHS among women 
undergoing ART treatment (139). Maternal exposure to SHS was self-reported on 
questionnaires and urinary cotinine levels adjusted for creatinine were measured at the 
time of ART treatment. Among all non-smokers, the median cotinine concentration 
adjusted for creatinine was 57.1 ng/mL. After adjusting for confounders, no significant 
association was found between urinary cotinine and SA (aOR: 0.51; 95% CI: 0.21, 1.24) 
(139). The authors then used a larger population of 1449 women to analyze women with 
childhood SHS exposure from their parents and SA, using self-reported exposure data. 
The authors also found no association with any current SHS exposure and SA (aOR: 
0.80; 95% CI: 0.30, 2.14), as well as, no significant dose-response effects (140). 
However, childhood SHS exposure was found to have significantly higher odds of SA 
compared to women with no childhood SHS exposure (140). Limitations for the latter 
study included the lack of external validity and the high levels of discordance between 
urinary cotinine and self-reported SHS exposures. The authors stated that other places of 
exposures besides at home and at work were not assessed and given cotinine’s half-life, 
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one measurement can lead to misclassification (139,140). They also discussed the dose-
response fallacy where the exposure threshold is lower than expected for the lowest 
exposed group, leading to underestimated effects (140). 
As described earlier, Benedict and associates also examined SHS exposure on 
IVF success rates with a retrospective analysis of a prospective cohort study. Cotinine in 
follicular fluid was measured at the time of egg retrieval per cycle. Women with levels 
greater than 1.11 ng/mL were defined as SHS exposed nonsmokers and levels less than or 
equal to 1.11 ng/mL were defined as unexposed nonsmokers (122). Treatment and 
outcome information were extracted from subject’s medical record. The final population 
included 1909 self-reported non-smoking women undergoing IVF (122). After adjusting 
for age, BMI, year of IVF and the type of down-regulation, SHS exposed nonsmokers 
were significantly associated with decreased live birth rates after IVF, compared to 
unexposed nonsmokers ((OR: 0.75; 95% CI: 0.57, 0.99) and (aRR: 0.81; 95% CI: 0.66, 
0.99)) (122). Previously mentioned limitations remained including generalizability of 
results given the specific population and the cross-sectional nature which is a weak 
design to infer causality. 
Summary 
There is also suggestive but insufficient evidence to support a causal relationship 
between SHS exposure and SA. However, most studies described earlier did not find a 
significant association and few that did used designs that are more subject to biases such 
as confounding and selection bias. The only two prospective cohort studies done were 
inconclusive and did not use an objective biomarker such as cotinine to verify exposure 
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status. Of the three studies listed in Table 4 that showed significant associations, two used 
self-reported exposure information and only one found a significant dose-response effect. 
Self-reported SHS exposure data are subjected to recall bias and under-reporting, which 
can create misclassification and null associations. Almost every study measured SHS 
exposures during pregnancy on SA; however, pre-conception SHS exposure may also 
affect SA through similar mechanisms. Adjusting for important confounders and taking 
into account infertility diagnoses among the MAR population is also crucial to 
understand the biological mechanism of SHS exposure on SA.   
 
Table 4: Studies on Secondhand Smoke Exposures and Spontaneous Abortion 
                    Study  
                   Design 
N ART Exposure Outcome Estimate 95% 
CI 
Ahlborg & 
Bodin, 
1991 
(149) 
  
PCS 4,687  
women 
No Self-
reported 
First-
trimester 
fetal loss  
2.16a 1.23 –
3.81 
Windham  
et al., 1992 
(150) 
CAC
O 
626 
cases 
1,300 
controls 
  
No Self-
reported 
SA 1.50b 1.2 –
1.9 
Windham 
et al., 1999 
(152) 
  
PCS ~ 5000 
women 
  
No Self-
reported 
SA 1.01b 0.80 –
1.27  
George et 
al., 2006 
(151) 
CAC
O 
463 
cases 
and 864 
controls 
  
No Plasma 
cotinine 
SA 1.67b 1.17 –
2.38 
Meeker et 
al., 2007a 
(139)  
CS 
of 
PCS 
1449 
women  
No Self-
reported 
SA 0.80b 0.30 - 
2.14 
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Meeker et 
al., 2007b 
(140) 
CS 
of 
PCS 
921 
women  
Yes Urinary 
cotinine 
SA 0.51b 0.21–
1.24 
Benedict et 
al., 2011 
(122) 
CS 
of 
PCS 
1909 
women 
Yes Follicular 
fluid 
cotinine 
Live Birth 0.81a, 
0.75b 
0.57–
0.99, 
0.66–
0.99  
Hyland et 
al., 2015 
(145) 
CS 77 805 
women  
No Self-
reported 
SA 1.17b 1.05 - 
1.30 
Salmasi et 
al., 2010 
(153) 
MA 9 
studies 
Both Self-
reported& 
biomarker 
SA 1.17c* 0.97 - 
1.41 
Leonardi-
Bee et al., 
2011 
(154)  
MA 6 
studies 
No Self-
reported 
and 
biomarker 
SA 1.17c* 0.88–
1.54 
Pineles et 
al., 2014 
(148) 
MA 17 
studies 
Both Self-
reported 
and 
biomarker 
SA 1.11c* 0.95 - 
1.31 
CS - Cross-sectional, RCS - Retrospective cohort study, PCS - Prospective cohort study, 
CACO - Case-control, MA - Meta-analysis 
a - Adjusted risk ratio 
b - Adjusted odds ratio 
c - Pooled OR/RR 
* - Some individual studies adjusted for confounders
SECTION E - N-Acetyltransferase 2 
As previously mentioned, there are over 7,000 chemicals in tobacco smoke and 
over 70 that are carcinogenic (96). Carcinogens such as polycyclic aromatic 
hydrocarbons and heterocyclic amines have been found to cause DNA adducts which can 
lead to mutations, that can initiate carcinogenesis (13,155). N-Acetyltransferase 2 
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(NAT2) is a vital enzyme used in the metabolism and detoxification of xenobiotic 
substances, including therapeutic drugs and exogenous chemicals such as the ones found 
in tobacco smoke (13). NAT2 is primarily expressed in the liver and gastrointestinal tract, 
and catalyzes the transfer of an acetyl group to compounds, either activating or 
deactivating it. (13,155). 
Single nucleotide polymorphisms (SNPs) within the NAT2 alleles are responsible 
for determining NAT2 genotype and phenotype status. Seven most frequent SNPs studied 
are rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C), rs1799929 
(481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A) (156). One 
study compared the accuracy of using different NAT2 SNP genotyping panels and found 
that a four SNP genotype panel of rs1801279 (191G>A), rs1801280 (341T>C), 
rs1799930 (590G>A) and rs1799931 (857G>A) produced the highest accuracy in 
predicting NAT2 acetylator status (156). NAT2 acetylator status is usually coded by the 
number of variants within the four SNP panel. If the subject had no variants among the 
four SNPs, they were classified as a rapid acetylator; one variant as an intermediate 
acetylator and two or more variants as a slow acetylator (156). NAT2 acetylator status 
explains the effectiveness of therapeutic medicines, differences in cancer risk and how 
the body metabolizes environmental toxins (14). 
In 2011, Sabbagh and colleagues compiled frequency data for the most important 
NAT2 variants from 128 population samples, to examine whether different dietary 
patterns and lifestyles can account for inter-population differences in NAT2 variation 
(14). They grouped together intermediate and rapid acetylators because there had similar 
acetylation rates and were compared to slow acetylators. The population was categorized 
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into four major continental areas (Africa, America, Asia and Europe). The highest 
percentage of genetic variation was found within populations at 87.4% and 8.3% genetic 
variation across continents (14). The authors found that the slow acetylators accounted 
for 59% of individuals in Europe and higher percentages of slow acetylators in other 
places such as the Middle East, Southeast Asia and India (14). On the other hand, the 
slow acetylator status was uncommon in Northeast Asia, with a prevalence of 18%, 
which also showed higher percentages of the rapid/intermediate acetylator status (14). 
Furthermore, the distribution of slow acetylators within Africa and America were highly 
heterogenous with notable differences between the populations. 
Several studies have investigated the association of NAT2 polymorphisms and 
several cancers such as bladder and colorectal cancer and allergic disorders such as 
asthma (157) with inconsistent results. A few of those studies further explored effect 
modification by smoking status. The research showed significant interactions between 
current smoking and slow acetylation status, with increased risk of bladder cancer (158–
161), breast cancer (162,163), colorectal cancer (164,165) and lung cancer (166,167). 
NAT2, Smoking, and Fertility-related Outcomes 
Some recent studies have examined the relationship between NAT2 
polymorphisms and endometriosis: one study found that there was an increased risk of 
endometriosis among slow acetylators (168), another found no association (169), one 
meta-analysis showed a significant risk only among Asians (170) and lastly, one study 
showed that some SNPs may increase risk of endometriosis and others may be protective 
(171). There have been few studies to date that have examined the interaction of NAT2 
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polymorphisms with tobacco smoke on fertility. In 2011, Taylor and associates showed 
that among slow acetylators, current smoking was significantly associated with reduced 
fecundability (fecundability odds ratio (FOR): 0.34: 95% CI, 0.22, 0.90) among office 
working women after adjusting for significant confounders (15). 
More studies on NAT2 polymorphisms and its interaction with smoking were 
focused on male infertility. Two recent contradicting case-control studies included Jiang 
and colleagues who showed no significant association between NAT2 polymorphisms 
and risk of idiopathic male infertility (IMI) (16), while Trang and associates showed that 
the rs1799929 and rs1799930 SNPs significantly increased the risk of IMI (17). In 2014, 
Yarosh and colleagues found that among men with a slow-acetylation status, cigarette 
smoking was significantly associated with an increased risk of IMI (OR 1.71, 95% CI 
1.02, 2.87, P = 0.042) (172). These studies have emphasized the importance of further 
understanding gene-environmental interactions on fertility outcomes, and the need for 
more research. 
SECTION F - Selection Bias in Prospective Cohort Studies 
Selection bias due to differential loss of follow-up, also known as attrition bias, is 
one major source of potential bias in prospective cohort studies and randomized 
controlled trials (173). This occurs when loss to follow-up of study participants is jointly 
associated with both the outcome and the exposure (173). Figure 1 shows two examples 
of selection bias due to loss to follow-up where the main exposure is smoking (A), the 
outcome is conception (Y), a set of measured confounders (L) and a set of unmeasured 
 65 
confounders (U) are displayed in a casual diagram. When subjects are censored (C) either 
because of loss to follow-up or missing outcome data, they are removed from the study at 
the time of being censored. This restricts the data to the uncensored observations, which 
is why C is conditioned on in Figure 1. Conditioning on a collider C as in the bottom 
diagram in Figure 1 or conditioning on a descendent of a collider L in the top diagram in 
Figure 1 induces selection bias on the path between exposure A smoking and outcome Y 
conception (Figure 1) (174).  
 
 
Figure 1. Example of Selection Bias Due to Censoring 
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Causal diagrams such as directed acyclic graphs are one way to help to identify 
potential selection bias. Another method to identify potential selection bias due to 
censoring is to compare the prevalence of exposures and covariates of non-responders or 
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partial responders to those who remained in the study and identify significant differences. 
Sensitivity analyses can also help to assess the potential impact of attrition bias, by 
assuming a particular distribution of the outcome among all non-responders for example, 
all censored subjects conceived or all censored subjects did not. However, this technique 
yields conditional estimates which are difficult to interpret and have shown to be 
insufficient in correcting selection bias. 
A more robust method used to control for selection bias due to censoring is the 
inverse probability weighting (IPW) technique. In an IPW analysis, a pseudo-population 
is created by weighting the probability of being followed up in the study given a set of 
risk factors associated with being lost to follow-up and the outcome. The inverse of the 
probability of being followed up is computed and included in a weighted analysis for 
everyone who were lost to follow-up. (173,175). Hence, the subjects who were followed 
up, account for themselves and those lost to follow-up up with similar characteristics. For 
example, there are five nonsmokers in a cohort study of the same age, BMI, race and 
AMH levels, and 4 are lost to follow-up. In this scenario the estimated probability of 
being followed up (uncensored) is 1/5 = 0.2 and the nonsmoker who was followed up 
received a weight of 5 (1/0.2). This means that in the pseudo-population, there will be 5 
copies of the uncensored nonsmoker to account for the 4 who were censored (176). 
In IPW, there are assumptions that must be met in order for valid estimation of 
casual effect measures. The first assumption of IPW is conditional exchangeability, 
which assumes that there are no other factors, L, that contribute to the loss of follow-up 
or selection bias. Sensitivity analyses can be done to test the robustness of estimates by 
including additional variables, L, that may explain the selection bias (177). The second 
67 
assumption is positivity, which assumes a non-zero probability of being censored within 
every unique exposure combination. And lastly, the model used to estimate the weights 
must be correctly specified (177). All these assumptions must hold in order to accurately 
estimate effect that have been adjusted for selection bias due to lost to follow-up. 
Rationale 
Tobacco smoke exposure is one of the leading preventable causes of mortality and 
morbidity in the U.S. (11), and its effect on natural and assisted conception and adverse 
pregnancy outcomes needs to be further examined with more substantial and conclusive 
evidence. There is a lack of exposure data validation with biomarkers, assessment of the 
cumulative effects of active smoking and SHS exposure, evaluation of dose-response 
effects and the use of tobacco smoke exposure at different time points to fully capture the 
effect and its biological mechanisms. Many studies in the past have not adjusted for all 
important confounders or explored potential effect modifiers. More large-scale, 
longitudinal prospective studies are needed with different age groups to fully determine 
differences throughout the reproductive lifespan. Lastly, reducing the potential for bias, 
and conducting appropriate statistical tests should be taken into consideration. 
The objectives of this study will help to address some of the gaps in the literature 
and add new, relevant knowledge in regard to the effect of pre-conception tobacco smoke 
exposures on fertility and pregnancy outcomes and the interaction with NAT2 acetylator 
status. This study will add new evidence of the association between tobacco smoke 
exposures and fecundability and SA within in a clinical population. Validation of 
exposures using cotinine measurement and adjustment of selection bias due to loss of 
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follow-up can also strengthen the accuracy of estimates. Findings from this study has 
clinical implications for fertility care and counseling and can help to bring about more 
public health policies and interventions to reduce the impact of smoking and SHS 
exposures. 
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IV. METHODS
Study Design 
The data used in this study came from the Louisville Tobacco Smoke Exposure, 
Genetic Susceptibility and Infertility (LOUSSI) study (Granting institution- Eunice 
Kennedy Shriver National Institute of Child Health and Human Development; grant 
number- 1R15HD087911-01; Principal Investigator - Dr. Kira Taylor). Its objective was 
to estimate the cumulative impact of tobacco smoke exposure and its interaction with 
NAT2 acetylator status on ovarian reserve and IVF-related outcomes. This study had 
both cross-sectional and prospective data collection components. The prospective 
component of the LOUSSI study, examining conception and pregnancy outcomes, was 
used for this dissertation. Institutional Review Board approval for this study was obtained 
from the University of Louisville, IRB number: 16.0063. 
Study Setting and Subjects 
Study participants were recruited from existing and new patients attending the 
University of Louisville Reproductive Endocrinology and Infertility (REI) clinic. The 
clinic’s clientele included women of reproductive age seeking fertility counselling and/or 
treatment and who resided in the Louisville and southern Indiana area. The inclusion 
criteria for the LOUSSI study were all women aged 21 years and older seeking fertility 
counselling and/or treatment at the University of Louisville REI clinic. Women illiterate 
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in the English language or found to be pregnant at the time of enrollment were excluded 
from the study. 
Participating physicians and fellows assessed a potential subject’s eligibility and 
invited her to take part in the study. If the patient expressed interest, a research assistant 
present at the clinic would explain the benefits and risks of the research study and obtain 
informed consent. Participating subjects were offered compensation with a $25 VISA gift 
card. In July 2017, after 99 subjects were enrolled, the informed consent was modified to 
include a section requesting permission to recontact the subject. If the subject agreed to 
be recontacted, they were asked to leave a phone number, email and mailing address. The 
final sample size of 264 women were enrolled from November 2016 through May 2018. 
Data Collection and Study Instruments 
After informed consent was obtained, each subject was assigned a unique 
identification number which was used to label biological samples, questionnaires and 
medical report extracts. One patient key recording the subject’s name and their respective 
identification number was made and kept in a secured and locked cabinet at the clinic. 
Three sources of data were used to retrieve all information from each subject after 
informed consent was obtained. A supplemental smoking questionnaire (SSQ; appendix 
A) was given to each subject to measure and record active (current and lifetime) and SHS
exposures (recent and the past year). Information from medical records were extracted to 
obtain demographic data, medical history and other relevant variables. Laboratory assays 
were done on urine samples collected to assess cotinine and NAT2 acetylator status. 
Subjects were then followed to determine whether the subject conceived. Among those 
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who conceived, pregnancy outcomes were also collected. Patients who gave permission 
to be recontacted by email, phone or mailing address, were contacted after a period 
greater than 6 months from enrollment to record any fertility treatments/procedures, and 
conception and pregnancy outcomes. Medical records were re-reviewed at least 6 months 
after the end of enrollment to update fertility treatments/procedures and pregnancy 
outcomes. The subjects who gave permission were personally recontacted twice: 
September 2018 through January 2019 and July 2019 through September 2019, to obtain 
further information on conception and pregnancy outcomes. 
 
Study Instrument – Supplemental Smoking Questionnaire  
The SSQ (appendix A) was used to estimate current and the previous years’ 
tobacco smoke exposure, for both active and SHS exposures. Questions used were 
initially adapted from two nationally validated surveys: the National Health and Nutrition 
Examination Survey III and the National Health Interview Survey but were revised to 
more precisely address the research questions and the population of the LOUSSI study. 
There were three questionnaires provided: one each for current smokers, former smokers 
(women who quit over a month ago), and non-smokers. The current and former smokers’ 
questionnaire contained questions regarding the total amount of years smoking and 
number of cigarettes or packs smoked per day. The former smoker’s questionnaire also 
included the month and year the participant last smoked.  
All questionnaires included three questions to assess SHS exposures (recent and 
the past year) measured using a four-point scale (never (1), rarely (2), often (3) and every 
day (4)). Early childhood SHS exposure was assessed by asking subjects “how often were 
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you exposed to secondhand smoke inside your home while growing up?” There were two 
questions regarding SHS exposures in the past year, specifically “how often were you 
exposed to secondhand smoke inside your home in the past year?” and “how often have 
you been exposed to secondhand smoke inside other places besides your home (example: 
a friend or relative’s house, your workplace, bars or restaurants, in your car or someone 
else’s car) in the past year?” The questionnaires were later modified and approved by the 
IRB in July 2017 to include questions asking if the participant is living with smoker/s; 
and if so, how many smokers and their relationship to the smokers. Lastly, the revised 
version also included a question regarding other sources of nicotine such as nicotine gum 
and e-cigarettes, since their use would be reflected by cotinine in the urine sample. 
Study Instrument – Medical Record Data 
The medical record data collection form (appendix B) was created to document 
important risk factors of both fertility-related outcomes and tobacco smoke exposure, 
based on the current literature. Research assistants trained by co-investigators and 
research physicians extracted the information from the subject’s intake history form and 
medical records. 
Variables collected from the medical record are listed below: 
• Demographics (date of visit, age at enrollment, ancestry or race);
• Anthropometrics and physiological characteristics (height, weight, BMI, and blood
pressure); 
• Social history and behavioral variables (occupation, marital status, partner status,
length of time with current partner, routine exercise; hours of exercise per week, 
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times per week and type of exercise; routine exposure to chemicals, diet restrictions, 
how many meals per day, current tobacco use; packs per day with total amount of 
years smoked; ever smoked 100 cigarettes; alcohol consumption; number of alcoholic 
drinks per week; caffeine consumption; number of caffeinated drinks per week and 
use of other drugs); 
• Obstetrics and gynecology (OB/Gyn) variables (gravidity, regularity of periods,
average menstrual cycle length, age at menarche, consistent ovulation, and history of 
sexually transmitted infections); 
• Reproductive measurement variables (AMH values and dates, AFC values and dates,
duration of infertility, type of infertility diagnoses and self-reported PCOS); 
• Medically assisted reproduction variables (any MAR procedures done after
enrollment, date of procedures, and type of treatment (OI/IUI/IVF/FET)); 
• Conception (first clinical conception outcome since enrollment, method of the first
conception since enrollment, last menstrual period of first conception or date of 
conception (for OI/IUI/IVF/FET), expected due date); 
• Pregnancy outcomes (first pregnancy outcome since enrollment).
Data Source – Cotinine Assays 
Each urine sample collected at enrollment, labelled with the corresponding 
patient’s identification number was divided into two samples: one for cotinine analysis 
and the other for DNA extraction to perform NAT2 genotyping. All urine samples for 
cotinine analysis were stored at 4 degrees Celsius for up to 72 hours and then aliquoted 
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and frozen at -80 until the day of the cotinine assay. Cotinine assays were done at the 
University of Louisville’s Medical Dental Research Building. 
Cotinine ELISA kits (Calbiotech, Spring Valley, CA) were used to measure the 
patient’s cotinine levels to differentiate active, passive and no exposure to tobacco smoke 
in the past 24 to 72 hours. Standard controls and a negative control (water) were done in 
triplicate, while patients’ samples were either assayed in triplicate or duplicate. A 
spectrophotometer was used to measure the absorbances of the standards, controls and 
samples. The mean, standard deviation and relative standard deviation were calculated 
for all absorbances. Outliers among triplicate samples were removed, and if the relative 
standard deviation was greater than 0.1, the sample was re-assayed in triplicate. 
 Firstly, a standard curve was constructed by plotting the mean absorbances of the 
cotinine standards versus the cotinine standard concentrations on a line graph. Using the 
fitted standard curve, cotinine concentrations of each subject was derived from their 
corresponding average absorbance. Urinary cotinine concentrations were estimated to the 
nearest 0.50ng/mL and the maximum detectable level of cotinine for this assay kit was 
100ng/mL. All assay analyses were done by two research assistants and compared to 
increase the accuracy and reliability of results. 
 
Data Source – Genotyping Assays 
DNA was extracted using the ZR Urine Isolation Kit TM (Irvine, CA, USA). DNA 
extractions were done on a weekly basis then stored at -20 degrees Celsius until time of 
genotyping. NAT2 genotyping was done at the University of Louisville’s Clinical and 
Translational Research building.   
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NAT2 acetylator status was assessed using a four SNP genotype panel with the 
assistance of a trained laboratory technician. Twenty percent or more of the samples in 
each batch were done in duplicate along with a negative control (blank or water). If the 
genotype status was not clear from the four SNPs due to a lack of DNA amplification or 
contamination, samples were repeated in duplicate if there were remaining DNA. All 
assay analyses were done by two research assistants and compared to increase the 
accuracy and reliability of results. 
Different alleles of NAT2 have been associated with rapid and slow acetylation. 
The four SNPs (rs1801279(191G>A), rs1801280(341T>C), rs1799930(591G>A), 
rs1799931(857G>A)) were coded by the number of variants. If the subject had no 
variants among the four SNPs, they were classified as a rapid acetylator; one variant 
classified them as an intermediate acetylator and two or more variants as a slow 
acetylator (Table 5). Intermediate and rapid acetylators were grouped together as they 
have been shown in the literature to have similar acetylation characteristics (14). 
Table 5. Example of NAT2 Phenotype Status Using Four (4) SNPs 
SNP 191 341 590 857 # of variant alleles Phenotype 
Patient A 0 0 0 0 0 Rapid 
Patient B 0 0 1 0 1 Intermediate 
Patient C 1 0 1 0 2 Slow 
Patient D 1 1 0 1 3 Slow 
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Study Instrument – Recontact Questionnaire 
Subjects who agreed to be recontacted by either phone, email or mailing address 
as indicated on their informed consent were contacted at least 6 months after enrollment 
to obtain information on fertility treatments/procedures, and conception and pregnancy 
outcomes. If an email address was provided, an initial email was sent out to notify 
subjects of the recontact and they were given the option to answer the questions by email 
or reply with convenient times to call via phone. The next method was phone call, if a 
phone number was given and working. Three attempts were made, leaving a brief 
voicemail if no one answered. If no contact was made, another email with the questions 
was sent. And lastly, if mailing addresses were given and up to date, a letter was mailed 
using the U.S. postal service as a final attempt to recontact the patient.  
Using the recontact questionnaire (appendix C), they were first asked “Have you 
conceived since enrollment in the LOUSSI Study(yes/no)”. If the subject answered yes, 
they were then asked whether it was a natural conception or if they used MAR 
procedures. The type of MAR procedure used and its date, if conception was attained, the 
last menstrual cycle date or conception date, the due date of the first conception, whether 
or not they were currently pregnant, and the pregnancy outcome were recorded. If the 
subject answered that they had not conceived since enrollment, they were asked whether 
or not they were still trying to conceive. If they were no longer trying, they were then 
asked how long after enrollment did they stop trying and if they were using any form of 
contraception. Subjects were recontacted twice after enrollment ended, firstly from 
September 2018 through January 2019 and then from July 2019 through September 2019 
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to obtain further information on conception and pregnancy outcomes if they gave 
permission. 
Data collection and entry, as well as assay analyses for all sources of data were 
done by two trained research assistants and compared for accuracy. Discrepancies were 
resolved by reviewing the medical records and hard copies of the SSQ. 
 
Outcome Assessment 
Conception outcomes were either extracted from medical records or from the 
patients who were successfully recontacted. For this study, the first conception and 
corresponding pregnancy outcome since enrollment were used in the analysis.  
Follow-up time measured in months or TTC, for those who conceived was 
prospectively observed and measured by calculating the number of months between 
enrollment and first conception, including the month of enrollment and the month of 
conception. This was a straightforward calculation for spontaneous conceptions, by 
subtracting the month of enrollment from last menstrual cycle and adding 2.  For subjects 
who had MAR procedure(s), their TTC was calculated in cycles/intervals at risk with 
MAR cycles used as a time-varying covariate from enrollment to first conception.  
Among those who did not conceive and did not use MAR during the study period, 
follow-up time measured in months was calculated from enrollment to either the date of 
the last visit at the clinic in the medical record that indicated that the subject was not 
pregnant or month of last personal re-contact, if the permission was given. For subjects 
who had MAR procedure(s) and did not conceive, their follow-up time was calculated in 
intervals at risk with MAR cycles as a time-varying covariate from enrollment to the 
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same endpoints stated above based on whether or not they gave permission to re-
contacted. 
If subjects were seen only once at the clinic, were not personally recontacted, and 
did not have at-risk follow-up time, they were removed from the TTC analysis. Months 
with contraception use and months noted on subject’s medical record that intercourse was 
advised against, were excluded from the follow-up time because the subjects were 
theoretically not at risk for pregnancy during those months. Same-sex couples who did 
not use MAR after enrollment were also excluded from the TTC analysis. 
Pregnancy outcomes of the first conception since enrollment were either extracted 
from medical records or retrieved from successful recontact. The answers included live 
birth, SA, ectopic pregnancy, molar pregnancy and stillbirth or fetal death. Live birth and 
SA were used in the analysis due to lack of events in the other categories. 
Exposure Assessment - Current, Active Smoking 
Current, active smoking was measured and assessed using the SSQ and cotinine 
levels. A current, active smoker by the SSQ was defined when the subject self-reported as 
a current smoker or if the subject reported quitting smoking under a month ago. Also, if 
any subject had a urinary cotinine level of 100ng/mL, they were defined as a current, 
active smoker, regardless of which questionnaire was filled out, otherwise were defined 
as a nonsmoker. 
A cumulative lifetime smoking variable using pack-years was created by 
multiplying the number of packs of cigarettes smoked per day by the number of years the 
person has smoked. For example, 1 pack-year is equal to smoking 1 pack per day for 1 
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year. If the participant reported number of cigarettes per day, that number was initially 
divided by 20 to convert it to packs. The pack-years variable was further categorized into 
three groups. Subjects with no pack-years (referent) was compared to pack-years of 5 or 
less and pack-years greater than 5. Self-reported smokers and former smokers provided 
either the number of cigarettes smoked per day or the number of packs smoked per day, if 
it were the latter, that number was multiplied by 20. The total number of cigarettes per 
day for all subjects was also calculated and grouped into three categories: 0 cigarettes 
(referent), 9 cigarettes or less and greater than or equal to 10 cigarettes. 
 
Exposure Assessment – SHS Exposure (Recent and Past Year) 
Recent and the past year’s SHS exposure was assessed for only women defined as 
nonsmokers, using the objective measure described above. Current, active smokers were 
excluded from the SHS analysis. To examine current SHS exposure, cotinine values were 
categorized into three groups.  Subjects with cotinine values of 0 ng/mL were place in an 
unexposed group (referent), values greater than 0 ng/mL and less than 4.0 ng/mL were 
considered as low exposure; and cotinine values greater than or equal 4.0 ng/mL and less 
than 100 ng/mL were considered highly exposed to SHS.  
Using the SSQ, a score was created for adult SHS exposure in the past year. The 
two SHS exposure questions on the SSQ “how often were you exposed to secondhand 
tobacco smoke in your home in the past year?” and “how often were you exposed to 
secondhand tobacco smoke in other places such as work, restaurants, friends and family’s 
homes in the past year?” were combined to create the score. The responses to each 
question were given a numerical value as follows: never (1), rarely (2), often (3) and 
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every day (4) and summed. The combined score for adult SHS exposure in the past year 
variable ranged from 2 to 8 and was grouped into 4 categories. A description of how the 
SHS exposure in the past year variable was categorized is presented in Table 6. 
Table 6. Description of SHS Exposure in the Past Year Variable from SSQ 
Score Answers to 2 SHS Questions 
from SSQ  (SHS in the home, 
SHS in other places) 
4-Level Group Final 
Grouping 
2 (never, never) None (0) 
Low SHS 
exposure 3 (never, rarely) Low (1) 
4 (never, often) or (rarely, rarely) Intermediate (2) 
High SHS 
exposure 
5 (never, everyday) or (rarely, often) Intermediate (2) 
6 (rarely, everyday) or (often, often) High (3) 
7 (rarely, often) High (3) 
8 (everyday, everyday) High (3) 
Exposure Assessment – Combined Effect Exposure 
A combined effect variable using the objective, current active smoking variable 
and the final SHS exposure variable from the SSQ was created. The new combined effect 
variable included three groups: non-smokers with low SHS exposure (referent), non-
smokers with high SHS exposure and current, active smokers. Table 7 shows the 
treatment of all exposure variables used in this study. 
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Table 7: Exposure Variable Definitions and Treatment in Modeling 
Variable Definition 
Current, active smoking 
Dichotomous 
Smoker (1) = Cotinine level of 100 ng/mL or Self-
reported as a Current Smoker 
Non-Smoker (0) = Cotinine level < 100 ng/mL and 
No Self-report of Current Smoker (Referent) 
Pack-years 
Categorical 
0 = 0 pack-years (Referent) 
1 = ≤ 5 pack-years 
2 = > 5 pack-years 
Total Number of cigarettes 0 = 0 cigarettes per day 
Categorical 1 = ≤ 9 cigarettes per day 
2 = ≥10 cigarettes per day 
Cotinine* 
Categorical 
0 = 0 ng/mL (Referent) 
1 = 0 < cotinine ≤ 4 ng/mL 
2 = ≥ 5 ng/mL 
Adult SHS exposure in the 
past year* 
Categorical
No/Low 
Intermediate/High 
Adult SHS Score ≤ 3 (Referent) 
Adult SHS Score  4 
Combined effect exposure 
(Current, Active Smoking and 
Adult SHS Score) 
Categorical Non-smoker with Low Adult SHS exposure 
(Referent) 
Non-smoker with High Adult SHS exposure 
Current, Active Smokers 
* - Among objectively defined non-smokers
Important Covariates 
Relevant covariates were chosen based on a theorized directed acyclic graph 
(DAG) developed from a priori knowledge and were either collected at time of 
enrollment if it was the patient’s first visit or extracted from the medical record at time of 
the first clinic visit. These included age at the time of enrollment, BMI recorded by the 
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clinic at time of enrollment, ethnicity/race, gravidity, age of menarche, average cycle 
length, menstrual cycle regularity, history of previously diagnosed sexually transmitted 
diseases, marital status, current routine exercise, alcohol consumption, caffeine 
consumption, AMH level, self-reported length of infertility, ART treatment cycles, type 
of ART treatment, and infertility diagnoses.  
Age at enrollment, BMI at enrollment, gravidity, average cycle length, age of 
menarche, self-reported length of infertility and AMH levels were recorded continuously. 
Menstrual cycle regularity, history of past diagnosed sexually transmitted diseases, 
marital status, routine exercise, alcohol consumption, caffeine consumption and MAR 
cycle were dichotomized no or yes. Ethnicity was recorded as Caucasian, African 
American, Asian/Pacific Islander, American Indian/Alaska Native, Middle Eastern, 
Hispanic/Latin American and other. Lastly, the type of infertility diagnosis was collected 
and included unexplained, tubal, uterine, ovarian, male factor, PCOS, other, unknown 
and none. The infertility diagnoses were not mutually exclusive, and many women had 
more than one diagnosis.  
 
Data Analysis 
Descriptive Statistics 
All statistical analyses were performed using R Studio version 1.2.5 (Boston, MA, 
USA). Descriptive statistics were calculated for covariates to examine their distributions. 
Univariate analyses were conducted to examine the crude association between covariates 
and exposure variables from Table 7 within three different populations (all individuals, 
MAR users, and non-MAR users). This was done using Chi-square/Fisher exact test for 
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categorical variables and Student’s T-test for normally distributed, continuous variables 
or Wilcoxon rank-sum for non-normally distributed, continuous variables. Significant 
differences were defined with  p-value <0.05. 
Covariates in the final multivariable logistic regression and survival analysis 
models were initially chosen using both theory and data-based methods. Covariates 
associated with the exposure with a p-value of less than 0.2 from univariate analyses 
were included. However, age and BMI were retained in all models regardless of p-value 
given their well-established associations with fertility or birth outcomes. Table 8 shows 
the description and treatment of all chosen covariates used in the final models. Age was 
dichotomized at the median, which demonstrated a shift in fecundability in this 
population; BMI was dichotomized at the WHO’s obesity threshold (30 kg/m2). Age and 
BMI had been previously shown to have a non-linear association with fecundability in 
past studies. Race was dichotomized into African American and other races because it 
showed the most significant association with pregnancy within the dataset compared to 
other categorizations. 
Table 8: Covariate Definitions and Treatment in Modeling 
Variable Type of variable Definition 
Age (years) Dichotomous (at median) 0 =  33    1 = > 33 
BMI (kg/m2) Dichotomous 
Continuous (Aim 2) 
0 =  30    1 = > 30 
MAR cycle Dichotomous 0 = No       1 = Yes 
Gravidity Dichotomous  (Aim 2) 
Categorical (Aim 1) 
0 = no prior pregnancies 
1 = ≥ 1 prior pregnancy 
0 = no prior pregnancies 
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 1 = 1 prior pregnancy 
2 = ≥ 2 prior pregnancies 
 
Marital Status Dichotomous 0 = No       1 = Yes 
 
Race Dichotomous 0 = Other races  
1 = African American  
 
Alcohol Use  Dichotomous (Aim 2) 0 = No        1 = Yes 
 
NAT2 Acetylator 
Status 
Dichotomous 0 = Fast/Intermediate 
1 = Slow 
 
MAR Type* Dichotomous 0 = OI/IUI  1 = IVF/FET 
* - Used only when modeling MAR cycles only population 
 
Multivariable Models 
Survival Analyses - Cox Proportional Hazard Regression Models 
 The dataset for survival analyses was constructed in a counting process structure 
to include MAR cycle as a time-varying covariate. Each row in the dataset indicated a 
time interval in months at risk for conception, categorized by whether or not the month 
was a MAR cycle. The coxph and surv function in the survival package was used to run 
Cox models. A cluster term for participant’s ID was included in the model to show that 
participants may have multiple rows of data and produced estimates with robust standard 
errors to address non-independence. Start time was defined as the month of enrollment 
(time 0) and the stop time referred to either the month the subject had the event 
(conception) or the month the subject was censored. Month of censorship was defined by 
either the date of last re-contact, the date of last medical record visit, or the date the 
subject reported last actively trying to conceive.  
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A statistical test using the cox.zph function was used to assess the proportional 
hazards assumption on all variables in the full models. The test examined the correlation 
between survival time (or ranked survival times) and Schoenfeld residuals. A p-value less 
than 0.05 indicated that the proportional hazards assumption was violated and the 
Schoenfeld residuals were dependent on survival time. If this were the case, the 
appropriate models were adjusted for an interaction term of the variable in violation and 
time. 
All models were evaluated for multicollinearity using variance inflation factors 
using the vif function in the rms package, before and after confounding assessment. 
Confounders were assessed using a combination of theory and data-based approaches. 
The full models were initially fitted and variables that changed the estimate of the main 
exposure by 10% when removed from the model were defined as data-based 
confounders, and hence remained in the model. Age and BMI, however, were retained in 
all models because of the consistent and strong evidence of associations with fertility in 
the literature. Statistically significant variables were defined by a p-value less than 0.05. 
There were six different exposure variables, and each were examined within the 
following sub-populations:  all follow-up time, MAR cycles only, and natural conception 
(NC) follow-up time only. Women in the natural conception follow-up sub-population 
contributed intervals of at-risk follow-up time for natural conception and did not use 
MAR procedures during these intervals. The number of NC follow-up was estimated 
using calendar months, as there was not data on ovulation available. 
Among all follow-up time models, the time-varying MAR cycle variable (yes/no) 
was included as a covariate.  In the model that included MAR cycles only, the MAR type 
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in the MAR cycle (IVF/FET vs. OI/IUI) was included as a time-varying covariate, as it 
changed over intervals. Within these two sub-populations, models were analyzed using 
Extended Cox regression because they included a time-varying covariate; whereas, the 
NC follow-up time models used Cox proportional hazards regression. Hazard ratios of 
fecundability also called fecundability ratios (FR) and 95 % confidence intervals were 
estimated and reported. Main exposure variables with two or more categories such as 
cotinine levels among non-smokers and the combined effect variable were further 
examined ordinally for a dose-response effect, and their respective p-values for trend 
were reported.  
Specific Aim 1a: Current, Active Smoking and Fecundability 
The effect of current, active smoking on fecundability was assessed using survival 
analysis. The objectively measured smoking variable was used to compare current, active 
smokers to non-smokers. The effect of cumulative lifetime smoking on TTC was also 
analyzed, using pack-years as exposure. Fecundability ratios and 95% CI’s were 
calculated and adjusted for potential confounders. 
Specific Aim 1b: Recent and Past Year’s SHS Exposure and Fecundability 
The effect of recent and past year’s SHS exposure on fecundability was assessed 
using survival analysis among non-smokers. Firstly, current SHS exposure was assessed 
using urinary cotinine levels collected at enrollment. Secondly, the SHS exposure scores 
from the SSQ was used to compare low and high SHS exposure in the past year. 
Fecundability ratios and 95% CI’s were calculated, adjusted for potential confounders. 
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Specific Aim 1c: Combined Effect of Active Smoking With SHS Exposure and 
Fecundability  
The combined effect variable using current, active smoking and SHS score in the 
past year on fecundability was assessed using survival analysis. Current smokers and 
nonsmokers with high SHS exposure was compared to nonsmokers with low SHS 
exposure. A dose-response effect or trend test was estimated by modelling the 3-level 
categorical variable, ordinally. Fecundability ratios and 95% CI’s for were calculated, 
adjusted for potential confounders.  
 
Specific Aim 1d: Interaction of Active Smoking With NAT2 Acetylator Status and 
Fecundability 
Effect modification by NAT2 acetylator status on current smoking and 
fecundability was examined by adding an interaction term for current, active smoking 
and NAT2 acetylator status to the full model from the survival analysis in specific aim 
1a. Fecundability ratios and 95% CI’s were calculated, adjusted for potential 
confounders. Significant interaction was defined with a p-value <0.05 for the interaction 
term. 
 
Multivariable Logistic Regression Models 
The effect of tobacco smoke exposures on spontaneous abortion versus live birth 
was examined using multivariable logistic regression, among women who conceived. 
Pregnancy outcomes variable was defined as either a live birth (0) or spontaneous 
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abortion (SA)/miscarriage (1). The different tobacco smoke exposures from Table 7, 
were analyzed with the pregnancy outcomes among all women who conceived. 
Variables chosen for the full models included age, BMI, gravidity, marital status, 
race and alcohol consumption, because of its known association with spontaneous 
abortion. All models were evaluated for multicollinearity using variance inflation factors 
with the vif function in the rms package, before and after confounding assessment. 
Similar to Aim 1, age and BMI were retained in all models. Dose-response relationships 
were assessed for exposure variables with more than 2 categories, by treating the variable 
ordinally and their respective p-values for trend were reported. 
Specific Aim 2a: Current, Active Smoking and Spontaneous Abortion 
The effect of current, active smoking on the probability of SA was assessed using 
multivariable logistic regression, comparing current active smokers to non-smokers. A 
dose-response relationship was also assessed, using the total number of cigarettes per 
day. The cumulative lifetime smoking on probability of pregnancy outcome was analyzed 
using pack-years. Odds ratios and 95% CI’s were calculated, adjusted for potential 
confounders. 
Specific Aim 2b: Recent and Past Year’s SHS Exposure and Spontaneous Abortion 
The effect of recent and past year’s SHS exposure among nonsmokers on 
probability of SA was assessed using multivariable logistic regression. Firstly, current 
SHS exposure was assessed using urinary cotinine collected at enrollment, grouped into 3 
categories. Secondly, SHS exposure in the past year variable from the SSQ was assessed 
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comparing high SHS exposure to low SHS exposure in the past year. Odds ratios and 
95% CI’s were calculated, adjusted for potential confounders. 
Specific Aim 2c: Interaction of Active Smoking With NAT2 Acetylator Status and 
Spontaneous Abortion 
Effect modification by NAT2 acetylator status on probability of SA was 
examined by adding an interaction term for current, active smoking and NAT2 acetylator 
status to the full multivariable logistic regression model from Aim 2a. Odds ratios and 
95% CI’s were calculated, adjusted for potential confounders. 
Specific Aim 2d: Combined Effect of Active Smoking and SHS Exposure and 
Spontaneous Abortion 
The combined effect variable using current, active smoking and SHS score in the 
past year on probability of SA was assessed using multivariable logistic regression. 
Current smokers and nonsmokers with high SHS exposure was compared to nonsmokers 
with low SHS exposure. A dose-response effect or trend test was estimated by modelling 
the 3-level categorical variable, ordinally. Odds ratios and 95% CI’s were calculated, 
adjusted for potential confounders. 
Selection Bias 
Specific Aim 3a: Evaluation of Selection Bias due to Loss to Follow-up 
The full dataset included women that contributed no follow-up time (n=257). The 
dataset was divided into two groups: Group 1 contained women that were not asked 
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permission to be personally followed up and Group 2 contained the remaining women 
who were asked permission for personal follow-up. The groups were then each stratified 
by the type of follow-up they received: either no follow-up, follow-up through medical 
record only or personal follow-up by phone, email or mailing address only. 
Characteristics of women in each group were then compared by the type of follow 
up they received to evaluate the potential for selection bias due to loss to follow-up also 
known as attrition bias or differential loss to follow-up. Group 1 compared women with 
no follow-up data (n=21) to those with only medical record follow-up (n=74), whereas 
group two compared no follow-up (n=7) to medical record follow-up only (n=35) and to 
personal follow-up only (n=120). Differences between types of follow-up within each 
group were assessed using Chi-square/Fisher exact test for categorical variables and 
Student’s T-test for normally distributed, continuous variables or Wilcoxon rank-sum for 
non-normally distributed, continuous variables. Significant differences were defined with 
p-value <0.05. If there were no significant differences among Group 2 between medical 
record follow-up only and to personal follow-up only, then Group 1 and Group 2 would 
be combined and women with no follow-up would be compared to women with follow-
up. 
Specific Aim 3b: Inverse Probability Weighting 
Current smoking was significantly associated with attrition, in that smokers were 
more likely to be censored (lost to follow-up). Inverse probability weighting (IPW) was 
used to account for differential loss to follow-up and for the aforementioned confounding 
variables to examine the associations between current smoking status and the 
91 
development of two outcomes: conception as a dichotomous variable (yes/no) and 
fecundability as the probability of conception over the entire follow-up period. 
IPW: Conception Outcome - Dichotomously 
To adjust for confounding using IPW, a pseudo-population was made by 
weighting each subject by the reciprocal (inverse) of the conditional probability of being 
a smoker conditional on MAR cycle, age, BMI, gravidity, marital status and race, such 
that in the pseudo-population there is no relationship between smoking and the 
aforementioned confounders. The denominator of the stabilized inverse probability 
weights was estimated fitting a logistic regression of being a smoker, conditioned on 
MAR cycle, age, BMI, gravidity, marital status and race. While the numerator of the 
stabilized inverse probability weights was estimated by fitting a logistic regression model 
for the probability of being a smoker with only the intercept. 
The geeglm function in the geepack package in R was used to fit a generalized 
estimating equations (GEE) model using a robust variance estimator to allow for 
correlated observations created by weighting. The GEE model was fitted to examine the 
association of smoking on conception in the weighted pseudo-population adjusted for 
confounding. The inverse-probability weighted ORs adjusted for confounding, along with 
95% CIs were reported and compared to the estimates from the original aims. 
Selection bias due to loss to follow-up was also adjusted for using IPW. A 
pseudo-population was made by weighting each subject by the reciprocal (inverse) of the 
probability of being uncensored conditional on age, BMI, gravidity, race and current 
smoking. The denominator of the stabilized inverse probability weights was estimated by 
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fitting a logistic regression model for the probability of being uncensored, conditional on 
current smoking, age, BMI, gravidity and race. While the numerator of the inverse 
probability weights was estimating using a logistic regression model for the probability of 
being uncensored, conditioned on only smoking.  
The stabilized inverse probability weights estimated from confounding and 
selection bias due to loss of follow-up were multiplied, to adjust for them simultaneously. 
The GEE model was fitted to examine the association of smoking on conception in the 
weighted pseudo-population adjusted for both confounding and selection bias. The 
weighted ORs adjusted for both confounding and selection bias to loss of follow-up, 
along with 95% CIs were reported and compared to the estimates from previous aims. 
These steps were then repeated to adjust for confounding and selection bias due to loss to 
follow-up among non-MAR users and estimates were documented and compared.  
 
IPW: Fecundability  
Confounding and selection due to loss of follow-up within the fecundability data 
were adjusted for separately and jointly using IPW, with the ipwtm function in the ipw 
package in R. The function was used to estimate stabilized inversed probability weights 
at each time interval at-risk during follow-up, taking into account fixed and time-varying 
confounders. The longitudinal data was coded in the counting process format and was 
used to fit Cox proportional hazard models.  
 Stabilized inverse probability weights to adjust for confounding only were 
estimated by fitting two Cox proportional hazard models. The denominator of the 
stabilized inverse probability weights was estimated from a model that examined 
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probability of smoking at each time-interval, given MAR cycle, age, BMI, gravidity, 
marital status and race. While, the numerator of the stabilized inverse probability weights 
was estimated by fitting a logistic regression model for the probability of being a smoker 
with only the intercept at each time-interval. The stabilized time-interval-specific weights 
were then used to fit a marginal structured model (MSM) that assessed the effect of 
smoking on fecundability, to estimate measures of association adjusted for confounding 
only. Inverse-probability weighted FRs adjusted for confounding, along with 95% CIs 
were reported and compared to the estimates from original aims. 
Selection bias due to loss of follow-up was adjusted for using stabilized inverse 
probability of censoring weights similarly to the weights used for confounding 
adjustment. The denominator of the stabilized inverse probability weights was estimated 
by fitting the regression model for the probability of being uncensored at each time-
interval, conditional on current smoking, age, BMI, gravidity and race. While the 
numerator of the inverse probability weights was estimating using a regression model for 
the probability of being uncensored, conditioned on only smoking at each time-interval. 
Stabilized inverse probability of censoring weights were then used to fit a MSM that 
assessed the effect of smoking on fecundability. 
The stabilized inverse probability weights from confounding and selection bias 
due to loss of follow-up were multiplied to adjust for them simultaneously. The stabilized 
time-interval-specific weights were then used to fit a MSM that assessed the effect of 
smoking on conception, to estimate measures of association adjusted for confounding and 
selection bias due to loss of follow-up. Inverse-probability weighted FRs adjusted for 
both confounding and selection bias to loss of follow-up along with 95% CIs were 
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reported and compared to the estimates from previous aims.  These steps were then 
repeated to adjust for confounding and selection bias due to loss to follow-up among NC 
follow-up time and estimates were documented and compared. 
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V. RESULTS 
Among 264 participants enrolled in the LOUSSI study, seven women were 
excluded: three were under the age of 21 and four were found to be pregnant at the time 
of enrollment. Out of the remaining 257 women, 229 (89.1%) were successfully followed 
up after baseline either through information extracted from medical records and/or if they 
gave permission through personal re-contact via phone, email or postal mail. Figure 2 
illustrates the follow-up methods of participants with and without permission to 
recontact. 
Figure 2: Study Flow Diagram Showing Follow-Up Data among Participants 
All participants enrolled in the LOUSSI study 
264 
GROUP 2 
Participants who were asked to be 
personally recontacted (#100 – 264) 
162 (3 were excluded above) 
Lost to follow-up  
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21 
Successful follow-up 
(using medical records) 
74 
6 of the7 that declined 
permission were followed 
up through medical 
records 
Successful follow-up  
(only medical records) 
35 
Successful follow-up (only 
personal recontact) 
120 
6 lost to follow-up 
7 declined permission 
GROUP 1 
Participants who were not asked to be 
personally recontacted (#1-99) 
95 (4 were excluded above) 
7 excluded 
(Under 21 years of age or 
pregnant at enrollment) 
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Of the 120 women who were personally recontacted from Group 2, five women 
reported that they did not continue to pursue conception since enrollment and one women 
did not provide TTC data at recontact, hence these 6 women did not contribute at-risk 
months and were removed. These 114 women in addition to the women followed up by 
medical record only (74 women from the Group 1 and 35 women Group 2), brought the 
final sample size for the fecundability analyses to 223 women. These 223 women were 
followed up to 28 months and contributed a total of 1,967 at-risk months (median: 7 
months; Q1-Q3: 3 - 15 months). 
Figure 3 shows the distribution of conception and pregnancy outcomes by MAR. 
Among the 223 women with TTC data, 83 (37.2%) had a documented and/or self-
reported pregnancy since enrollment. Among the total 83 pregnancies reported, there 
were documented or self-reported pregnancy outcomes for 72 pregnancies. Of the eleven 
women with missing pregnancy outcomes, 5 were still pregnant at the end of follow-up 
from Group 2 and 6 were from Group 1 that did not return to the clinic. These eleven 
women were excluded from the SA analysis. Forty-one (56.9%) of the documented 
pregnancy outcomes were live births, and 31 (43.1%) were SAs. Among the 130 (58.3%) 
women who did not use any MAR treatment since enrollment, 29 (22.3%) had 
spontaneous pregnancies. Of the 93 women who had at least one MAR treatment since 
enrollment, 47 (50.5%) had successful MAR treatments resulting in a pregnancy and 7 
(7.53%) had a spontaneous pregnancy after unsuccessful MAR treatments. 
Within the study population (n=223), fifty-four (24.2 %) were verified as current, 
active smokers, 112 (50.2%) were nonsmokers with low SHS exposure, and 57 (25.6%) 
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were nonsmokers with high SHS exposure. Cotinine levels were correlated with self-
reported SHS exposure (r = 0.39, p < 0.001) among all women. 
Figure 3: Flow Diagram of Conception and Pregnancy Outcomes 
Descriptives Statistics 
Descriptive analyses were conducted for four different tobacco smoke 
comparisons of active and second-hand smoke exposures within the full study population 
(n=223). The four different smoking status comparisons included: 1) current smokers (n= 
54) versus former or never-smokers (n=169 ); 2) current SHS exposure via urinary
cotinine among nonsmokers with any exposure (cotinine >0 ng/mL) (n=78)  vs.  
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unexposed (cotinine=0 ng/mL, n=82);3) self-reported SHS exposure in the past year via 
the SSQ score among nonsmokers: high SHS exposure = score ≥ 4 (n=57) compared to 
low SHS exposure = score ≤ 3 (referent, n=112); and 4) nonsmokers with low SHS 
exposure score (referent, n=112) were compared to nonsmokers with high SHS exposure 
score (n=57) and current smokers (n=54). We additionally stratified analyses by MAR to 
examine women that used MAR after enrollment (n=130) and women who did not use 
MAR prior enrollment (n=93) (Appendix D Table S1-8).  
In all descriptive tables, categorical variables are presented with N(%), normally 
distributed continuous variables are presented with their mean ± standard deviations (SD) 
and continuous variables that did not follow a normal distribution are presented with their 
median and interquartile range(Q1-Q3). 
 
1) Current Active Smokers Compared to Current Nonsmokers 
Table 9 shows the characteristics of all 223 women with follow-up time, stratified 
by current active smoking. Smokers were defined as women with a cotinine level of 
>=100 ng/mL or who had self-reported as a current smoker. A nonsmoker was defined as 
anyone with a cotinine level < 100 ng/mL and did not self-report as a current smoker.  
Current smokers had longer average menstrual cycle lengths (P = 0.01), were 
more likely to have a previous STD (P = 0.07), less likely to be married (P <0.001), less 
likely to exercise (P = 0.10), more likely to be of African American race (P <0.001), 
more likely to not use MAR (P <0.001) and more likely to have a SA (P = 0.03) 
compared to nonsmokers. Cotinine levels were also significantly correlated with current 
active smoking (r=0.98, p-value <0.001). Descriptive statistics comparing current 
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smokers and nonsmokers stratified by MAR can be found in the Appendix D (Table S1-
2). 
Table 9 : Characteristics among Women with Follow-up Data Stratified by Current 
Smoking (N=223) 
Nonsmoker 
N = 169 
Current Smoker 
N = 54 
P - value 
Cotinine Levels, mg/dL 
median (Q1-Q3) 
0.00(0.00-4.00) 100(100-100) <0.001 
Cotinine Categories, n (%) <0.001 
0 mg/dL 82(51.25) 0(0.00) 
<100 mg/dL 78(48.75) 2(3.85) 
100mg/dL 0(0.00) 50(96.15) 
Age in years,  
median (Q1-Q3) 
33.00(28.00-37.00) 32.50(27.25-36.00) 0.48  
Age in years, n (%) 0.59 
≤33 91(53.85) 32(59.26) 
>33 78(46.15) 22(40.74) 
BMI, median (Q1-Q3), 
(kg/m2)  
28.54(24.82-35.17) 30.36(26.77-34.46) 0.22 
BMI Category kg/m2, n 
(%) 
0.31 
<25 (Underweight and 
Normal) 
46(27.22) 11(20.37) 
25 - 29.9 (Overweight) 49(28.99) 13(24.07)  
≥ 30 (Obese) 74(43.79) 30(55.56) 
BMI kg/m2, n (%) 0.18 
≤30 95(56.21) 24(44.44) 
>30 74(43.79) 30(55.56) 
Gravidity, n (%) 0.44 
0 74(43.79) 19(35.19) 
1 38(22.49) 12(22.22) 
>=2 57(33.73) 23(42.59)  
Regular Period, n (%) 1.00 
100 
No 58(34.32) 18(33.33) 
Yes 111(65.68) 36(66.67) 
Average Cycle Length 
(days), median (Q1-Q3) 
28.00(27.50-30.00) 29.50(28.00-30.00) 0.01 
Age of Menarche, in years, 
median (Q1-Q3) 
13.00(12.00-14.00) 12.00(11.00-13.00) 0.11 
Previous STD, n (%) 0.07 
No 107(63.69) 25(48.08) 
Yes 61(36.31) 27(51.92)  
Marital Status, n (%) <0.001 
No 46(27.22) 37(68.52) 
Yes 123(72.78) 17(31.48)  
Routine Exercise, n (%)  0.10 
No 67(41.36) 28(56.00) 
Yes 95(58.64) 22(44.00)  
Alcohol Use, n (%) 0.75 
No 97(57.40) 29(53.70) 
Yes 72(42.60) 25(46.30)  
Caffeine Use, n (%) 0.52 
No 34(20.36) 8(15.09) 
Yes 133(79.64) 45(84.91)  
Race, n (%) <0.001 
Other 128(75.74) 27(50.00) 
Black 41(24.26) 27(50.00) 
AMH  
(ng/mL), median (Q1-Q3) 
2.49(1.11-5.01) 2.48(1.52-5.66) 0.55 
Length of Infertility  
(years), median (Q1-Q3) 
2.00(1.00-4.46) 2.50(1.33-5.50) 0.16 
Treatment Cycles, n (%) <0.001 
0 87(51.48) 43(79.63) 
1 35(20.71) 3(5.56) 
2 and more 47(27.81) 8(14.81) 
NAT2 Acetylator Status, 
n (%) 
0.32 
Rapid 84(57.93) 33(67.35) 
Slow 61(42.07) 16(32.65)  
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Pregnant, n (%) 0.14 
No 101(59.76) 39(72.22) 
Yes 68(40.24) 15(27.78)  
Pregnancy Outcome, 
n (%) 
0.03 
Live Birth 37(63.79) 4(28.57) 
SA 21(36.21) 10(71.43) 
Total Follow-up Time  
(years), median (Q1-Q3) 
6.00(3.00-14.00) 7.00(2.25-15.00) 0.94 
2) Secondhand Smoke Exposure – Recent SHS Exposure (Urinary Cotinine)
among Nonsmokers 
Of the 169 nonsmoking women, 9 did not provide urine samples which left a final 
sample size of 160 nonsmoking women for this analysis. Recent SHS exposure as defined 
using urinary cotinine levels. A level of 0 ng/mL was used as the referent group (n=82). 
Those with cotinine levels less than and equal to 4 ng/mL were classified as low recent 
SHS exposure (n=42), and those with cotinine levels greater than 4 ng/mL were classified 
as high recent SHS exposure (n=36). Women with urinary cotinine values of 100 ng/mL 
or self-reported as a current smoker or that quit smoking less than a month ago were 
excluded from this analysis. Table 10 presents the characteristics of 160 nonsmoking 
women stratified by their amount of SHS exposure measured through urinary cotinine 
levels. 
As shown in Table 10, nonsmoking women with highest recent SHS exposure 
(urinary cotinine levels greater than 4 ng/mL) were younger in age (P = 0.06), more 
likely to be obese (P = 0.04), more likely to have children (P = 0.002), less likely to 
exercise (P = 0.10), less likely to use MAR (P = 0.07), more likely to have a SA (P = 
0.17), more likely to be slow acetylators (P = 0.072) and have less follow-up time (P = 
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0.03) compared to nonsmoking women with no recent SHS exposure (urinary cotinine 
level of 0 ng/mL).  Descriptive statistics comparing urinary cotinine levels stratified by 
MAR can be found in the Appendix D (Table S3-4). 
Table 10: Characteristics of Nonsmoking Women Stratified by Recent SHS 
Exposure Using Urinary Cotinine (N=160) 
Cotinine = 0 
mg/dL 
N=82 
0 < Cotinine ≤ 
4mg/dL 
N=42 
4 < Cotinine 
≤ 47 mg/dL 
N=36 
P-
value 
Age in years,  
median (Q1-Q3) 
34.0        
(30.00-37.75) 
31.50     
(27.25-35.75) 
31.00 
(26.00-35.25)  
0.06 
Age in years, n (%) 0.08 
≤33 37(45.12) 26(61.90) 23(63.89) 
>33 45(54.88) 16(38.10) 13(36.11) 
BMI (kg/m2), 
median (Q1-Q3) 
27.18 
(23.76-32.07) 
31.49 
(27.73-37.66) 
31.14 
(25.46-36.41) 
0.003 
BMI Category kg/m2, 
n (%) 
0.13 
<25 (Underweight and 
Normal) 
26(31.71) 7(16.67) 9(25.00) 
25 - 29.9 (Overweight) 27(32.93) 11(26.19) 8(22.22)  
≥ 30 (Obese) 29(35.37) 24(57.14) 19(52.78) 
BMI kg/m2, n (%) 0.04 
≤30 53(64.63) 18(42.86) 17(47.22) 
>30 29(35.37) 24(57.14) 19(52.78) 
Gravidity, n (%) 0.002 
0 30(36.59) 29(69.05) 10(27.78) 
1 19(23.17) 7(16.67) 10(27.78) 
>=2 33(40.24) 6(14.29) 16(44.44)  
Regular Period, n (%)  0.26 
No 25(30.49) 19(45.24) 12(33.33) 
Yes 57(69.51) 23(54.76) 24(66.67) 
Average Cycle Length 
(days), median (Q1-Q3) 
28.00 
(27.25-30.00) 
28.00 
(27.50-29.25) 
29.00 
(26.50-30.00) 
0.85 
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Age of Menarche, in 
years, median (Q1-Q3) 
13(12-14) 12(11-14) 12(12-14) 0.50  
Previous STD, n (%) 0.91 
No 52(63.41) 27(65.85) 22(61.11) 
Yes 30(36.59) 14(34.15) 14(38.89)  
Marital Status, n (%) 0.20 
No 21(25.61) 9(21.43) 14(38.89) 
Yes 61(74.39) 33(78.57) 22(61.11)  
Routine Exercise, n (%)  0.10 
No 27(34.18) 16(40.00) 19(55.88) 
Yes 52(65.82) 24(60.00) 15(44.12)  
Alcohol Use, n (%) 0.94 
No 73(90.12) 37(90.24) 31(88.57) 
Yes 8(9.88) 4(9.76) 4(11.43)  
Caffeine Use, n (%) 0.75 
No 45(54.88) 26(61.90) 21(58.33) 
Yes 37(45.12) 16(38.10) 15(41.67)  
Race, n (%) 0.33 
Other 66(80.49) 30(71.43) 25(69.44) 
Black 16(19.51) 12(28.57) 11(30.56) 
AMH (ng/mL), 
median (Q1-Q3) 
2.17 
(0.86-3.95) 
3.23 
(1.09-5.56) 
2.60 
(1.59-5.61) 
0.33  
Length of Infertility 
years, median (Q1-Q3)  
2.00 
(1.00-4.00) 
2.00 
(1.31-4.25) 
2.21 
(1.00-5.81) 
0.54 
Treatment Cycles, 
 n (%) 
0.07 
0 38(46.34) 23(54.76) 21(58.33) 
1 17(20.73) 7(16.67) 10(27.78) 
2 12(14.63) 4(9.52) 5(13.89) 
3 and more 15(18.29) 8(19.05) 0(0.00) 
NAT2 Acetylator 
Status, n (%)  
0.07 
Rapid 47(64.38) 23(60.53) 14(41.18) 
Slow 26(32.62) 15(39.47) 20(58.82)  
Pregnant, n (%) 0.82 
No 49(59.76) 23(54.76) 22(61.11) 
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Yes 33(40.24) 19(45.24) 14(38.89)  
Pregnancy Outcome, n 
(%) 
0.17 
Live Birth 21(72.41) 9(60.00) 5(41.67) 
SA 8(27.59) 6(40.00) 7(58.33) 
Total Follow-up Time  
(years), median (Q1-Q3) 
8.00 
(4.00-16.00) 
5.00 
(3.00-14.00) 
5.00 
(2.75-9.75) 
0.03 
3) Secondhand Smoke Exposure – Past Year’s SHS Exposure (SSQ) among
Nonsmokers 
Self-reported SHS exposure in the past year was measured using two questions 
from the SSQ. Each question was scored never (1), rarely (2), often (3) and every day (4) 
and then summed. High SHS exposure was defined with a combined SSQ score  ≥ 4 
(n=57) and compared to low SHS exposure with a combined SSQ score ≤ 3 (n=112). 
Women with urinary cotinine values of 100 ng/mL or self-reported as a current smoker or 
that quit smoking less than a month ago were excluded from this analysis. Table 11 
presents the characteristics of 169 nonsmoking women stratified by SHS exposure in the 
past year measured from the SSQ. 
Nonsmoking women who self-reported high SHS exposure (combined SSQ score 
of ≥ 4) in the past year (n=57) were less likely to be married (P=0.01), more likely to be 
of African American race (P = 0.03), reported longer lengths of infertility (P = 0.02), 
were less likely to use MAR (P = 0.04) and less likely to conceive (P = 0.14), and were 
more likely to have a SA (P = 0.16), compared to nonsmoking women who self-reported 
low SHS exposure (combined SSQ score ≤ 3) in the past year. Descriptive statistics for 
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SHS exposure via the SSQ, stratified by MAR can be found in the Appendix D (Table 
S5-6). 
Table 11: Characteristics of Nonsmoking Women Stratified by SHS Exposure in the 
Past Year Using the SSQ (N=169) 
No and Low 
exposure (score=2,3) 
N=112 
Med and High 
exposure (score ≥4) 
N=57 
P-value 
Cotinine Levels, mg/dL 
median (Q1-Q3) 
0.00 
(0.00-1.00) 
2.50 
(0.00-10.40) 
<0.001 
Cotinine Categories, 
n (%) 
<0.001 
0 mg/dL 65(61.90) 17(30.91) 
<4 mg/dL 26(24.76) 11(20.00) 
>= 4 mg/dL 14(13.33) 27(49.09) 
Age in years  
median (Q1-Q3)  
33.00 
(29.00-37.00) 
32.00  
(27.00-35.00) 
0.36 
Age in years, n (%) 0.56 
≤33 58(51.79) 33(57.89) 
>33 54(48.21) 24(42.11) 
BMI, kg/m2 
median (Q1-Q3) 
28.43 
(24.81-32.39) 
24.95 
(24.95-37.25) 
0.23 
BMI Category, kg/m2, 
n (%) 
0.65 
<25 (Underweight and 
Normal) 
30(26.79) 16(28.07) 
25 - 29.9 (Overweight) 35(31.25) 14(24.56) 
≥ 30 (Obese) 47(41.96) 27(47.37) 
BMI kg/m2, n (%) 0.52 
≤30 65(58.04) 30(52.63) 
>30 47(41.96) 27(47.37) 
Gravidity, n (%) 0.90 
0 48(42.86) 26(45.61) 
1 26(23.21) 12(21.05) 
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>=2 38(33.93) 19(33.33)  
Regular Period, n (%) 0.51 
No 36(32.14) 22(38.60) 
Yes 76(67.86) 35(61.40) 
Average Cycle Length, 
(days), median (Q1-Q3) 
28.00  
(28.00-30.00) 
28.00 
(27.00-23000)  
0.82  
Age of Menarche 
in years, median (Q1-Q3) 
13.00 
(12.00-14.00) 
12.00 
(12.00-13.75) 
0.39 
Previous STD, n (%) 0.79 
No 72(64.86) 35(61.40) 
Yes 39(35.14) 22(38.60)  
Marital Status, n (%) 0.01 
No 23(20.54) 23(40.35) 
Yes 89(79.46) 34(59.65)  
Routine Exercise, n (%) 0.21 
No 40(37.38) 27(49.09) 
Yes 67(62.62) 28(50.91)  
Alcohol Use, n (%) 0.21 
No 60(53.57) 37(64.91) 
Yes 52(46.43) 20(35.09) 
Caffeine Use, n (%) 0.97 
No 22(19.82) 12(21.43) 
Yes 89(80.18) 44(78.57)  
Race, n (%) 0.03 
Other 91(81.25) 37(64.91) 
Black 21(18.75) 20(35.09) 
AMH, ng/mL  
median (Q1-Q3)  
2.46 
(1.13-4.96) 
2.51 
(1.14-6.28) 
0.62  
Length of Infertility, in 
years, median (Q1-Q3)   
1.75 
(1.00-3.17) 
3.00 
(1.25-6.42) 
0.02 
Treatment Cycles, n (%) 0.04 
0 50(44.64) 37(64.91) 
1 25(22.32) 10(17.54) 
2 and more 37(33.04) 10(17.54) 
NAT2 Acetylator Status, 
n (%) 
0.83 
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Rapid 55(59.14) 29(55.77) 
 
Slow 38(40.86) 23(44.23)  
 
Pregnant, n (%) 
  
0.14 
No 62(55.36) 39(68.42) 
 
Yes 50(44.64) 18(31.58)  
 
Pregnancy Outcome,  
n (%) 
  
0.16 
Live Birth 29(70.73) 8(47.06) 
 
SA 12(29.27) 9(52.94) 
  
 
Total Follow-up Time, 
(years), median (Q1-Q3)  
7.00(3.00-15.00) 5.00(3.00-13.00) 0.60 
  
 
 
4) Combined Exposure – Active Smoking and SHS Exposure 
The combined exposure variable compared nonsmokers with low SHS exposure 
in the past year (n=112) to nonsmokers with high SHS exposure (n-=57) and then to 
current smokers (n=54). The characteristics of 223 women using the combined effect 
exposure variable are shown in Table 12. Current smokers were more likely to have a 
previous STD (P = 0.12), less likely to be married (P<0.001), less likely to exercise (P = 
0.07), more likely to be of African American race (P<0.001), less likely to use MAR 
(P<0.001), less likely to conceive (P = 0.07) and more likely to have a SA/miscarriage (P 
= 0.014), when compared nonsmokers with high SHS exposure (n=57) then to 
nonsmokers with low SHS exposure (n=112). Descriptive statistics for the combined 
exposure, stratified by MAR can be found in the Appendix D (Table S7-8). 
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Table 12: Characteristics of Women Using the Combined Effect Variable (N=223) 
Nonsmokers 
with low SHS 
N=112 
Nonsmokers 
with high SHS 
N=57 
Smokers 
N=54 
P - 
value 
Cotinine Levels, 
mg/dL,  
median (Q1-Q3) 
0.00 
(0.00-1.00) 
2.50 
(0.00-10.40) 
100.00 
(100.0-100.0) 
< 0.001 
Cotinine Categories, 
n (%) 
0 mg/dL 65(61.90) 17(30.91) 0(0.00) < 0.001 
<100 mg/dL 40(38.10) 38(69.09) 2(3.85) 
100mg/dL 0(0.00) 0(0.00) 50(96.15) 
Age in years, 
median (Q1-Q3)  
33.00 
(29.00-32.76) 
32.00 
(27.00-35.00) 
32.50 
(27.25-36.00) 
0.51 
Age in years, n (%) 0.59 
≤33 58(51.79) 33(57.89) 32(59.26) 
>33 54(48.21) 24(42.11) 22(40.74) 
BMI, kg/m2,  
median (Q1-Q3) 
28.43 
(24.81-32.39) 
29.04 
(24.95-37.25) 
30.36 
(26.77-34.46) 
0.21 
BMI Category 
kg/m2, n (%) 
0.53 
<25 (Underweight 
and Normal) 
30(26.79) 16(28.07) 11(20.37) 
25 - 29.9 
(Overweight) 
35(31.25) 14(24.56) 13(24.07) 
≥ 30 (Obese) 47(41.96) 27(47.37) 30(55.56) 
BMI kg/m2, n (%) 0.26 
≤30 65(58.04) 30(52.63) 24(44.44) 
>30 47(41.96) 27(47.37) 30(55.56) 
Gravidity, n (%) 0.78 
0 48(42.86) 26(45.61) 19(35.19) 
1 26(23.21) 12(21.05) 12(22.22) 
>=2 38(33.33) 19(33.33) 23(42.59)  
Regular Period, 
n (%) 
0.70 
No 36(32.14) 22(38.60) 18(33.33) 
109 
Yes 76(67.86) 35(61.40) 36(66.67) 
Average Cycle 
Length, (days), 
median (Q1-Q3) 
28.00 
(28.00-30.00) 
28.00 
(27.00-30.00) 
29.50     
(28.00-30.00)  
0.03 
Age of Menarche, in 
years, median (Q1-
Q3) 
13.00 
(12.00-14.00) 
12.00 
(12.00-13.75) 
12.00 
(11.00-13.00) 
0.19 
Previous STD, 
n (%) 
0.12 
No 72(64.86) 35(61.40) 25(48.08) 
Yes 39(35.14) 22(38.60) 27(51.92) 
Marital Status, 
n (%) 
<0.0001 
No 23(20.54) 23(40.35) 37(68.52) 
Yes 89(79.46) 34(59.65) 17(31.48) 
Routine Exercise, 
n (%) 
0.07 
No 40(37.38) 27(49.09) 28(56.00) 
Yes 67(62.62) 28(50.91) 22(44.00) 
Alcohol Use, n (%) 0.33 
No 60(53.57) 37(64.91) 29(53.70) 
Yes 52(46.43) 20(35.09) 25(46.30) 
Caffeine Use, n (%) 0.68 
No 22(19.82) 12(21.43) 8(15.09) 
Yes 89(80.18) 44(78.57) 45(84.91) 
Race, n (%) <0.001 
Other 91(81.25) 20(35.09) 27(50.00) 
Black 21(18.75) 37(64.91) 27(50.00) 
AMH, ng/mL 
median (Q1-Q3) 
2.46 
(1.13-4.96) 
2.51 
(1.14-6.28) 
2.48 
(1.52-5.66) 
0.73 
Length of Infertility, 
years, median (Q1-
Q3) 
1.75 
(1.00-3.17) 
3.00 
(1.25-6.42) 
2.50 
(1.33-5.50) 
0.02 
Treatment Cycles, <0.001 
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n (%) 
0 50(44.64) 37(64.91) 43(79.63) 
 
1 25(22.32) 10(17.54) 3(5.56) 
 
2 and more 37(33.04) 10(17.54) 8(14.81) 
  
 
NAT2 Acetylator 
Status, n (%) 
  
0.47 
Rapid 55(59.14) 29(55.77) 33(67.35) 
 
Slow 38(40.86) 23(44.23) 16(32.65) 
  
 
Pregnant, n (%) 
  
0.07 
No 62(55.36) 39(68.42) 39(72.22) 
 
Yes 50(44.64) 18(31.58) 15(27.78) 
  
 
Pregnancy 
Outcome, n (%) 
  
0.02 
Live Birth 29(70.73) 8(47.06) 4(28.57) 
 
SA 12(29.27) 9(52.94) 10(71.43) 
  
 
Total Follow-up 
Time, years, median 
(Q1-Q3) 
7.00 
(3.00-15.00) 
5.00 
(3.00-13.00) 
7.00 
(2.25-15.00) 
0.88 
 
 
Descriptive statistics comparing the characteristics of all 223 women stratified by 
MAR use is displayed in Table 13. Overall, MAR users since enrollment were 
significantly older (P = 0.04), less likely to be obese (P = 0.06), more likely to be married 
(P = 0.01), more likely to drink alcohol (P = 0.03), more likely to get pregnant (P 
<0.001), less likely to be a current smoker (P <0.001), and less likely to have high urinary 
cotinine levels (P <0.001), compared to women who did not use MAR since enrollment.  
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Table 13 : Characteristics of Women Stratified by MAR Use 
No MAR 
N = 130 
MAR 
N = 93 
P value 
Age in years 
median (Q1-Q3)  
31.50 
(27.00-36.00) 
34.00 
(30.00-38.00) 
0.04 
Age in years, n(%) 0.06 
≤33 79(60.77) 44(47.31) 
>33 51(39.23) 49(52.69) 
BMI (kg/m2) 30.45 
(24.85-36.33) 
28.53 
(25.16-32.71) 
0.10 
BMI Category kg/m2, n(%) 0.04 
<25 (Underweight and 
Normal) 
34(26.15) 23(24.73) 
25 - 29.9 (Overweight) 28(21.54) 34(36.56)  
≥ 30 (Obese) 68(52.31) 36(38.71) 
BMI kg/m2, n(%) 0.06 
≤30 62(47.69) 57(61.29) 
>30 68(52.31) 36(38.71) 
Gravidity, n(%) 0.46 
0 51(39.23) 42(45.16) 
1 28(21.54) 22(23.66) 
≥2 51(39.23) 29(31.18)  
Regular Period, n(%) 0.53 
No 47(36.15) 29(31.18) 
Yes 83(63.85) 64(68.82) 
Average Cycle Length 
(days) median (Q1-Q3) 
28.50 
(28.00-30.00) 
29.00 
(28.00-30.00) 
0.87 
Age of Menarche (in years) 
median (Q1-Q3)  
12.00 
(11.00-14.00) 
13.00 
(12.00-13.75) 
0.62 
Previous STD, n(%) 0.72 
No 75(58.59) 57(61.96) 
Yes 53(41.41) 35(38.04)  
Marital Status, n(%) 0.01 
No 58(44.62) 25(26.88) 
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Yes 72(55.38) 68(73.12)  
Routine exercise, n(%) 0.23 
No 59(48.76) 36(39.56) 
Yes 62(51.24) 55(60.44)  
Alcohol Use, n(%) 0.03 
No 82(63.08) 44(47.31) 
Yes 48(36.92) 49(51.69)  
Caffeine Use, n(%) 1.00 
No 24(18.90) 18(19.35) 
Yes 103(81.10) 75(80.65)  
Race, n(%) 0.004 
Black 50(38.46) 18(19.35) 
Other 80(61.54) 75(80.65) 
AMH (ng/mL)  
median (Q1-Q3) 
2.54 
(1.06-5.60) 
2.40 
(1.37-4.99) 
0.78 
Length of Infertility (in 
years) median (Q1-Q3) 
2.00 
(1.50-2.00) 
1.50 
(1.00-5.00) 
0.02 
NAT2 Acetylator Status, 
n(%) 
0.82 
Rapid 70(61.40) 47(58.75) 
Slow 44(38.60) 33(41.25)  
Pregnant, n(%) <0.001 
No 101(77.69) 39(41.94) 
Yes 29(22.31) 54(58.06)  
Pregnancy Outcome, n(%) 0.67 
Live Birth 15(62.50) 26(54.17) 
SA 9(37.50) 22(45.83) 
Total Follow-up Time in 
years, median (Q1-Q3)   
8.00 
(3.00-15.00) 
5.00 
(3.00-12.00) 
0.13 
Cotinine Levels mg/dL, 
median (Q1-Q3)  
4.75 
(0.00-100.00) 
0.20 
(0.00-5.13) 
<0.001 
Cotinine mg/dL, n(%) <0.001 
0 38(30.64) 44(50.00) 
<100 46(37.10) 34(38.64) 
10 40(32.26) 10(11.36) 
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Current Active Smoker, 
n(%) 
<0.001 
No 87(66.92) 82(88.17) 
Yes 43(33.08) 11(11.83) 
Self-reported SHS 
Exposure among 
Nonsmokers, n(%) 
0.28 
No/Low 93(71.54) 73(78.49) 
Intermediate/High 37(28.46) 20(21.51) 
Self-reported SHS 
Exposure among All, 
n(%) 
0.05 
No 24(24.74) 27(30.68) 
Low 30(30.93) 37(42.05) 
Intermediate 29(29.90) 20(22.73) 
High 14(14.43) 4(4.55) 
Specific Aim 1a: The Effect of Active Smoking on Fecundability 
The association of active smoking (current and lifetime) on fecundability was 
modelled among three populations which included all follow-up time, MAR cycles and 
NC follow-up time. Full models were adjusted for MAR cycle, age, BMI, marital status, 
gravidity and race, as described in Table 8. Age and BMI were retained in all models, 
along with confounders that changed the effect of smoking by at least 10%. Dose-
response relationships were assessed by treating the exposure variable ordinally and p-
values and 95% confidence intervals were reported. The proportional hazards assumption 
was met for all variables in each model. The results for active smoking on fecundability 
are presented in Table 14. 
Among all 223 women, current active smoking was not significantly associated 
with fecundability. Smokers had a 27% higher rate of fecundability compared to 
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nonsmokers, minimally adjusted for age, BMI and marital status (aFR: 1.27; 95% CI: 
0.68, 2.38; p = 0.46). Compared to nonsmokers, women with 6 or more pack-years 
showed a 17% lower rate of fecundability (95% CI: 0.40, 1.70) and those with 1-5 pack-
years had a 17% higher rate of fecundability (95% CI: 0.58, 2.38), after adjusting for age 
and BMI. The estimates and the test for trend, however, were also not statistically 
significant (p-trend = 0.83). The total number of cigarettes per day was not associated 
with fecundability, nor was a dose-response established (p-trend = 0.99). 
The sub-population that analyzed MAR cycles only included 93 women. The full 
model included the same variables as the previous, but MAR type was included as the 
time-varying covariate instead of MAR cycle. The results among MAR cycles were 
similar to the all follow-up time models, in that current, active smoking was not 
significantly associated with fecundability. Smokers showed an insignificant 88% higher 
rate of fecundability (95% CI: 0.73, 4.85) compared to nonsmokers with adjustment for 
age, BMI and marital status. Among MAR cycles, women with 6 or more pack-years and 
1-5 pack-years had a 20% (95% CI: 0.42, 3.46) and 31% higher rate of fecundability 
(95% CI: 0.65, 2.65) compared to women with no pack-years, respectively. The test for 
trend was not significant (p-trend = 0.44). Total number of cigarettes per day was not 
associated with fecundability, nor was a dose-response effect established (p-trend = 0.22). 
The sub-population that analyzed NC follow-up time only included 212 women. 
The full models included age, BMI, gravidity, marital status and race. In this group, 
smoking was generally associated with a non-significant reduction in fecundability. 
Among NC follow-up time, current, active smokers showed a 22% reduction in 
fecundability (95% CI: 0.34, 1.79) compared to nonsmokers after adjusting for age, BMI 
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and marital status, but the estimate was not significant (p = 0.56). Women with NC 
follow-up time that had 6 or more pack-years and 1-5 pack-years had a 24% and 9% 
decrease in fecundability compared to women with no pack-years, respectively. The 
estimates were adjusted for age and BMI and were not statistically significant, along with 
the test for trend (p-trend=0.54). After adjusting for age, BMI and marital status, women 
who smoked a total of 10 or more cigarettes a day had a 33% (95% CI: 0.28, 1.58) 
reduction in fecundability and women who smoke 1 to 9 cigarettes a day had a 4% (95% 
CI: 0.32, 2.89) reduction in fecundability, compared to nonsmokers. The test for trend 
were also not statistically significant (p-trend = 0.37). 
Table 14: Multivariable Cox Regression Models for Active Smoking (Current and 
Lifetime) on Fecundability among Three Populations 
N 
(#events) 
FULL MODEL*  MINIMALLY 
ADJUSTED MODELa 
Fecundability 
Ratio 
(95% CI) 
P-
value 
Fecundability 
Ratio 
95% CI 
P-
value 
ALL FOLLOW-UP TIME 
Current Active Smoking 
Nonsmoker 169(68) 1.00 (Referent) 1.00 (Referent) 
Current active 
smoker 
54(15) 1.26 (0.66, 2.41) 0.48 1.27b (0.68, 2.38) 0.46 
Total Cigarettes Smoked 
per Day 
p-trend = 0.99 
Nonsmokers 156(59) 1.00 (Referent) 1.00 (Referent) 
≤ 9 30(12) 1.08 (0.49, 2.36) 0.85 1.17 (0.58, 2.38) 0.66 
≥ 10 37(12) 1.03 (0.52, 2.05) 0.92 0.83 (0.40, 1.70) 0.61 
Pack-years p-trend = 0.83 
Nonsmokers 156(59)  1.00 (Referent) 1.00 (Referent) 
≤ 5 37(15) 1.21 (0.60, 2.45) 0.59 1.17 (0.58, 2.38) 0.66 
≥ 6 30(9) 0.85 (0.40, 1.78) 0.66 0.83 (0.40, 1.70) 0.61 
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MAR CYCLES 
Current Active Smoking 
Nonsmoker 82(41) 1.00 (Referent) 1.00 (Referent) 
Current active 
smoker 
11(6) 1.97 (0.72, 5.37) 0.19 1.88b (0.73, 4.85) 0.19 
Total Cigarettes Smoked 
per Day 
p-trend = 0.22 
Nonsmokers 71(34) 1.00 (Referent) 1.00 (Referent) 
≤ 9 11(8) 1.11 (0.50, 2.45) 0.80 1.09b (0.52, 2.29) 0.82 
≥ 10 11(5) 1.78 (0.75, 4.23) 0.19 1.87b (0.85, 4.11) 0.12 
Pack-years p-trend = 0.44 
Nonsmokers 71(34) 1.00 (Referent) 1.00 (Referent) 
≤ 5 13(10) 1.36 (0.63, 2.96) 0.44 1.31b (0.65, 2.65) 0.45 
≥ 6 9(3) 1.09 (0.37, 3.19) 0.88 1.20b (0.42, 3.46) 0.73 
NC FOLLOW-UP TIME 
Current Active Smoking 
Nonsmoker 160(27) 1.00 (Referent) 1.00 (Referent) 
Current active 
smoker 
52(9) 0.73 (0.31, 1.68) 0.45 0.78b (0.34, 1.79) 0.56 
Total Cigarettes Smoked 
per Day 
p-trend = 0.37 
Nonsmokers 148(25) 1.00 (Referent) 1.00 (Referent) 
≤ 9 28(4) 0.91 (0.31, 2.68) 0.86 0.96b (0.32, 2.89) 0.94 
≥ 10 36(7) 0.64 (0.26, 1.54) 0.32 0.67b (0.28, 1.58) 0.36 
Pack-years p-trend = 0.54 
Nonsmokers 148(25) 1.00 (Referent) 1.00 (Referent) 
≤ 5 36(5) 0.82 (0.31, 2.17) 0.68 0.91 (0.33, 2.48) 0.85 
≥ 6 28(6) 0.65 (0.25, 1.69) 0.38 0.76 (0.31, 1.83) 0.54 
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race 
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital 
status and Race 
Full models for All follow-up time models adjusted for MAR cycle, Age, BMI, 
Gravidity, Marital status and Race 
a - Adjusted for Age and BMI 
b - Adjusted for Age, BMI and Marital Status  
Abbreviations: MAR - Medically Assisted Reproduction, NC - Natural Conception 
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Specific Aim 1b: The Effect of SHS Exposure on Fecundability among Nonsmokers 
The association of SHS exposure (recent and past) on fecundability was modelled 
for the same three populations among nonsmokers: all follow-up time, MAR cycles, and 
NC follow-up time. Recent SHS exposure was measured using urinary cotinine levels 
and past SHS exposure using the SSQ. All models under this aim excluded current, active 
smokers. The proportional hazards assumption was met for all variables in the models. 
The results for SHS exposure (recent and past year) on fecundability are presented in 
Table 15. 
In general, SHS exposure was not significantly associated with fecundability. 
Among all nonsmokers (n = 169), women with high SHS exposure in the past year 
reported in the SSQ had a 17% higher rate of fecundability (95% CI: 0.69, 1.99) 
compared to low SHS exposure, adjusted for age, BMI and marital status. However, the 
estimate did not reach statistical significance (p = 0.56).  Similarly, nonsmoking women 
with high recent SHS exposure (urinary cotinine levels 5-99 mg/dL) (FR: 2.12; 95% 
CI:1.08, 4.15) and low recent SHS exposure (urinary cotinine levels from 1-4 mg/dL) 
(FR: 1.04; 95% CI: 0.57, 1.91) had a higher rate of fecundability than unexposed women 
(urinary cotinine levels = 0 mg/dL), adjusted for age and BMI. The test for trend with 
urinary cotinine was also not significant (p-trend = 0.08). 
Among nonsmoking women with MAR cycles, the full models included the same 
covariates as the previous models, but MAR type was used as the time-varying covariate 
instead of MAR cycle. In these women, high SHS exposure from the past year showed an 
insignificant 45% increase in fecundability (95% CI: 0.74, 2.87) compared to low SHS 
exposure from the past year, adjusted for age, BMI and marital status. Nonsmoking 
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women with high urinary cotinine and low urinary cotinine had an 84% increase and 28% 
decrease in fecundability compared to unexposed women, respectively. These estimates 
were adjusted for age, BMI, gravidity, marital status and race; and were not statistically 
significant, along with the test for trend (p-trend = 0.59). 
Among NC follow-up time, the full models were adjusted for age, BMI, gravidity, 
marital status and race. Nonsmoking women with high SHS exposure from the past year 
had a 4% insignificant reduction in fecundability adjusted for age and BMI (95% CI: 
0.32, 1.51), compared to low SHS exposure from the past year. However, in the same 
population, nonsmoking women who had high and low levels urinary cotinine levels had 
a 36% (95% CI: 0.49, 3.74) and 22% (95% CI: 0.50, 3.01) higher rate of fecundability 
compared to unexposed women, respectively. The test for trend (p-trend = 0.53) was not 
significant. 
Table 15: Multivariable Cox Regression Models for SHS Exposure (Recent and Past 
Year) and Fecundability among Nonsmokers 
N 
(#events) 
FULL MODEL*  MINIMALLY 
ADJUSTED MODELa 
Fecundability 
Ratio 
(95% CI) 
P-
value 
Fecundability 
Ratio 
(95% CI) 
P-
value 
ALL FOLLOW-UP TIME 
SHS Exposure in the Past 
Year From SSQ  
Low  112(50) 1.00 (Referent) 1.00 (Referent) 
High  57(18) 1.33 (0.78, 2.28) 0.29 1.17b (0.69, 1.99) 0.56 
Cotinine mg/dL p-trend = 0.08 
0 mg/dL 82(33) 1.00 (Referent) 1.00 (Referent) 
≤ 4 mg/dL 42(19) 1.08 (0.57, 2.05) 0.81 1.04 (0.57, 1.91) 0.90 
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5 - 99 mg/dL 36(14) 2.31 (1.15, 4.64) 0.02 2.12 (1.08, 4.15) 0.03 
 
MAR CYCLES  
 
SHS Exposure in the Past 
Year From SSQ 
 
    
Low  62(33) 1.00 (Referent)  1.00 (Referent)  
High  20(8) 1.51 (0.71, 3.19) 0.29 1.45b (0.74, 2.87) 0.28 
 
Cotinine mg/dL     p-trend = 0.59 
0 mg/dL 43(20) 1.00 (Referent)  1.00 (Referent)  
≤ 4 mg/dL 8(3) 0.72 (0.26, 1.96) 0.52 0.72c (0.26, 1.96) 0.52 
5 - 99 mg/dL 15(8) 1.84 (0.67, 5.03) 0.24 1.84c (0.67, 5.03) 0.24 
 
NC FOLLOW-UP TIME  
 
SHS Exposure in the Past 
Year From SSQ 
 
    
Low  104(17) 1.00 (Referent)  1.00 (Referent)  
High  56(10) 1.01 (0.41, 2.46) 0.99 0.96b (0.43, 2.15) 0.92 
 
Cotinine mg/dL     p trend = 0.53 
0 mg/dL 77(13) 1.00 (Referent)  1.00 (Referent)  
≤ 4 mg/dL 38(7) 1.41 (0.55, 3.62) 0.48 1.22 (0.50, 3.01) 0.66 
5 - 99 mg/dL 35(6) 1.23 (0.36, 4.16) 0.74 1.36 (0.49, 3.74) 0.56 
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status 
and Race 
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital 
status and Race 
Full models for All follow-up time models adjusted for MAR cycle, Age, BMI, 
Gravidity, Marital status and Race 
a - Models adjusted for Age and BMI  
b - Models adjusted for Age, BMI and Marital status  
c - Models adjusted for Age, BMI, Gravidity, Marital status and Race 
Abbreviations: MAR - Medically Assisted Reproduction, NC - Natural Conception 
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Specific Aim 1c: The Effect of the Combined Exposure Effect on Fecundability 
The association of the combined effect of current, active smoking and SHS 
exposure on fecundability was modelled for the same three populations: all follow-up 
time, MAR cycles, and NC follow-up time. The same set of covariates in the active 
smoking and SHS exposure models were used in the full models. The proportional 
hazards assumption was not violated for any variables. The results for combined effect of 
active smoking and SHS on fecundability are presented in Table 16. 
Similar to the previous models, tobacco smoke exposure was not associated with 
fecundability in these models. In the MAR cycles, tobacco smoke exposure was 
associated with a non-significant increase in fecundability; whereas in the NC follow-up 
time, it was associated with a non-significant decrease in fecundability. 
Among all women, current smokers and nonsmokers with high SHS had a 39% 
(95% CI: 0.70, 2.64) and 29% (95% CI: 0.75, 2.13) increase in fecundability compared to 
nonsmokers with low SHS exposure, respectively. The estimates were adjusted for age, 
BMI and marital status and were not significant, along with the trend test (p-trend = 
0.27). 
Among 93 women who contributed MAR cycles, it was found that current 
smokers (aFR: 2.08; 95% CI: 0.79, 5.49) and nonsmokers with high SHS exposure (aFR: 
1.31; 95% CI: 0.63, 2.73) had increased fecundability compared to nonsmokers with low 
SHS exposure, adjusted for age, BMI and marital status. These estimates, along with the 
test for dose-response effect (p-trend = 0.12) were insignificant. 
Among the 212 women that contributed NC follow-up time, current smokers and 
nonsmokers with high SHS exposure showed a 22% (95% CI: 0.32, 1.91) and 1% (95% 
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CI: 0.45, 2.17) reduction in fecundability compared to nonsmokers with low SHS 
exposure, respectively. The estimates were adjusted for age, BMI and marital status; the 
test for trend was not significant (p = 0.60).  
 
Table 16: Multivariable Cox Regression Model for Combined Effect of Active 
Smoking and SHS Exposure on Fecundability among Three Populations 
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status 
and Race 
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital 
status and Race 
                                 N 
(#events) 
FULL MODEL*  MINIMALLY 
ADJUSTED MODELa 
Fecundability  
Ratio 
(95% CI) 
P-
value 
Fecundability  
Ratio 
(95% CI) 
P-
value 
 
ALL FOLLOW-UP TIME 
 
Combined Effect   p-trend = 0.27  
NS w/low SHS  112(50) 1.00 (Referent)  1.00 (Referent)  
NS w/high SHS  57(18) 1.31 (0.78, 2.20) 0.30 1.29 (0.75, 2.13) 0.34 
Current smokers 54(15) 1.39 (0.71, 2.75) 0.34 1.39 (0.70, 2.64) 0.33 
 
MAR CYCLES  
 
Combined Effect   p-trend = 0.12  
NS w/low SHS  62(33) 1.00 (Referent)  1.00 (Referent)  
NS w/high SHS  20(8) 1.23 (0.59, 2.57) 0.59 1.31 (0.63, 2.73) 0.47 
Current smokers 11(6) 2.10 (0.76, 5.77) 0.15 2.08 (0.79, 5.49) 0.14 
 
NC FOLLOW-UP TIME 
 
Combined Effect   p-trend = 0.60  
NS w/low SHS  103(17) 1.00 (Referent)  1.00 (Referent)  
NS w/high SHS  57(10) 0.96 (0.40, 2.28) 0.93 0.99 (0.45, 2.17) 0.98 
Current smokers 52(9) 0.71 (0.28, 1.81) 0.47 0.78 (0.32, 1.91) 0.58 
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Full models for All follow-up time models adjusted for MAR cycle, Age, BMI, 
Gravidity, Marital status and Race 
Abbreviations: NS - Nonsmokers, MAR - Medically Assisted Reproduction, NC - 
Natural Conception 
a - Models adjusted for Age, BMI and Marital status 
Specific Aim 1d: Interaction of Current, Active Smoking and NAT2 Acetylator 
Status on Fecundability 
Effect modification of NAT2 acetylator status on the effect of smoking on 
fecundability was examined by adding an interaction term into the models used from Aim 
1a, among the three populations. NAT2 acetylator status compared slow and rapid 
acetylators. A total of 29 women did not have NAT2 acetylator status, either because they 
did not provide a urine sample or had issues with DNA amplification/contamination, 
reducing the total sample to 194. All full models were adjusted for age, BMI, gravidity, 
marital status, race and NAT2 acetylator status. No statistically significant interactions 
were detected among any of the populations (Table 17). In the NC follow-up time model, 
current smokers with a slow acetylation status had a 41% reduction in fecundability 
compared to nonsmoking women with rapid acetylation status. The estimate was adjusted 
for age and BMI but was not statistically significant (95% CI:0.11, 3.27). Among the 
MAR cycles only model, current smokers with a slow acetylation status had 6.85 times 
the increase in fecundability compared to nonsmoking women with rapid acetylation 
status. However, this association may have been due to the fact that there were only 3 
women in the highest risk group and all 3 conceived. 
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Table 17: Interaction of Current Active Smoking and NAT2 Acetylator Status on 
Fecundability 
NAT2 
Status/ 
Smoking 
Exposure 
N 
(#events) 
FULL MODEL* MINIMALLY ADJUSTED 
MODELa 
Fecundability 
Ratio 
(95% CI) 
P-value for 
interaction 
Fecundability 
Ratio 
(95% CI) 
P-value 
for 
interaction 
ALL FOLLOW-UP TIME 
Rapid/ 
Nonsmoker 
84(38) (Referent) 0.55 (Referent) 0.52 
Rapid/ 
Smoker 
33(9) 0.97 (0.45, 2.12) 1.28 (0.58, 2.82) 
Slow/ 
Nonsmoker 
61(21) 0.73 (0.42, 1.27) 0.75 (0.44, 5.14) 
Slow/ 
Smoker 
16(5) 1.42 (0.53, 3.80) 
1.92 (0.70, 5.25) 
MAR CYCLES 
Rapid/ 
Nonsmoker 
30(22) (Referent) 0.007 (Referent) 0.04 
Rapid/ 
Smoker 
5(3) 1.09 (0.37, 3.23) 1.38 (0.34, 5.58) 
Slow/ 
Nonsmoker 
21(13) 1.10 (0.49, 2.46) 1.10 (0.50, 2.39) 
Slow/ 
Smoker 
3(3) 6.85 (2.72, 17.14) 8.22 (2.54, 26.74 ) 
NC FOLLOW-UP TIME 
Rapid/ 
Nonsmoker 
54(16) (Referent) 0.64 (Referent) 0.63 
Rapid/ 
Smoker 
28(6) 0.95 (0.37, 2.45) 0.89 (0.33, 2.38) 
Slow/ 
Nonsmoker 
40(8) 0.82 (0.36, 1.87) 0.80 (0.34, 1.88) 
Slow/ 
Smoker 
13(2) 0.59 (0.11, 3.27 ) 0.54 (0.09, 3.33) 
* - Full models for NC follow-up time adjusted for Age, BMI, Gravidity, Marital Status
and Race 
Full models for MAR cycles adjusted for MAR Type, Age, BMI, Gravidity, Marital 
status and Race 
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Full models for All follow-up time models adjusted for MAR cycle, Age, BMI, 
Gravidity, Marital status and Race 
a – Models adjusted for age and BMI for all cycles 
Specific Aim 2a (Active Smoking), Specific Aim 2b (SHS Exposure) 
and Specific Aim 2c (Combined Effect Exposure) on Probability of 
Spontaneous Abortion 
The association of active smoking (current and lifetime) and SHS exposure 
(recent and past year) and the combined effect exposure on SA were assessed using 
multivariable logistic regression. It should be reiterated that all tobacco smoke exposures 
were assessed pre-conception. The main outcome was SA, which was compared to live 
birth. Current active smoking compared smokers to nonsmokers, and a dose-response 
effect was examined using total cigarettes smoked per day. Lifetime smoking exposure 
was assessed using pack-years. Recent SHS exposure was measured using urinary 
cotinine levels and SHS exposure in the past year was measured using the SSQ score. 
Full models were adjusted for MAR, age, BMI, gravidity, marital status, race and alcohol 
use. Age and BMI were retained in all minimally adjusted models, along with 
confounders that changed smoking estimates more than 10%. Dose-response 
relationships were assessed using a test for trend and p-values were reported. Results are 
displayed in Table 18. 
In general, tobacco smoke exposure (both active smoking and secondhand) was 
associated with an increase in the odds of spontaneous abortion. Among the 72 women 
with known pregnancy outcome data, fully adjusted models had similar estimate effects 
to the minimally adjusted models. Current, active smokers (aOR:4.14; 95% CI:0.99, 
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21.25) had a marginally significant increase in the odds of SA compared to nonsmokers, 
adjusted for age, BMI and marital status. Women with 6 or more pack-years (aOR:1.77; 
95% CI: 0.48, 6.66) and 1-5 pack-years (aOR: 3.18; 95% CI: 0.58, 20.00) had increased 
odds of SA compared to nonsmokers. These estimate were adjusted for age, BMI, 
gravidity and marital status, and the test for trend was not significant (p = 0.10). Women 
who smoked 10 or more cigarettes a day (aOR: 2.03; 95% CI: 0.43, 9.29) and women 
who smoked 9 or fewer cigarettes a day (aOR: 1.93; 95% CI: 0.47, 9.38) had an 
insignificant increase in odds of SA compared to nonsmokers. These estimates were 
adjusted for age, BMI, gravidity, marital status and alcohol use and also, no dose-
response effect was found (p-trend = 0.28). 
Nonsmoking women with high SHS exposure in the past year had a significant 
increase in the odds of SA (aOR: 4.30; 95% CI: 1.14, 19.06) compared to low SHS 
exposure in the past year, adjusted for age and BMI. Among nonsmokers, high levels 
(aOR: 5.77; 95% CI: 1.09, 38.65, p = 0.05) and low levels (aOR: 2.67; 95% CI: 0.52, 
16.23) of urinary cotinine showed an increased odds of SA compared to unexposed 
women, adjusted for age, BMI, gravidity and race. The test for trend revealed a 
significant dose-response (p-trend = 0.04). 
Using the combined effect of active smoking and SHS exposure, current smokers 
(aOR: 6.28; 95% CI: 1.31, 37.92) and nonsmokers with high SHS exposure (aOR:3.20; 
95% CI: 0.87, 12.70) also had a significantly increased odds of SA compared to 
nonsmokers with low SHS exposure. These estimates were adjusted for age, BMI, 
gravidity and marital status; and produced a significant dose-response effect (p-trend = 
0.02). 
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Table 18: Multivariable Logistic Regression Models of Smoking Exposures and 
Spontaneous Abortion among All Conceptions 
 
                              N 
(#events) 
FULL MODEL* MINIMALLY 
ADJUSTED MODEL  
Odds Ratio 
(95% CI) 
P-
value 
Odds Ratio 
(95% CI) 
P-
value 
Current Active 
Smoking 
72 
    
Nonsmoker 58(21) 1.00 (Referent)  1.00 (Referent)  
Current, Active  
Smoker  
14(10) 3.94 (0.85, 24.07) 0.10 4.14b (0.99, 21.25) 0.06 
Total Cigarettes Smoked 
per Day 
  p-trend = 0.28 
Nonsmokers 49(17) 1.00 (Referent)  1.00 (Referent)  
≤ 9  11(7) 1.92 (0.43, 9.26) 0.40 1.93e (0.43, 9.29) 0.39 
≥ 10 12(7) 2.07 (0.47, 9.66) 0.34 2.03e (0.47, 9.38) 0.35 
 
Pack-years 
  
p trend = 0.10 
Nonsmokers 49(17) 1.00 (Referent) 1.00 (Referent) 
≤ 5 14(8) 1.62 (0.42, 6.45) 0.48 1.77c (0.48, 6.66) 0.39 
≥ 6 9(6) 2.93 (0.52, 18.88) 0.23 3.18c (0.58, 20.0) 0.19 
 
SHS Exposure in the Past Year •  
   
Low 41(12) 1.00 (Referent) 1.00 (Referent) 
High 17(7) 4.24 (1.05, 20.61) 0.05 4.30a (1.14, 19.06) 0.04 
 
Cotinine mg/dL • 
   
p trend = 0.04 
0 mg/dL 29(8) 1.00 (Referent) 1.00 (Referent) 
 
 
≤ 4 mg/dL 15(6) 2.58  
(0.50, 15.82) 
0.27 2.67d  
(0.52, 16.23) 
0.25 
5 - 99 mg/dL 12(7) 5.26  
(0.98, 35.51) 
0.06 5.77d   
(1.09, 38.65) 
 
0.05 
Combined Effect   
 
p trend =  0.019 
NS w/Low SHS 
Exposure 
41(12) 1.00 (Referent) 1.00 (Referent) 
NS w/High 
SHS Exposure 
17(9) 3.17 (0.86, 12.58) 0.09 3.20c (0.87, 12.7) 0.09 
Smokers  14(10) 6.56 (1.24, 46.54) 0.04 6.28c (1.31, 37.92) 0.03 
• - Models exclude current, active smokers        
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* - Full models adjusted for MAR conception, Age, BMI, Gravidity, Marital status, Race
and Alcohol use 
a - Models adjusted for MAR conception, Age and BMI 
b - Models adjusted for MAR conception, Age, BMI, Marital status 
c - Models adjusted for MAR conception, Age, BMI, Marital status and Gravidity 
d - Models adjusted for MAR conception, Age, BMI (continuous), Gravidity and Alcohol 
use 
e - Models adjusted for MAR conception, Age, BMI, Gravidity, Marital status and 
Alcohol use 
Abbreviations: NS - Nonsmoker 
Specific Aim 2d: Interaction of Current, Active Smoking and NAT2 Acetylator 
Status on Spontaneous Abortion 
Effect modification between current active smoking and NAT2 acetylator status 
on SA was examined by adding an interaction term into the models used from Aim 2a, 
among the three populations. NAT2 acetylator status was defined as rapid or slow. 
However, 10 participants from this analysis were missing NAT2 acetylator status, either 
because they did not provide a urine sample, or had issues with DNA 
amplification/contamination, making a final sample of 62. All models were adjusted for 
age, BMI, gravidity, marital status, race, alcohol use and NAT2 acetylator status. Results 
showed no statistically significant interaction (Table 19). Current smokers with a slow 
acetylator status had a 69% increase (95% CI: 0.08, 37.6) in the odds of SA compared to 
nonsmoking women with rapid acetylator status. The estimate was adjusted for age, BMI 
and MAR conception but was not statistically significant (P = 0.28).  This analysis was 
not stratified by MAR use because the samples became unreasonably small after 
stratification. 
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Table 19: Interaction of Current Active Smoking and NAT2 Acetylator Status with 
Spontaneous Abortion  
NAT2 
Status/ 
Smoking 
Exposure 
N 
FULL MODEL* MINIMALLY ADJUSTED 
MODELa 
Fecundability 
Ratio 
(95% CI) 
P-value for 
Interaction 
Fecundability 
Ratio 
(95% CI) 
P-value for 
Interaction 
ALL Conceptions (72) 
Rapid/ 
Nonsmoker 32(8) (Referent) 0.28 (Referent) 0.14 
Rapid/ 
Smoker 8(6) 9.36 (1.65, 79.5) 8.91 (0.92, 136.3) 
Slow/ 
Nonsmoker 17(12) 5.95 (1.61, 25.02) 9.07 (1.98, 55.39) 
Slow/ 
Smoker 5(4) 1.69 (0.08, 37.6) 0.55 (0.03, 11.56) 
a – Models adjusted for Age and BMI  
b – Models adjusted for MAR conception, Age, BMI, Gravidity, Marital status, Race, 
Alcohol use and NAT2 Acetylator status 
Specific Aim 3a: Assessment of Selection Bias Due to Loss to Follow-up 
The full dataset including women that contributed no follow-up time (n=257) was 
divided into two groups. Group 1 contained women that were not asked permission to be 
followed up (n=95) and Group 2 contained those who were asked (n=162). The 
population was then each stratified by the type of follow-up they received: either no 
follow-up, follow-up through medical record only; or personal follow-up by phone, email 
or mailing address. The characteristics of women from Group 1 and Group 2 can be 
found in the Appendix D (Table S9-10). 
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Characteristics of women in Group 2 were stratified by the type of follow-up: no 
follow-up, medical record follow-up only, and personal follow-up only. No significant 
differences were found between medical record follow-up and personal follow-up; 
therefore, these groups were combined for subsequent analyses.. This left “any follow-
up” to be compared with “no follow-up” (Table 20). 
Women lost to follow-up were more likely to have a higher BMI (P = 0.15), more 
likely to be of African American race (P = 0.02), more likely to be a current smoker (P = 
0.01), more likely to have higher urinary cotinine levels (P = 0.004) and more likely to 
report higher SHS exposure in the past year (P = 0.09). 
Table 20: Characteristics of Women Stratified by Follow-up Type(None vs. Any) 
(N=257) 
Lost to 
Follow-up 
N=28 
Medical Record or 
Personal  
N=229 
P-value 
Age in years, 
median (Q1-Q3) 
30.00      
(25.50-35.00) 
33.00 
(28.00-37.00) 
0.21 
Age in years, n (%) 0.36 
≤33 18(66.67) 127(55.46) 
>33 9(33.33) 102(44.54) 
BMI, kg/m2 
median (Q1-Q3) 
31.32 
(24.43-42.54) 
29.04 
(24.82-34.85) 
0.15 
BMI Category, kg/m2, n (%) 0.70 
<25 (Underweight 
and Normal) 
7(26.92) 61(26.64) 
25 - 29.9 
(Overweight) 
5(19.23) 63(27.51) 
≥ 30 (Obese) 14(53.85) 105(45.85) 
BMI kg/m2, n (%) 0.57 
≤30 12(66.67) 124(55.46) 
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>30 14(33.33) 105(44.54)  
Gravidity, n (%) 0.26 
0 7(25.93) 97(42.36) 
1 8(29.63) 51(22.27) 
>=2 12(44.44) 81(35.37)  
Regular Period, 
n (%) 
0.11 
No 14(51.85) 78(34.06) 
Yes 13(48.15) 151(65.94) 
Average Cycle 
Length, days, 
median (Q1-Q3) 
28.00 
(27.50-29.50) 
29.00 
(28.00-30.00) 
0.36 
Age of Menarche in 
years, median  
(Q1-Q3) 
12.00 
(11.00-13.00) 
12.00 
(11.00-14.00) 
0.11 
Previous STD, 
n (%) 
0.78 
No 17(65.30) 136(60.44) 
Yes 9(34.62) 89(39.56)  
Marital Status, 
n (%) 
0.76 
No 11(42.31) 85(37.12) 
Yes 15(57.69) 144(62.88)  
Routine Exercise,  
n (%) 
0.37 
No 13(56.52) 96(44.24) 
Yes 10(43.48) 121(55.76)  
Alcohol Use, n (%) 0.93 
No 16(59.26) 129(56.33) 
Yes 11(40.74) 100(43.67) 
Caffeine Use, n (%) 0.43 
No 3(11.54) 45(19.91) 
Yes 23(88.46) 181(80.09)  
Race, n (%) 0.02 
Other 12(44.44) 158(69.00) 
Black 15(55.56) 71(31.00) 
AMH (ng/mL), 
median (Q1-Q3) 
2.03 
(0.76-4.82) 
2.49 
(1.30-5.03) 
0.49 
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Length of 
Infertility, years 
median (Q1-Q3) 
1.75 
(0.79-4.00) 
2.00 
(0.92-4.25) 
0.82 
NAT2 Acetylator Status, n (%) 1.00 
Rapid 15(60.00) 119(60.41) 
Slow 10(40.00) 78(39.59) 
Cotinine (mg/dL), 
median (Q1-Q3)  
100.00 
(2.25-100.00) 
1.50 
(0.00-38.00) 
0.004 
Cotinine mg/dL, n 
(%) 
0.01 
0 5(18.52) 84(38.71) 
<100 8(29.63) 81(37.33) 
100 14(51.85) 52(23.96) 
Current Active Smoker, n (%) 
No 14(50.00) 173(75.55) 0.01 
Yes 14(50.00) 56(24.45) 
Self-reported SHS Exposure, n (%) 0.09 
Low 9(32.14) 117(51.09) 
High 19(67.86) 112(48.91) 
Specific Aim 3b: Inverse Probability Weighting 
Table 21 shows the weighted ORs and weighted FRs estimates adjusting for 
confounding and selection bias due to loss to follow-up, separately and jointly for 
conception as a dichotomous variable and fecundability. Results showed that there was 
little difference between adjusting for confounding only and adjusting for both 
confounding and selection bias due to loss of follow-up in all models. This may suggest 
that the results are not biased to loss to follow-up. These estimates were also compared to 
the estimates from the original analysis (Table 14).  The original results from Table 14 
showed an adjusted effect estimate in the opposite (anticipated) direction (aFR=1.26 95% 
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CI 0.66, 2.41); however, compared to the effect estimate from Table 21 that was adjusted 
for both confounding and selection bias due to loss of follow-up (aFR=0.87 95% CI 0.45, 
1.68), the effect was in the anticipated direction. Overall, the conclusions remained 
consistent with no association between current smoking and fecundability.  
 
Table 21: Weighted Estimates Using Inverse Probability Weighting 
Model Estimate 95% CI 
Logistic Regression - Conception (All Women) OR  
 
Unadjusted and Unweighted 0.57 0.29, 1.10 
Adjusted for Confounding Only 0.99a 0.79, 1.23 
Adjusting for Both Confounding and Selection Bias Due to 
Loss of Follow-up 
  
0.98 0.80, 1.21 
Logistic Regression - Conception (NC Follow-up Months) OR  
 
Unadjusted and Unweighted 0.74 0.30, 1.69 
Adjusted for Confounding Only 0.89b 0.77, 1.03 
Adjusting for Both Confounding and Selection Bias Due to 
Loss of Follow-up 
  
0.90 0.78, 1.05 
Survival Analysis - Fecundability (All Follow-up Time) FR  
 
Unadjusted and Unweighted 0.69 0.38, 1.23 
Adjusted for Confounding Only 0.90a 0.46, 1.76 
Adjusting for Both Confounding and Selection Bias Due to 
Loss of Follow-up 
  
0.87 0.45, 1.68 
Survival Analysis - Fecundability (NC Follow-up Months) FR  
 
Unadjusted and Unweighted 0.95 0.44, 2.05 
Adjusted for Confounding Only 0.70b 0.29, 1.70 
Adjusting for Both Confounding and Selection Bias Due to 
Loss of Follow-up  
0.73 0.31, 1.74 
a - Adjusted for MAR cycle, Age, BMI, Gravidity, Marital status and Race 
b - Adjusted for Age, BMI, Gravidity, Marital status and Race 
Abbreviation: MAR - Medically Assisted Reproduction, NC- Natural Conception 
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VI. DISCUSSION
This preconception cohort study was done to examine the association of tobacco 
smoke exposures on fertility and fertility-related outcomes, among women of 
reproductive age seeking fertility counselling and treatment. Overall, smoking and SHS 
exposure were not appreciably associated with fecundability, but the directions of 
associations were opposite for women who used MAR vs. those who conceived naturally. 
Smoking and high SHS exposure were associated with increased odds of spontaneous 
abortion among women who conceived.  
Active Smoking and Fecundability 
 Although no significant associations between tobacco smoke exposure and 
fecundability were observed in this study, the difference in the direction of association in 
those using MAR techniques vs. those who conceived naturally indicates that the effects 
of smoking in these two groups may be fundamentally different. Different biological 
mechanisms may be at play, which are discussed in more detail below. Additionally, the 
population who used MAR was different in that they were significantly older, less likely 
to be obese, more likely to be married, less likely to be a current smoker, and had lower 
urinary cotinine levels. Some of these factors may be modifying or attenuating the effect 
of smoking on the probability of conception using MAR. For example, the women using 
MAR may be ‘healthier’ in terms of their ability to conceive, due their lower BMI and 
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lower stress, because of a presumably better support system. Women using MAR were 
more likely to be married, which can act as a proxy for sexual intercourse frequency, 
emotional support or the seriousness of intention to become pregnant.  These factors may 
directly or indirectly modify the effect of smoking on conception. 
Our results did not show an effect of active smoking on probability of conception 
using MAR, which is consistent with other studies (178–181). However, there have been 
many studies that show associations with smoking and lower success among MAR, 
specifically using IVF (131,132,182,183). A recent meta-analysis in 2018, examined 26 
studies with samples ranging from 40 to 834, found a significant overall association 
between active smoking on ART outcomes (Pooled OR: 0.53, 95%CI: 0.41, 0.68). 
Associations remained significant when the analysis was restricted to IVF cycles (16 
studies, Pooled OR:0.52, 95%CI:0.39, 0.68). While, the authors did report a moderate 
amount of heterogeneity between studies, and heavy reliance on self-reported exposure 
data, there is strong evidence to suggest an association between smoking and conception 
among women using MAR. Our results are still consistent with a possible harmful effect; 
inference is difficult due to the small number of smokers (11) who ever used MAR, 
leading to wide confidence intervals. 
For natural conceptions, there is a plethora of studies supporting the association of 
active smoking with longer time to conception and increased risk of infertility 
(38,125,127,130). However, the magnitude of the associations is not overwhelming, with 
the majority of studies producing weak effect sizes. Few studies have found significant 
dose-response effects for female cigarette use with infertility and fecundability 
(38,125,128). Curtis and colleagues found a significant dose-response effect among 
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heavier smokers when examining the effect of smoking on fecundability. Women 
smoking 11–20 cigarettes (aFR:0.87; 95%CI: 0.77, 0.99) and more than 20 cigarettes per 
day (aFR:0.74; 95%CI: 0.59, 0.92) had reduced fecundability (38). Wesselink and 
colleagues found similar weak associations and noted that the dose-response effect on 
fecundability may only be among heavy smokers (135). Other studies also found 
associations at higher intensities (25,126,184). Our study also found stronger reductions 
in fecundability with increasing smoking intensity and cumulative lifetime exposure.  
Although approximately 25% of our study population were active smokers, consistent 
with what is seen in Kentucky (92), we had few heavy smokers, and our estimates were 
not statistically significant. Overall, the evidence suggests that the effect of smoking on 
fecundability may be limited to the heavy smokers. 
Secondhand Smoke Exposure and Fecundability 
Overall, our results showed no effect of recent or past year’s SHS exposure on 
fecundability among nonsmokers. The difference in the direction of association between 
women using MAR and women who conceived naturally can be explained similarly to 
the active smoking exposure. Within this population, nonsmoking women using MAR 
were significantly different, in that they had characteristics that have been shown to help 
increase fertility. These nonsmoking women using MAR were less likely to be obese, 
more likely to be married and had lower urinary cotinine levels, meaning they are 
healthier in some ways than women who did not use MAR, and had lower levels of 
exposure  
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For women who conceived naturally, a small but insignificant reduction in 
fecundability was reported for high SHS exposure compared to low SHS exposure. 
These results are consistent with the previous literature showing either weak associations 
(122,127) or no effect (126,139,140). Authors Radin and Wesselink both used 
prospective cohort studies to examine self-reported SHS exposure on fecundability with 
weak, insignificant findings (aFR: 0.92; 95% CI: 0.83,1.03) and (aFR: 0.93; 95%CI: 
0.70,1.25), respectively(126,135). Benedict and colleagues retrospectively analyzed a 
cohort study among verified nonsmoking women undergoing IVF treatment and found 
that women with follicular fluid cotinine concentrations between 1.11 and 10 ng/ml had 
increased risk of implantation failure (aRR: 1.17;95%CI: 1.20,1.92) (122). Sapra and 
associates used prospective cohort study to examine heavy metals and serum cotinine 
concentrations on TTC. Authors found a significant association for serum cotinine levels 
greater than 10 ng/mL and longer TTC in females (aFR:0.64; 95%CI:0.41,.0.98) (127). 
However, the association was greatly attenuated after adjusting for cadmium levels, 
suggesting that cadmium may be responsible for some of the association between tobacco 
use and longer TTC. 
There are several proposed mechanisms to explain how tobacco smoke exposure 
may affect fecundability. Studies have shown tobacco smoke toxins accumulate within 
follicular fluid and surrounding tissues (106,110). The harmful substances within tobacco 
smoke can affect gametogenesis, which can increase the risk of aneuploidies within 
embryos and affect folliculogenesis by lowering ovarian reserve through impaired follicle 
growth or development of oocytes (107,114). Some of the mechanisms include meiosis 
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impairment, abnormal intercellular crosstalk, DNA damage, high levels of oxidative 
stress, and activation of cell death pathways (107,108,110,114). 
Heavy metals and toxins in tobacco smoke promote oxidative stress which can 
lead to deleterious effects on cell membranes, DNA and proteins (107,110). DNA 
damage can then lead to chromosomal abnormalities which in turn adversely affect 
fertilization (114). Cadmium and benzo(A)pyrene, which are commonly found in tobacco 
smoke, can also impair steroidogenesis, resulting in hormonal imbalances that can affect 
both fertilization and implantation (107,108). Nicotine is a well-known strong 
vasoconstrictor that can impair blood flow to the uterus. The structural function within 
the fallopian tubes, uterus and cervix is also compromised, as the toxins act as adhesions 
to lower ciliary cell activity, impair smooth muscle contraction and lower oocyte retrieval 
rates (108,111). 
This study examined active smoking and SHS exposure from preconception in 
both natural and assisted conception, which allowed for detailed biological mechanisms 
to be hypothesized. Among natural conceptions, the observed effect of tobacco smoke 
exposures on reduced fecundability supported the mechanisms described earlier. 
However, for women using MAR, fecundability may not be affected by tobacco smoke 
exposure after OI or oocyte retrieval for IVF. This suggests that the toxins from cigarette 
smoke may only affect fecundability via folliculogenesis through impaired follicle 
growth or development of oocytes and steroidogenesis through hormonal imbalances that 
impair ovulation. However, after OI and oocyte retrieval for IVF-ET, smoking may not 
affect to a large extent other aspects such as implantation and/or development of the 
trophoblast. 
138 
This study is the first to analyze effect modification by NAT2 acetylator status on 
active smoking and fecundability among a clinical population. While no statistically 
significant interactions were detected among any of the populations, results may suggest 
lower fecundability for current smokers who are slow NAT2 acetylators for natural 
conceptions. However, the lack of significant associations may have been due to small 
sample sizes among subgroups of smokers within this study. One other study that found 
similar results examined the interaction of NAT2 and current smoking on fecundability 
among women office workers. They found significantly reduced fecundability among 
currents smokers with a slow acetylation status (15). The possible mechanism of effect 
modification may be through polycyclic aromatic hydrocarbons and heterocyclic amines, 
that are known constituents of tobacco smoke and are also metabolized by NAT2. Slow 
acetylators may experience greater accumulation of these constituents within the ovarian 
tissue and follicular fluid inducing higher levels of ovarian toxicity. Fecundability may be 
also affect by several mechanisms, including increased oxidative stress and DNA 
damage. 
Active Smoking and Spontaneous Abortion 
Among 72 conceptions with documented pregnancy outcomes, a marginally 
significant association between current active smoking and SA was observed. Results 
also showed increasing odds of SA with increasing intensity of smoking and cumulative 
lifetime exposure. However, no significant dose-response effect was established for 
either. Our results are consistent with Nielsen and colleagues, who also used 
preconception smoking exposure on SA in a nested case-control study. However, their 
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results showed a significant dose-response effect for every 5 cigarettes smoker per day 
(aOR: 1.20; 95%CI: 1.04,1.39) (144). Another recent case-control study also found a 
significant dose-response effect but for maternal smoking ≥20 cigarettes a day and SA 
(aOR: 2.39; 95%CI:1.26, 4.25) (185). While, there are a few studies that found 
significant dose-response effects, other studies reported no significant effect for smoking 
intensity and SA (143,186).   
Studies among women undergoing ART have shown an association between 
maternal smoking and adverse ART outcomes, particularly SA. Budani and colleagues 
conducted a meta-analysis using 8 studies and found significantly increased odds of SA 
per clinical pregnancy rate and maternal smoking (Pooled OR: 2.22; 95%CI: 1.10,4.48). 
However, the authors did report a substantial amount of heterogeneity between the 
studies. The majority of studies within the literature used self-reported information about 
smoking, which can result in misclassification as women can either under-report their 
exposures or change their behaviors throughout the pregnancy. Variation in the accuracy 
of smoking exposures may explain some of the heterogeneity across studies. In our study, 
we verified recent smoking using urinary cotinine; however, we did not ask or verify 
whether the women continued to smoke during pregnancy. In addition, we were unable to 
stratify the SA analysis by MAR, due to small numbers. Nonetheless, our findings are 
consistent with the previous studies for both medically assisted and natural conceptions 
and demonstrate a harmful effect of smoking on ongoing conceptions, leading to 
spontaneous abortion.  
The rate of spontaneous abortion in this study (43%) was noticeably higher than 
in the general population, commonly estimated to be 15-20%.  However, these 
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pregnancies were closely followed, allowing for detection of early losses that might 
usually go unnoticed, especially for women who use MAR.  Preconception tobacco 
smoke exposure captures a critical exposure period that can help elucidate potential 
biological mechanisms. It may be that through its proximal effects on the uterine 
environment, preconception smoking is more likely to cause early pregnancy losses (loss 
of ‘biochemical pregnancies’), as opposed to later, clinical pregnancy losses. More 
studies examining preconception smoking exposures on both planned natural conceptions 
and MAR/ART outcomes are needed to understand the biological mechanisms of this 
critical exposure period. 
Secondhand Smoke Exposure and Spontaneous Abortion 
Among verified nonsmokers, high SHS exposure in the past year was 
significantly associated with increased odds of SA, with a significant dose-response 
effect for preconception urinary cotinine. The combined effect exposure also showed 
increased odds of SA for nonsmokers with high SHS exposure and even greater increased 
odds of SA for current smokers compared to nonsmokers with low SHS exposure, 
supporting the association with a significant test for trend. 
It is possible that the effect of preconception maternal SHS exposure may be 
confounded by paternal smoking, whereby the observed effect of maternal SHS on SA is 
actually mediated by damaged sperm from the father. We investigated this possibility. 
We did not find evidence that the association of preconception maternal SHS was 
confounded by paternal smoking; of the women whose spouses smoked, the spouses were 
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not diagnosed with male factor infertility. This suggests that the estimate was not biased 
by confounding from spousal smoking or male factor infertility.  
Several previous studies examined maternal exposure to SHS on SA found 
significant associations; however, there is lack of studies examining preconception SHS 
exposures on pregnancy outcomes. Many of the studies that found significant effects for 
maternal smoking on SA used weaker study designs and relied on unverified self-
reported exposure data (145,149,150), likely attenuating any associations. One case-
control study used plasma cotinine levels to examine SHS exposure on SA. The authors 
found a significant association for plasma cotinine levels between 0.1 and 15 ng/mL and 
increased odds of SA (aOR:1.67; 95%CI: 1.17,2.38) (151). There are, however, several 
studies that reported no association between SHS exposure during pregnancy and SA 
(139,140,152). Pineles and colleagues conducted a meta-analysis examining SHS 
exposure during pregnancy and SA using 17 studies. Researchers found no significant 
association between SHS exposure during pregnancy and SA (148). Sensitivity analyses 
retained insignificant estimates when studies among nonsmokers only were used. This 
study may have been able to detect small effects due to the sensitive measures of SHS 
from both urinary cotinine and a questionnaire; the ability to adjust for more relevant 
confounders than previous studies; and the ability to detect very early pregnancy losses. 
It is difficult to make inferences regarding whether NAT2 acetylator status 
modified the effect of smoking on SA, because there were very few women in some of 
the subgroups. For example, there were only 3 smokers who were slow acetylators and all 
3 conceived. 
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Several mechanisms by which tobacco smoke exposure affects spontaneous 
abortions have been hypothesized. These include DNA damage, apoptosis, impairment of 
tissue development, or disruptions within cell division and other processes (75,79). 
Aneuploidies can also form from DNA damage and increase the odds of chromosomal 
abnormalities which is the most common cause of SA (10,79). Cadmium and nicotine 
directly constrict blow flow to the uterus, impairing development of the placenta and 
consequently resulting in EPL (108). Other mechanisms include impairment of 
trophoblast growth, impairment of adhesions cells for embryo post-implantation and 
apoptosis of placental cells (108,111). A detailed exploration of tobacco smoke exposures 
during different critical periods of development will be important in elucidating potential 
biological mechanisms and much needed to infer causality. 
This study examined active smoking and SHS exposure on SA within a 
population that is composed of infertile or subfertile women/couples. The majority of SA 
occurred among women who conceived using MAR (64.5%). Some potential 
mechanisms behind tobacco smoke exposure and SA among MAR users include 
accumulation of cotinine or other harmful toxins within the uterus, affecting processes 
after implantation such as restricting blood flow to the uterus and impairing placental 
development.  
Strengths and Limitations 
This study has several strengths. Firstly, its prospective cohort design allowed for 
assessment of preconception tobacco smoke exposures; and prospectively following the 
subjects from enrollment to pregnancy and pregnancy outcomes establishes temporality, 
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boosting the evidence for a causal association. Conception and pregnancy outcome data 
were either extracted from medical records in duplicate which increased their accuracy, 
or self-reported by women at follow-up intervals. Women who gave permission were 
personally contacted in approximately 6-month intervals after their enrollment to collect 
data. This allowed an ample amount of time for pregnancy, but short enough to minimize 
recall bias. Also, using a prospective cohort allows for time to conception analysis and 
adjustment for time-varying exposures and confounders. The analytic approach allowed 
for use of time-to-event data, as opposed to simply modeling the probability of a 
dichotomous outcome. Survival analyses therefore yield ratio estimates that are more 
robust and meaningful, compared to binary regression such as logistic regression. 
A second strength of this study includes the high retention rate. Out of all 257 
women, 229 (89.1%) were successfully followed up, either through information extracted 
from medical records and/or through personal re-contact if they gave permission. Female 
smoking was found to be related to attrition in that current smokers were more likely to 
be lost to follow-up. If the smokers who were lost to follow-up had a lower chance of  
conceiving than the smokers who remained in the study, the probability of conception 
among the smokers would be overestimated. However, after investigating the potential 
effects of selection bias due to loss of follow-up using IPW, the results showed little 
difference between adjusting for confounding only and adjusting for both confounding 
and selection bias due to loss of follow-up for both outcomes. This may suggest that the 
results are not biased due to loss to follow-up. 
A third important strength of the study is the use of an objective biomarker to 
verify smoking status. As shown in this study, women tend to under-report their smoking 
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behaviors, which can cause misclassification and may cause bias towards the null, as it 
adds smokers to a presumably non-smoking group. In this study, 16 women reported 
being a nonsmoker or a former smoker, but their high cotinine levels indicated that they 
were currently smoking (>100 ng/mL).  These women were grouped with verified current 
smokers based on their urinary cotinine levels at the time of enrollment.  
Lastly, to the best of our knowledge, this is the only study to explore effect 
modification by NAT2 acetylator status on the relationship between smoking and 
fecundability, as well as spontaneous abortion in a clinical population. Investigating 
possible gene-environmental interactions can help to uncover potential biological 
mechanisms and also can help to explain heterogeneity in results of prior studies.  
There are a few limitations that should be acknowledged. Firstly, external validity 
may be limited, given the specific clinical population used for this study. The results may 
not be generalizable to the public, as they may have significantly different characteristics 
compared women seeking fertility care. Secondly, the results were limited by the small 
sample size of heavy/intense smokers (≥10 cigarettes per day, n=37). Also, after 
stratifying the results for fecundability by MAR cycles only (n=70) and NC follow-up 
time only (n=153), there were even smaller samples within sub-groups, especially the 
MAR-cycles-only models. The analysis for SA was also a small subset of the original 
population (n=72 conceptions). This reduced the power to detect any possible interactions 
with NAT2 acetylator status on smoking with fecundability and SA. Small sample sizes 
within sub-groups affected the precision of the estimates, resulting in wide confidence 
intervals. Furthermore, given the small numbers there is a possibility that the associations 
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for tobacco smoke exposure on SA reported were due to chance, though this association 
is biologically plausible and has other support in the literature.  
Preconception smoking is a critical exposure period that has not been fully 
explored especially with regard to SA. However, most women change or under-report 
their smoking behaviors when they become pregnant. Given that smoking was measured 
at one point in this study, it is not clear whether the effect of preconception smoking on 
SA is truly a lasting result of smoking prior to pregnancy, or if the effect is seen because 
the women kept smoking during pregnancy.  
A fourth limitation of the study includes the restriction to women planning a 
pregnancy. Women seeking fertility care and treatment, with the intention of conceiving 
were eligible for the study. Theoretically, less fertile smokers would have been enrolled, 
given that smokers are more likely to have unplanned pregnancies either because of lack 
of contraceptive use or risky behaviors. 
There is also the possibility of residual confounding from both measured and 
unmeasured confounders. To create a parsimonious model, many variables were treated 
continuously or simply dichotomized. The estimates for tobacco smoke exposure and SA 
were larger compared to past studies. This may reflect residual confounding from 
unmeasured variables. While the results were likely not confounded by spousal smoking 
or male factor infertility, there may have been other unmeasured confounders; high 
secondhand smoke exposure may reflect other adverse environmental exposures, or 
unhealthy social or behavioral exposures. 
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The rate of SA was significantly higher than expected at 43%. This is likely 
because it included early biochemical pregnancy losses.  Information was not collected to 
separate early from late SA, which could have provided more insight into mechanism.  
Time to conception was measured in months and not by menstrual cycles. Women 
with irregular menstrual cycles which is common among anovulatory infertility may not 
ovulate every month. Hence, using months may have overestimated time to conception 
and not accurately reflect cycles-at-risk.  
 
Suggestions for Future Research 
The 2020 U.S. Surgeon General report is still stating that there is insufficient 
evidence to infer an association between tobacco smoke exposure and SA because of 
many methodological concerns. Future studies should consider using more large-scale, 
longitudinal prospective studies to help infer causality and biomarkers to validate self-
reported exposures. Dose-response effects and measuring tobacco smoke exposures at 
critical exposure periods and developmental windows, and at multiple intervals can help 
to fully capture the effects and elucidate biological mechanisms. Additionally, many of 
the studies that examined MAR procedures only took IVF into account; however, more 
research is needed to address whether the effects of smoking are observed across all 
treatment procedures including OI, IUI and FET.   
When examining natural follow-up time, ovulation kits should be used so that the 
number of cycles of follow-up can be accurately determined. Careful consideration 
should also be taken when adjusting for all important confounders and examining 
potential effect modifiers, such as genetic variants and types of infertility diagnosis. 
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Information on paternal smoking should be collected. Lastly, cohort studies study should 
be designed to maximize retention and reduce potential selection bias and appropriate 
statistical analyses should also be done to assess and adjust for bias, such as selection and 
attrition bias, before reporting estimates that may reflect spurious associations. 
Conclusion 
Infertility and adverse pregnancy outcomes remain growing public health 
problems. There are several studies supporting the association of active smoking on 
lowered fecundability, increased infertility, and increased risk of adverse pregnancy 
outcomes. However, according to the latest U.S. Surgeon General’s report, the literature 
is still insufficient with regard to SHS exposures. This study used a prospective cohort 
study design, along with objective markers of exposure assessment, adjusted for potential 
biases and explored a gene-environment interaction, to further clarify the effect of active 
smoking on both assisted and natural conceptions, and added to the small body of 
literature regarding the effect of SHS exposure on fecundability and SA. 
Results from this study did not show an association for active smoking or SHS 
exposure on fecundability, but there was suggestive evidence that the effect of active 
smoking may be more pronounced among slow acetylators. Significant associations were 
found for preconception active smoking and SHS exposure with a significant dose-
response effect for urinary cotinine on SA. These findings suggest that current smokers 
and nonsmokers with high levels of SHS exposure may have increased risk of adverse 
birth outcomes. Data from this dissertation can ultimately be used to support public 
policies that discourage smoking and limit the public’s exposure to secondhand smoke.
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APPENDIX A - LOUSSI Supplemental Smoking Questionnaire 
LOUSSI SUPPLEMENTAL SMOKING QUESTIONNAIRE 
LIFETIME EXPOSURE TO TOBACCO SMOKE 
INSTRUCTIONS 
Dear Participant:   
Thank you for taking the time to answer this questionnaire. This form should take 5 to 10 
minutes to complete. Your answers will be used for research purposes only.  Your doctor 
will not know the answers you have marked.  Information gained from this study will 
help scientists and doctors understand the effect of smoking and secondhand smoke on 
fertility.   
This packet contains three questionnaires.   
Please choose ONE questionnaire to complete, depending on whether you are a 
current smoker, former smoker, or nonsmoker.  Leave the other two questionnaires 
blank. 
CURRENT SMOKERS:  Please answer Questionnaire 1.  You are considered a 
current smoker if you currently smoke at least 1 cigarette/week, or if you recently quit 
(less than 1 month ago) 
FORMER SMOKERS: Please answer Questionnaire 2.  You are considered a former 
smoker if you quit more than 1 month ago and used to smoke at least 1 cigarette/week. 
NONSMOKERS: Please answer Questionnaire 3. You are considered a nonsmoker if 
you have never smoked more than 1 cigarette/week. 
Please place questionnaire in the envelope provided and return it to the study 
personnel or place it inside the designated LOUSSI Study dropbox when you are 
finished.   
Thank you very much for your time! 
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QUESTIONNAIRE 1 (FOR CURRENT SMOKERS) 
Answer this questionnaire if you currently smoke at least 1 cigarette/week, 
or if you quit smoking less than 1 month ago. 
Smoking History 
1. How many years have you been smoking (at least 1 cigarette/week)? _____
years 
(If you have smoked on and off, please add up the total number of years 
you smoked.)  
2. On the average, how many cigarettes (or packs) do you now smoke per day?
___ cigarettes/day or ____ packs/day 
(If you quit less than 1 month ago, please indicate how much you used to 
smoke before you quit.) 
Secondhand Smoke 
3. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside the home?)
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
4. Think about your home in the past year.  How often have you been exposed
to secondhand smoke inside your home?
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
5. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.)  In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
Please see back 
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6. Does anyone else living in your home smoke cigarettes, cigars or a pipe?
☐ Yes
☐ No
If you answered “Yes”, how many other people living in your home smoke these
tobacco products?
____Enter number 
     What is your relationship with the smoker(s)? (Check all that apply) 
____Spouse or partner 
____Other 
Other sources of nicotine 
7. Please check whether you have used any of the following in the past week:
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 
_____ Other source of nicotine: ______________ 
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QUESTIONNAIRE 2 (FOR FORMER SMOKERS) 
Answer this questionnaire if you used to smoke at least 1 cigarette/week and quit at 
least 1 month ago. 
Past Smoking 
1. When is the last time you smoked a cigarette?  (Month, Year) ____,______
2. How many years did you smoke at least 1 cigarette/week?    ____years
(If you smoked on and off, please add up the total number of years you smoked.) 
3. On the average, how many cigarettes (or packs) did you used to smoke per
day? 
___ cigarettes/day or ____ packs/day 
Secondhand Smoke 
4. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside the home?)
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
5. Think about your home in the past year.  How often have you been exposed
to secondhand smoke inside your home?
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
6. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.)  In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never Rarely   Often  Every day 
(less than once/week)      (1-6 days/week) 
Please see 
back 
7. Does anyone living in your home smoke cigarettes, cigars or a pipe?
☐ Yes
☐ No
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If you answered “Yes”, how many people living in your home smoke these tobacco 
products? 
____Enter number 
     What is your relationship with the smoker(s)? (check all that apply) 
____Spouse or partner 
____Other 
Other sources of nicotine 
8. Please check whether you have used any of the following in the past week:
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 
_____ Other source of nicotine: ______________ 
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QUESTIONNAIRE 3 (FOR NONSMOKERS) 
Answer this if you have never smoked more than 1 cigarette/week 
The goal of this questionnaire is to determine how much exposure to secondhand smoke 
you have had in your lifetime. 
Secondhand Smoke  
1. Think about your home when you were growing up (less than 18 years old).
On average, how often were you exposed to secondhand smoke inside your
home? (For example, how often did your parents, guardians, or siblings smoke
inside your home?)
Never Rarely    Often  Every day 
(less than once/week)      (1-6 days/week) 
2. Think about your home in the past year.  How often have you been exposed
to secondhand smoke inside your home?
Never Rarely    Often  Every day 
(less than once/week)      (1-6 days/week) 
3. Think about other places you go on a regular basis. (For example, a friend or
relative’s house, your workplace, bars or restaurants, in your car or someone
else’s car, etc.)  In the past year, how often have you been exposed to
secondhand smoke inside other places besides your home?
Never Rarely    Often  Every day 
(less than once/week)      (1-6 days/week) 
4. Does anyone living in your home smoke cigarettes, cigars or a pipe?
☐ Yes   ☐ No 
If you answered “Yes”, how many people living in your home smoke these 
tobacco products? 
____Enter number 
What is your relationship with the smoker(s)? (check all that apply) 
____Spouse or partner 
____Other       Please see 
back  
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Other sources of nicotine 
5. Please check whether you have used any of the following in the past week:
_____ Nicotine patches 
_____ Nicorette gum or similar 
_____ E-cigarettes 
_____ Smokeless tobacco or chewing tobacco 
_____ Other source of nicotine: ______________ 
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APPENDIX B - Medical Record Data Extraction Form 
DATA COLLECTION FORM Subject Identification 
Number:  
Date of first visit (MM/YY):________________ 
Date of study enrollment (MM/YY):________ 
Age (years) at enrollment: ________________ 
Height: (feet, inches): ______feet_____inches 
Weight: _________pounds or __________ kg 
Body mass index: _________________kg/m2 
Total number of previous pregnancies: _____ 
Regular periods (yes/no): ________________ 
Average menstrual cycle length: _______days 
Age at first period: _________________years 
Sexually transmitted infections: _____(yes/no) 
   If yes, list:___________________________ 
 “Social History” Section: 
Occupation: __________________________ 
Married/single: _______________________ 
Partner/no partner? ___________________ 
Length of time with current partner: _______ 
Routine exercise (yes/no): ____________ 
       times/week: _____________________ 
       type of exercise: _________________ 
Hours per exercise time: _______________ 
Routine exposure to 
chemicals(Yes/no):______ 
If yes, list here: 
________________________ 
Diet restrictions: ____________________ 
Meals/day: ________________________ 
 Current tobacco use (yes/no): ________ 
Packs/day ________________________ 
     for how many years? ___________ 
Ever smoked 100 cigarettes? ________ 
Alcohol (yes/no) ________________ 
Alcoholic drinks/week___________ 
Caffeine (yes/no) __________________ 
Caffeinated drinks/day__________ 
Drugs (e.g. marijuana) (yes/no) _______ 
Ancestry or Race _________________ 
Consistent ovulation (yes/no)________ 
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Clinical measurements and records from patient visits:  
These will be updated as patient is followed up during the study period.  A date (MM/YY) will be 
included for all measurements. 
Blood Pressure (date of enrollment): ____________   Date: (MM/YY) 
__________________ 
Weight (at date of enrollment): ____________   Date: (MM/YY) 
__________________ 
Height: ___________ 
BMI (at date of enrollment) __________ 
Anti-Mullerian hormone level (1): ____________   Date: (MM/YY) __________________ 
Anti-Mullerian hormone level (2): ____________   Date: (MM/YY) __________________ 
Antral follicle count (1): ____________________ Date: (MM/YY) ___________________ 
Antral follicle count (2): ____________________ Date: (MM/YY) ___________________ 
Infertility diagnosis/diagnoses:  (More than one line is provided for multiple infertility diagnoses) 
How long has the couple been trying to conceive at baseline? _________years 
__________months 
Consistent ovulation? ________yes         __________no     __________unknown 
Patient’s Infertility Diagnoses (e.g., male factor, PCOS, fibroids, adhesions, tubal obstructions, 
etc.): 
_____________________      Date of diagnosis (MM/YY) _______________ 
_____________________      Date of diagnosis (MM/YY) _______________ 
_____________________      Date of diagnosis (MM/YY) _______________ 
Any diagnosis of PCOS (past or current?) YES/NO 
Comments on infertility diagnosis: 
Fertility treatments and interventions, and outcomes (This form may be 
photocopied if necessary) 
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IVF (1) :  Date of IVF procedure (MM/YY):  _____________ 
 ICSI (Intracytoplasmic sperm injection?)     YES/NO 
 Donor egg used?  YES/NO 
Type of ovarian stimulation (circle):   ORAL INJECTABLE  BOTH 
  Oocyte yield (the number of oocytes retrieved following ovarian stimulation): 
_____________ 
Number of zygotes created ______________ 
Number of embryos implanted _____________ 
Outcome of procedure (clinical pregnancy: yes/no) __________________ 
  
IVF (2) :  Date of IVF procedure (MM/YY):  _____________ 
 ICSI (Intracytoplasmic sperm injection?)    YES/NO 
 Donor egg used?  YES/NO 
Type of ovarian stimulation (circle):   ORAL INJECTABLE  BOTH 
Oocyte yield (the number of oocytes retrieved following ovarian stimulation): 
_____________ 
Number of zygotes created ______________ 
Number of embryos implanted______________ 
Outcome of procedure (ongoing pregnancy: yes/no) __________________ 
 
List other fertility interventions, date of treatment, and outcomes below: 
Examples: Ovulation induction (OI) + timed intercourse, OI + IUI (intrauterine insemination), 
surgical interventions 
1. Intervention: _____________________ 
 Date (MM/YY)________________________ 
Type of ovarian stimulation (circle):   ORAL INJECTABLE  BOTH 
Outcome of procedure (ongoing pregnancy: yes/no) __________________ 
2. Intervention: _____________________ 
 Date (MM/YY)________________________ 
Type of ovarian stimulation (circle):   ORAL INJECTABLE  BOTH 
Outcome of procedure (ongoing pregnancy: yes/no) __________________ 
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Did this patient become pregnant during the follow-up period (3 years from signing consent 
form)?   
YES/NO 
If YES, list estimated month and year of 
LMP (MM/YY):_______________  or 
Conception (MM/YY):_________  or 
Due date (MM/YY):___________  
Pregnancy outcome (circle on) 
(1) Live birth 
(2) Early pregnancy loss or Miscarriage 
(3) Ectopic pregnancy 
(4) Molar pregnancy 
(5) Stillbirth or fetal death 
Birthweight _________________ 
IF YES, what was the treatment or intervention that resulted in ongoing pregnancy? (or did she 
conceive without assistance?) 
_______________________________________ 
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APPENDIX C - Recontact Questionnaire 
Call script and Data Entry Form Participant 
ID____________________________ 
Instructions:  Call participants at least 24 hours after sending introductory email. Using 
phone numbers provided on informed consent form. 
If it goes to voicemail: 
Hello, my name is _______________ and I am calling from the University of Louisville 
school of public health.   
WE hope you received the email that we sent to you. In the past 18 months, you 
participated in a fertility study at the U of L fertility clinic.  To jog your memory, it was 
called the LOUSSI study, and you answered a short questionnaire and provided a urine 
sample. I am calling today to ask if you are still trying to conceive or if you have already 
conceived. This will take less than 5 minutes of your time. We will try to call you again 
in the next week. You can also call us at 502-852-4063 and leave us a voicemail with 
your name, phone number and most convenient time to call. Thank you very much again 
for your time. 
If someone answers: 
Hello, my name is _______________ and I am calling from the University of Louisville 
school of public health.  May I please speak with _________________?  
Hello, I’m the calling from the LOUSSI study that you participated in, at the U of L 
fertility clinic.  You answered a short smoking questionnaire and provided a urine 
sample. At your enrollment you gave us permission to contact you again and I am calling 
today to ask you a few follow-up questions. This will take less than 5 minutes of your 
time.  Is now a good time? 
If they say no- now is not a good time: 
“Okay, no problem.  When is a better time?” ____________________ 
  Or, Would you prefer us to send you an email with the questions? (get email 
address).  
Email address: _______________________________  
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If they agree to talk: 
1. Have you conceived since enrollment in the LOUSSI study? (YES or NO)
(if No, ask questions on this page) (if Yes, ask questions on the back) 
2. Are you still trying to conceive? (YES or NO)
(if NO, ask #3 and 4) 
3. How many months did you continue to try after being seen at the clinic?
______months 
4. Are you doing anything now to prevent pregnancy? (such as taking birth control
pills?) (Y/N)
Thank you so much for your time!  We really appreciate your participation 
in the study. Goodbye!  
FOR THOSE WHO HAVE CONCEIVED: 
5. How many times have you conceived since enrollment? __ times
6. (Let’s talk about the first time you became pregnant—if they have become
pregnant more than once.)  How did you become pregnant?
a. Did you conceive ‘naturally’?  (Yes/no)
If not, how did you conceive? 
b. Using ovulation induction? _________
c. Using intrauterine insemination? ____________
d. Using IVF or ICSI? __________
 If yes- Did you use donor eggs?  ______ 
7. When did you become pregnant—in other words, what was the date of the last
menstrual period before your pregnancy? _________
 (if they don’t remember LMP, ask for due date.) 
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8. Are you still pregnant now?   (Y or N)
If No:  8a. What the pregnancy outcome? (live birth, miscarriage, ectopic pregnancy, 
stillbirth, other) 
Thank you so much for your time!  We really appreciate your participation in the 
study. Goodbye!  
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APPENDIX D - Supplemental Tables 
S Table 1: Characteristic of Women by Current Smoking among non-MAR Users 
(N=130) 
Nonsmoker 
N=87 
Current Smoker 
N=43 
P - value 
Age in years, 
median (Q1-Q3) 
32.00 
(27.00-36.00) 
31.00 
(27.00-34.00) 
0.23 
BMI (kg/m2)  
median (Q1-Q3) 
30.44 
(24.58-36.78) 
30.64 
(25.93-34.65) 
0.82 
BMI kg/m2, n (%) 0.83 
<25 (Underweight and 
Normal) 
24(27.59) 10(23.26) 
25 - 29.9 (Overweight) 19(21.84) 9(20.93)  
≥ 30 (Obese) 44(50.57) 24(55.81)  
Gravidity, n (%) 0.38 
0 37(42.53) 14(32.56) 
1 16(18.39) 12(27.91) 
>=2 34(39.08) 17(39.53) 
Regular Period, n (%) 0.71 
No 30(34.48) 17(39.53) 
Yes 57(65.52) 26(60.47) 
Average Cycle Length 
(days), median (Q1-Q3) 
28.00 
(27.00-30.00) 
30.00 
(28.75-45.00) 
<0.001 
Age of Menarche, in 
years, median (Q1-Q3) 
13.00 
(12.00-14.00) 
12.00 
(11.00-13.00) 
0.23 
Previous STD, n (%) 0.03 
No 57(65.52) 18(43.90) 
Yes 30(34.48) 23(56.10) 
Marital Status, n (%) <0.001 
No 28(32.18) 30(69.77) 
Yes 59(67.82) 13(30.23) 
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 Exercise, n (%) 0.18 
No 36(43.90) 23(58.97) 
Yes 46(56.10) 16(41.03) 
Alcohol Use, n (%) 0.07 
No 60(68.97) 22(51.16) 
Yes 27(31.03) 21(48.84) 
Caffeine Use, n (%) 0.49 
No 18(21.18) 6(14.29) 
Yes 67(78.82) 36(85.71) 
Race, n (%) 0.021 
Other 60(68.97) 20(46.51) 
Black 27(31.03) 23(53.49) 
AMH (ng/mL),  
median (Q1-Q3) 
2.60 
(0.92-5.09) 
2.48 
(1.67-6.05) 
0.39 
Length of Infertility, 
years median (Q1-Q3) 
2.08 
(1.50-4.63) 
2.00 
(1.38-5.00) 
0.90 
NAT2 Acetylator Status, 
n (%)  
0.53 
Rapid 44(58.67) 26(66.67) 
Slow 31(41.33) 13(33.33) 
Pregnant, n (%) 0.97 
No 67(77.01) 34(79.07) 
Yes 20(22.99) 9(20.93) 
Pregnancy Outcome, 
n (%) 
0.021 
Live Birth 13(81.25) 2(25.00) 
Miscarriage 3(18.75) 6(75.00) 
Total Follow-up Time in 
years, median (Q1-Q3) 
8.00(4.00-15.00) 8.00(2.00-15.50) 0.58 
Cotinine Levels mg/dL, 
median (Q1-Q3) 
0.50(0.00-4.38) 100(100-100) < 0.001 
Cotinine Categories, 
n (%) 
< 0.001 
0 mg/dL 38(46.34) 0(0.00) 
<100 mg/dL 44(53.66) 2(4.76) 
100mg/dL 0(0.00) 40(95.24) 
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S Table 2: Characteristic of Women by Current Smoking among MAR Users 
(N=93) 
Nonsmoker 
N=81 
Current Smoker 
N=11 
P - value 
Age (years) 
median (Q1-Q3) 
33.00 
(29.25-37.00) 
36.00 
(34.50-38.50) 
0.06 
BMI, (mean ± SD), 
(kg/m2) 
29.01 ± 6.14 30.83 ± 4.98 0.35 
BMI kg/m2, n (%) 0.43 
<25 (Underweight and 
Normal) 
22(26.83) 1(9.09) 
25 - 29.9 (Overweight) 30(36.59) 4(36.36)  
≥ 30 (Obese) 30(36.59) 6(54.55) 
Gravidity, n (%) 0.07 
0 37(45.12) 5(45.45) 
1 22(26.83) 0(0.00) 
>=2 23(28.05) 6(54.55) 
Regular Period, n (%) 0.16 
No 28(34.15) 1(9.09) 
Yes 54(65.85) 10(90.91) 
Average Cycle Length 
(days), median (Q1-Q3) 
29.00 
(28.00-30.00) 
28.50 
(28.00-29.00) 
0.62 
Age of Menarche, in 
years, median (Q1-Q3) 
13.00 
(12.00-14.00) 
13.00 
(11.50-13.00) 
0.37 
Previous STD, n (%) 1 
No 50(61.73) 7(63.64) 
Yes 31(38.27) 4(36.36) 
Marital Status, n (%) 0.01 
No 18(21.95) 7(63.64) 
Yes 64(78.05) 4(36.36) 
Exercise, n (%) 0.75 
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No 31(38.75) 5(45.45) 
Yes 49(61.25) 6(54.55) 
Alcohol Use, n (%) 0.34 
No 37(45.12) 7(63.64) 
Yes 45(54.88) 4(36.36) 
Caffeine Use, n (%) 1 
No 16(19.51) 2(18.18) 
Yes 66(80.49) 9(81.82) 
Race, n (%) 0.21 
Other 68(82.93) 7(63.64) 
Black 14(17.07) 4(36.36) 
AMH (ng/mL), median 
(Q1-Q3) 
2.44 
(1.38-4.99) 
2.30 
(1.35-3.16) 
0.66 
Length of Infertility, 
years median (Q1-Q3) 
1.46 
(0.94-4.33) 
2.50 
(1.58-7.00) 
0.06 
NAT2 Acetylator 
Status, n (%)  
0.51 
Rapid 40(57.14) 7(70.00) 
Slow 30(42.86) 3(30.00) 
Pregnant, n (%) 1 
No 34(41.46) 5(45.45) 
Yes 48(58.54) 6(54.55) 
Pregnancy Outcome,  
n (%) 
0.39 
Live Birth 24(57.14) 2(33.33) 
Miscarriage 18(42.86) 4(66.67) 
Total Follow-up Time, 
years, median (Q1-Q3) 
5.00 
(3.00-12.00) 
7.00 
(3.50-8.00) 
0.85 
Cotinine Levels, mg/dL 
median (Q1-Q3) 
0.00 
(0.00-2.00) 
100 
(100-100) 
<0.001  
Cotinine mg/dL, n (%) <0.001 
0 44(56.41) 0(0.00) 
<100 34(43.59) 0(0.00) 
100 0(0.00) 10(100.00) 
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S Table 3: Characteristics of Nonsmoking Women Stratified by Recent SHS 
Exposure Measured With Urinary Cotinine among MAR Users (N=78) 
Cotinine = 0 
mg/dL 
N=44 
0 < Cotinine ≤ 
4mg/dL 
N=19 
4 < Cotinine ≤ 
47 mg/dL 
N=15 
P-value 
Age, years  
(mean ± SD) 
33.66 ± 5.26 32.89 ± 4.32 31.67 ± 5.30 0.42 
BMI, kg/m2 
(mean ± SD) 
27.77 ± 6.19 30.18 ± 4.39 32.06 ± 7.25 0.05 
BMI kg/m2, n (%) 0.44 
<25 (Underweight 
and Normal) 
15(34.09) 3(15.79) 3(20.00) 
25 - 29.9 
(Overweight) 
15(34.09) 8(42.11) 4(26.67) 
≥ 30 (Obese) 14(31.82) 8(42.11) 8(53.33) 
Gravidity, n (%) 0.011 
0 17(38.64) 14(73.68) 3(20.00) 
1 11(25.00) 2(10.53) 8(53.33) 
>=2 16(36.36) 3(15.79) 4(26.67) 
Regular Period, 
n (%) 
0.40 
No 12(27.27) 8(42.11) 6(40.00) 
Yes 32(72.73) 11(57.89) 9(60.00) 
Average Cycle 
Length 
(days), median 
(Q1-Q3) 
28.50 
(28.00-30.00) 
29.00 
(28.00-29.88) 
28.50 
(26.50-29.75) 
0.84  
Age of Menarche, 
in years, median 
(Q1-Q3) 
13.00 
(12.00-14.00) 
12.50      
(11.25-13.75) 
12.00          
(12.00-13.50)  
0.89 
Previous STD, 
n (%) 
0.73 
No 27(61.36) 12(66.67) 8(53.33) 
Yes 17(38.64) 6(33.33) 7(46.67) 
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Marital Status, 
n (%) 
0.32 
No 7(15.91) 5(26.32) 5(33.33) 
Yes 37(84.09) 14(73.68) 10(66.67) 
Exercise, n (%) 0.57 
No 14(33.33) 9(47.37) 6(40.00) 
Yes 28(66.67) 10(52.63) 9(60.00) 
Alcohol Use, 
n (%) 
0.45 
No 17(38.64) 10(52.63) 8(53.33) 
Yes 27(61.36) 9(47.37) 7(46.67) 
Caffeine Use, 
n (%) 
1 
No 9(20.45) 3(15.79) 3(20.00) 
Yes 35(79.55) 16(84.21) 12(80.00) 
Race, n (%) 0.81 
White 32(72.73) 12(63.16) 10(66.67) 
Black 6(13.64) 5(26.32) 3(20.00) 
Other 6(13.64) 2(10.53) 2(13.33) 
AMH  
(ng/mL), median 
(Q1-Q3) 
2.31         
(1.10-4.50) 
3.23         
(1.34-5.26) 
2.52
(1.87-4.44) 
0.73 
Length of 
Infertility, years 
median (Q1-Q3) 
1.04         
(0.88-3.33) 
1.50         
(1.19-5.50) 
2.21
(0.81-5.06) 
0.72 
Treatment 
Cycles, n (%) 
0.04 
1 17(38.64) 7(36.84) 10(66.67) 
2 12(27.27) 4(21.05) 5(33.33) 
3 and more 15(34.09) 8(42.11) 0(0.00) 
NAT2 Acetylator 
Status, n (%)  
0.40 
Rapid 25(64.10) 8(47.06) 7(50.00) 
Slow 14(35.90) 9(52.94) 7(50.00) 
Pregnant, n (%) 0.50 
No 20(45.45) 6(31.58) 5(33.33) 
Yes 24(54.55) 13(68.42) 10(66.67) 
Pregnancy 
Outcome, n (%) 
0.036 
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Live Birth 16(72.73) 5(50.00) 2(22.22) 
 
Miscarriage 6(27.27) 5(50.00) 7(77.78) 
  
 
Total Follow-up 
Time, years 
median (Q1-Q3) 
6.00 
(3.00-15.00) 
6.00 
(4.00-13.00) 
3.00         
 (2.00-10.50) 
  
0.17 
 
 
 
 
 
 
S Table 4: Characteristics of Nonsmoking Women Stratified by Recent SHS 
Exposure Measured with Urinary Cotinine among non-MAR Users (N=82) 
  
 Cotinine = 0 
mg/dL 
N=38 
0 < Cotinine 
≤ 4mg/dL 
N=23 
4 < Cotinine 
≤ 47 mg/dL 
N=21 
P-value 
Age, years  
(mean ± SD) 
 
33.47 ± 5.12 30.87 ± 6.06 31.00 ± 5.82 0.13 
  
BMI, kg/m2 
(mean ± SD) 
 
27.49         
(23.89-32.44) 
35.51             
(27.61-41.33) 
30.64     
(24.19-36.11) 
0.02 
BMI kg/m2, n (%) 
   
0.24 
<25 (Underweight and 
Normal) 
11(28.95) 4(17.39) 6(28.57) 
 
25 - 29.9 (Overweight) 12(31.58) 3(13.04) 4(19.05)  
 
≥ 30 (Obese) 15(39.47) 16(69.57) 11(52.38) 
 
Gravidity, n (%) 
   
0.02 
0 13(34.21) 15(65.22) 7(33.33) 
 
1 8(21.05) 5(21.74) 2(9.52) 
 
>=2 17(44.74) 3(13.04) 12(57.14) 
 
Regular Period, n (%) 
   
0.41 
No 13(34.21) 11(47.83) 6(28.57) 
 
Yes 25(65.79) 12(52.17) 15(71.43) 
  
 
Average Cycle Length 
(days), median (Q1-Q3) 
 
28.00      
(27.0-30.0) 
28.00      
(27.0-28.0) 
29.00      
(27.5-30.0) 
  
0.52 
Age of Menarche, in 
years, median (Q1-Q3) 
 
13(12-14) 12(11-13.5) 13(12-14) 0.43  
Previous STD, n (%) 
   
1 
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No 25(65.79) 15(65.22) 14(66.67) 
Yes 13(34.21) 8(34.78) 7(33.33) 
Marital Status, n (%) 0.15 
No 14(36.84) 4(17.39) 9(42.86) 
Yes 24(63.16) 19(82.61) 12(57.14)  
Routine Exercise, n (%) 0.04 
No 13(35.14) 7(33.33) 13(68.42) 
Yes 24(64.86) 14(66.67) 6(31.58) 
Alcohol Use, n (%) 0.64 
No 28(73.68) 16(69.57) 13(61.90) 
Yes 10(26.32) 7(30.43) 8(38.10) 
Caffeine Use, n (%) 0.56 
No 10(26.32) 3(13.04) 4(21.05) 
Yes 28(73.68) 20(86.96) 15(78.95) 
Race, n (%) 0.89 
White 15(39.47) 9(39.13) 8(38.10) 
Black 10(26.32) 7(30.43) 8(38.10) 
Other 13(34.21) 7(30.43) 5(23.81) 
AMH  
(ng/mL), median (Q1-
Q3) 
1.98        
(3.78-9.71) 
3.28         
(0.93-5.85) 
2.87
(1.04-6.93) 
0.41 
Length of Infertility, 
years median (Q1-Q3) 
2.00          
(1.50-4.00) 
2.08         
(1.50-3.38) 
2.50
(1.19-5.75) 
0.96 
NAT2 Acetylator 
Status, n (%)  
0.04 
Rapid 22(64.71) 15(71.43) 7(35.00) 
Slow 12(35.29) 6(28.57) 13(65.00) 
Pregnant, n (%) 0.89 
No 29(76.32) 17(73.91) 17(80.95) 
Yes 9(23.68) 6(26.09) 4(19.05) 
Pregnancy Outcome,  
n (%) 
1 
Live Birth 5(71.43) 4(80.00) 3(100.00) 
Miscarriage 2(28.57) 1(20.00) 0(0.00) 
Total Follow-up Time, 
years median (Q1-Q3) 
11.00     
(7.00-16.00) 
4.00         
(3.00-14.5) 
5.00  
(3.00-9.00) 
0.04 
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S Table 5: Characteristics of Nonsmoking Women Stratified by SHS Exposure 
Measured from SSQ among MAR Users (N=82) 
No and Low 
exposure 
(score=2,3) 
N=62 
Med and High 
exposure (score 
≥4) 
N=20 
P-value 
Age, years  
(mean ± SD) 
32.44 ± 5.15 34.2 ± 5.04 0.18 
BMI, kg/m2 
(mean ± SD) 
28.22 ± 5.58 31.47 ± 7.22 0.04 
BMI Category kg/m2, 
n (%) 
0.65 
<25 (Underweight and 
Normal) 
17(27.42) 5(25.00) 
25 - 29.9 (Overweight) 24(38.71) 6(30.00)  
≥ 30 (Obese) 21(33.87) 9(45.00)  
Gravidity, n (%) 0.85 
0 29(46.77) 8(40.00) 
1 16(25.81) 6(30.00) 
>=2 17(27.42) 6(30.00) 
Regular Period, n (%) 0.36 
No 19(30.65) 9(45.00) 
Yes 43(69.35) 11(55.00) 
Average Cycle Length 
(days), median (Q1-Q3) 
29.00 
(28.00-30.00) 
28.00 
(26.25-30.00) 
0.43 
Age of Menarche, in years, 
median (Q1-Q3) 
13.00 
(12.00-14.00) 
12.00 
(12.00-13.00) 
0.14 
Previous STD, n (%) 1 
No 38(62.30) 12(60.00) 
Yes 23(37.70) 8(40.00) 
Marital Status, n (%) 0.03 
No 10(16.13) 8(40.00) 
Yes 52(83.87) 12(60.00) 
Exercise, n (%) 1 
No 23(38.33) 8(40.00) 
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Yes 37(61.67) 12(60.00) 
Alcohol Use, n (%) 0.45 
No 26(41.94) 11(55.00) 
Yes 36(58.06) 9(45.00) 
Caffeine Use, n (%) 1 
No 12(19.35) 4(20.00) 
Yes 50(80.65) 16(80.00) 
Race, n (%) 0.63 
White 44(70.97) 12(60.00) 
Black 10(16.13) 4(20.00) 
Other 8(12.90) 4(20.00) 
AMH  
(ng/mL), median (Q1-Q3) 
2.44 
(1.34-4.98) 
2.40 
(1.55-5.47) 
0.86 
Length of Infertility, years 
median (Q1-Q3) 
1.02 
(0.31-2.77) 
2.52 
(0.77-7.00) 
0.04  
Treatment Cycles, n (%) 0.27 
1 25(40.32) 10(50.00) 
2 16(25.81) 7(35.00) 
3 and more 21(33.87) 3(15.00) 
NAT2 Acetylator Status,  
n (%) 
0.27 
Rapid 32(61.54) 8(44.44) 
Slow 20(38.46) 10(55.56) 
Pregnant, n (%) 0.53 
No 24(38.71) 10(50.00) 
Yes 38(62.30) 10(50.00) 
Pregnancy Outcome, n (%) 0.01 
Live Birth 22(68.75) 2(20.00) 
Miscarriage 10(31.25) 8(80.00) 
Total Follow-up Time, 
years median (Q1-Q3) 
5.00(3.00-12.00) 5.50(3.75-12.25) 0.55 
Cotinine Levels, mg/dL 
median (Q1-Q3) 
0.00(0.00-1.00) 1.25(0.00-15.63) 0.03  
Cotinine mg/dL, n (%) 0.01 
0 35(60.34) 9(45.00) 
<4 16(27.59) 2(10.00) 
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>= 4 7(12.07) 9(45.00) 
S Table 6: Characteristics of Nonsmoking Women Stratified by SHS Exposure 
Measured from SSQ among non-MAR Users (N=87) 
No and Low 
exposure (score=2,3) 
N=50 
Med and High 
exposure (score ≥4) 
N=37 
P-value 
Age, years  
(mean ± SD) 
33.16 ± 5.72 30.73 ± 5.23 0.045  
BMI, kg/m2 
median (Q1-Q3) 
30.45 
(24.75-35.02) 
29.04 
(24.14-37.25) 
1  
BMI kg/m2, n (%) 0.93 
<25 (Underweight and 
Normal) 
13(26.00) 11(29.73) 
25 - 29.9 (Overweight) 11(22.00) 8(21.62)  
≥ 30 (Obese) 26(52.00) 18(48.65)  
Gravidity, n (%) 0.61 
0 19(38.00) 18(48.65) 
1 10(20.00) 6(16.22) 
>=2 21(42.00) 13(35.14)  
Regular Period, n (%) 1 
No 17(34.00) 13(35.14) 
Yes 33(66.00) 24(64.86)  
Average Cycle Length 
(days), median (Q1-Q3) 
28.00 
(26.00-29.25) 
28.00 
(28.00-30.00) 
0.34  
Age of Menarche, in years, 
median (Q1-Q3) 
12.00 
(11.75-14.00) 
13.00 
(12.00-14.00) 
0.95  
Previous STD, n (%) 0.74 
No 34(68.00) 23(62.16) 
Yes 16(32.00) 14(37.84) 
Marital Status, n (%) 0.23 
No 13(26.00) 15(40.54) 
Yes 37(74.00) 22(59.46) 
189 
Exercise, n (%) 0.16 
No 17(36.17) 19(54.29) 
Yes 30(63.83) 16(45.71) 
Alcohol Use, n (%) 1 
No 34(68.00) 26(70.27) 
Yes 16(32.00) 11(29.73) 
Caffeine Use, n (%) 1 
No 10(20.41) 8(22.22) 
Yes 39(79.59) 28(77.78) 
Race, n (%) 0.02 
White 19(38.00) 16(43.24) 
Black 11(22.00) 16(43.24) 
Other 20(40.00) 5(13.51) 
AMH (ng/mL),  
median (Q1-Q3) 
2.48 
(0.81-3.84) 
2.67 
(0.99-6.28) 
0.52  
Length of Infertility, years 
median (Q1-Q3) 
2.00 
(1.04-4.00) 
3.00 
(1.03-5.00) 
0.73  
NAT2 Acetylator Status, 
n (%)  
0.79 
Rapid 23(56.10) 21(61.76) 
Slow 18(43.90) 13(38.24) 
Pregnant, n (%) 0.99 
No 38(76.00) 29(78.38) 
Yes 12(24.00) 8(21.62) 
Pregnancy Outcome, 
n (%) 
1 
Live Birth 7(77.78) 6(85.71) 
Miscarriage 2(22.22) 1(14.29) 
Total Follow-up Time, 
years median (Q1-Q3) 
9.00 
(4.25-10.48) 
5.00 
(3.00-13.00) 
0.13  
Cotinine Levels, mg/dL 
median (Q1-Q3) 
0.00 
(0.00-1.00) 
4.00 
(0.50-9.10) 
<0.001 
Cotinine mg/dL, n (%) <0.001 
0 30(63.83) 8(22.86) 
<4 10(21.28) 9(25.71) 
>= 4 7(14.89) 18(51.43) 
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S Table 7: Characteristics of Women that used ART Measured Using the 3-level 
Combined Effect Variable among MAR users (N=93) 
Nonsmokers 
with Low SHS 
N=62 
Nonsmokers 
with High SHS 
N=20 
Smokers 
N=11 
P - 
value 
Age, years  
median (Q1-Q3) 
33.00 
(29.00-37.00) 
35.00 
(31.00-38.25) 
36.00 
(34.50-38.50) 
0.07 
BMI, kg/m2 
(mean ± SD) 
28.22 ± 5.58 31.47 ± 7.22 30.83 ± 4.98 0.07  
BMI Category, 
kg/m2, n (%) 
0.61 
<25 (Underweight 
and Normal) 
17(27.42) 5(25.00) 1(9.09) 
25 - 29.9 
(Overweight) 
24(38.71) 6(30.00) 4(36.36) 
≥ 30 (Obese) 21(33.87) 9(45.00) 6(54.55)  
Gravidity, n (%) 0.22 
0 29(46.77) 8(40.00) 5(45.45) 
1 16(25.81) 6(30.00) 0(0.00) 
>=2 17(27.42) 6(30.00) 6(54.55)  
Regular Period, 
n (%) 
0.12 
No 19(30.65) 9(45.00) 1(9.09) 
Yes 43(69.35) 11(55.00) 10(90.91) 
Average Cycle 
Length (days), 
median (Q1-Q3) 
29.00 
(28.00-30.00) 
28.00 
(26.25-30.00) 
28.50 
(28.00-29.00) 
0.63 
Age of Menarche, 
years, median (Q1-
Q3) 
13.00 
(12.00-14.00) 
12.00 
(12.00-13.00) 
13.00 
(11.50-13.00)  
0.19 
Previous STD, 
n (%) 
1 
No 38(62.30) 12(60.00) 7(63.64) 
Yes 23(37.70) 8(40.00) 4(36.36)  
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Marital Status, 
n (%) 
0.002 
No 10(16.13) 8(40.00) 7(63.64) 
Yes 52(83.87) 12(60.00) 4(36.36) 
Exercise, n (%) 0.91 
No 23(38.33) 8(40.00) 5(45.45) 
Yes 37(61.67) 12(60.00) 6(54.55) 
Alcohol Use, n (%) 0.31 
No 26(41.94) 11(55.00) 7(63.64) 
Yes 36(58.06) 9(45.00) 4(36.36) 
Caffeine Use, n (%) 1 
No 12(19.35) 4(20.00) 2(18.18) 
Yes 50(80.65) 16(80.00) 9(81.82) 
Race, n (%) 0.29 
Black 10(16.13) 4(20.00) 4(36.36) 
Other 52(83.87) 16(80.00) 7(63.64) 
AMH  
(ng/mL), median 
(Q1-Q3) 
2.44 
(1.34-4.98) 
2.40 
(1.55-5.47) 
2.30 
(1.35-3.16) 
0.89 
Length of Infertility, 
years median (Q1-
Q3) 
1.21 
(0.94-2.94) 
2.75 
(0.94-7.00) 
2.50 
(1.58-7.00)  
0.02 
Treatment Cycles, 
n (%) 
0.39 
1 25(40.32) 10(50.00) 3(27.27) 
2 16(25.81) 7(35.00) 3(27.27) 
3 and more 21(33.87) 3(15.00) 5(45.45) 
NAT2 Acetylator 
Status, n (%) 
0.33 
Rapid 32(61.54) 8(44.44) 7(70.00) 
Slow 20(38.46) 10(55.56) 3(30.00) 
Pregnant, n (%) 0.66 
No 24(38.71) 10(50.00) 5(45.45) 
Yes 38(61.29) 10(50.00) 6(54.55)  
Pregnancy 
Outcome, n (%) 
0.01 
Live Birth 22(68.75) 2(20.00) 2(33.33) 
Miscarriage 10(31.25) 8(80.00) 4(66.67) 
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Total Follow-up 
Time, years median 
(Q1-Q3) 
 
5.00 
(12.00-3.00) 
5.50 
(12.25-3.75) 
7.00 
(8.00-3.50) 
  
0.81 
Cotinine Levels, 
mg/dL median (Q1-
Q3) 
 
0.00 
(0.00-1.00) 
1.25 
(0.00-15.63) 
100.00 
(100.0-100.0) 
<0.001 
Cotinine mg/dL, n 
(%) 
   
<0.001 
0  35(60.34) 9(45.00) 0(0.00) 
 
<4  23(39.66) 11(55.00) 0(0.00) 
 
>= 4  0(0.00) 0(0.00) 10(100.00) 
 
 
 
 
 
 
 
S Table 8: Characteristics of Women that used ART Measured Using the 3-level 
Combined Effect Variable among non-MAR Users (N=130) 
 
 Nonsmokers 
with low SHS 
N=50 
Nonsmokers 
with high SHS 
N=37 
Smokers 
 
N=43 
P - value 
Age, years  
median (Q1-Q3) 
 
34.00 
(29.00-37.75) 
31.00 
(26.00-35.00) 
31.00 
(27.00-34.00-)  
0.07 
BMI, kg/m2 
median (Q1-Q3) 
 
30.45 
(24.75-35.02) 
29.04 
(24.14-37.25) 
30.64 
(25.93-34.65) 
0.97 
BMI, kg/m2, n (%) 
   
0.97 
<25 (Underweight 
and Normal) 
13(26.00) 11(29.73) 10(23.26) 
 
25 - 29.9 
(Overweight) 
11(22.00) 8(21.62) 9(20.93) 
 
≥ 30 (Obese) 26(52.00) 18(48.65) 24(55.81)  
 
Gravidity, n (%) 
   
0.59 
0 19(38.00) 18(48.65) 14(32.56) 
 
1 10(20.00) 6(16.22) 12(27.91) 
 
>=2 21(42.00) 13(35.14) 17(39.53)  
 
Regular Period,  
n (%) 
   
0.85 
No 17(34.00) 13(35.14) 17(39.53) 
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Yes 33(66.00) 24(64.86) 26(60.47) 
Average Cycle 
Length (days), 
median (Q1-Q3) 
28.00 
(26.00-29.25) 
28.00 
(28.00-30.00) 
30.00 
(28.75-31.25)  
0.001 
Age of Menarche, 
years, median (Q1-
Q3) 
12.00 
(11.75-14.00) 
13.00 
(12.00-14.00) 
12.00 
(11.00-13.00) 
0.47 
Previous STD, 
n (%) 
0.06 
No 34(68.00) 23(62.16) 18(43.90) 
Yes 16(32.00) 14(37.84) 23(56.10) 
Marital Status, 
n (%) 
<0.001 
No 13(26.00) 15(40.54) 30(69.77) 
Yes 37(74.00) 22(59.46) 13(30.23) 
Exercise, n (%) 0.08 
No 17(36.17) 19(54.29) 23(58.97) 
Yes 30(63.83) 16(45.71) 16(41.03) 
Alcohol Use, n (%) 0.14 
No 34(68.00) 26(70.27) 22(51.16) 
Yes 16(32.00) 11(29.73) 21(48.84) 
Caffeine Use, n (%) 0.63 
No 10(20.41) 8(22.22) 6(14.29) 
Yes 39(79.59) 28(77.78) 36(85.71) 
Race, n (%) 0.006 
Black 11(22.00) 16(43.24) 23(53.49) 
Other 39(78.00) 21(56.76) 20(46.51)  
AMH  
(ng/mL), median 
(Q1-Q3) 
2.48 
(0.81-3.84) 
2.67 
(0.99-6.28) 
2.48 
(1.67-6.05) 
0.57 
Length of 
Infertility, years 
median (Q1-Q3) 
2.00 
(1.50-4.00) 
3.00 
(1.33-5.00) 
2.00 
(1.38-5.00)  
0.93 
NAT2 Acetylator 
Status, n (%) 
0.62 
Rapid 23(56.10) 21(61.76) 26(66.67) 
Slow 18(43.90) 13(38.24) 13(33.33)  
Pregnant, n (%) 0.93 
194 
No 38(76.00) 29(78.38) 34(79.07) 
Yes 12(24.00) 8(21.62) 9(20.93)  
Pregnancy Outcome, n (%) 0.04 
Live Birth 7(77.78) 6(85.71) 2(25.00) 
Miscarriage 2(22.22) 1(14.29) 6(75.00) 
Total Follow-up 
Time, years median 
(Q1-Q3) 
9.00 
(4.25-16.00) 
5.00 
(3.00-13.00) 
8.00 
(2.00-15.50) 
0.29 
Cotinine Levels, 
mg/dL median (Q1-
Q3) 
0.00 
(0.00-1.00) 
4.00 
(0.50-9.10) 
100.00 
(100.0-100.0) 
< 0.001 
Cotinine mg/dL, n 
(%) 
< 0.001 
0 30(63.83) 8(22.86) 0(0.00) 
<4 17(36.17) 27(77.14) 2(4.76) 
>= 4 0(0.00) 0(0.00) 40(95.24) 
S Table 9: Characteristics of Women from Group 1 Stratified by Type of Follow-up 
(None vs Medical Records) (N=95) 
No Follow Up 
N=21 
Medical Record 
(MR) 
N=74  
P-value 
Age, years,  
(mean ± SD) 
30.95  ± 7.28 32.35  ±  5.17 0.42  
BMI, kg/m2, median 
(Q1-Q3) 
32.20 
(29.35-42.89) 
30.32  
(26.59-35.97)  
0.11 
BMI kg/m2, n (%) 0.89 
<25 (Underweight and 
Normal) 
3(15.00) 14(18.92) 
25 - 29.9 (Overweight) 5(25.00) 21(28.38)  
≥ 30 (Obese) 12(60.00) 39(52.70) 
Gravidity, n (%) 0.71 
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0 6(28.57) 29(39.19) 
1 7(33.33) 21(28.38) 
>=2 8(38.10) 24(32.43)  
Regular Period, n (%) 0.24 
No 11(52.38) 26(35.14) 
Yes 10(47.62) 48(64.86) 
Average Cycle Length, 
days, median (Q1-Q3)  
28 
(26.50-29.75) 
29.00 
(28.00-30.00) 
0.29 
Age of Menarche, 
(years) median(Q1-Q3) 
12(11-13) 12(12-14) 0.11 
Previous STD, n (%) 0.70 
No 14(70.00) 46(62.16) 
Yes 6(30.00) 28(37.84) 
Marital Status, n (%) 0.31 
No 9(45.00) 22(29.73) 
Yes 11(55.00) 52(70.27) 
Routine Exercise, n (%) 0.40 
No 11(57.89) 31(43.66) 
Yes 8(42.11) 40(56.34) 
Alcohol Use, n (%) 0.74 
No 11(52.38) 44(59.46) 
Yes 10(47.62) 30(40.54) 
Caffeine Use, n (%) 0.39 
No 3(15.00) 19(25.68) 
Yes 17(85.00) 55(74.32) 
Race, n (%) 0.24 
Black 10(47.62) 48(64.86) 
Other 11(52.38) 26(35.14) 
AMH (ng/mL),  
median (Q1-Q3) 
1.85 
(0.67-3.79) 
2.77 
(1.13-5.45) 
0.33 
Length of Infertility, 
years, median(Q1-Q3) 
3.50 
(1.50-4.25) 
2.00 
(1.19-5.00) 
0.42 
NAT2 Acetylator 
Status, n (%)  
0.91 
Rapid 9(47.37) 34(52.31) 
Slow 10(52.63) 31(47.69) 
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Pregnant, n (%) 
  
<0.001 
No 21(100.00) 47(63.51) 
 
Yes 0(0.00) 27(36.49) 
 
Pregnancy Outcome,  
n (%) 
   
Miscarriage 0(0.00) 12(57.14) 
 
Live Birth 0(0.00) 9(42.86) 
  
 
Cotinine mg/dL, 
median (Q1-Q3) 
  
28.00 
(2.00-100) 
4.00 
(1.00-19.75) 
0.13 
Cotinine mg/dL, n (%) 
  
0.04 
0  4(19.05) 13(18.06) 
 
<100  7(33.33) 44(61.11) 
 
100 10(47.62) 15(20.83) 
  
 
Current, Active Smoker, n (%) 0.04 
No 11(52.38) 58(78.38) 
 
Yes 10(47.62) 16(21.62) 
  
 
Self-reported SHS Exposure, n (%) 0.35 
Low 8(38.10) 39(52.70) 
 
High 13(61.90) 35(47.30) 
 
 
 
 
 
 
 
S Table 10: Characteristics of Women from Group 2 Stratified by Type of Follow-
up (None vs Medical Records vs Personal) (N=162) 
 
 No Follow Up 
N=7 
Medical 
Record (MR) 
only N=35 
  
Personal only  
N=120 
P-value 
Age, years,  
median (Q1-Q3) 
 
29.50 
(26.00-37.50) 
33.00 
(26.00-34.00) 
33.00 
(28.00-37.00) 
  
0.45 
BMI, kg/m2, median 
(Q1-Q3) 
 
22.80 
(20.39-32.73) 
28.72 
(25.16-34.30) 
28.54 
(23.62-34.39)  
0.58 
BMI kg/m2, n (%) 
   
0.25 
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<25 (Underweight and 
Normal) 
4(66.67) 8(22.86) 39(32.50) 
25 - 29.9 (Overweight) 0(0.00) 12(34.29) 30(25.00)  
≥ 30 (Obese) 2(33.33) 15(42.86) 51(42.50) 
Gravidity, n (%) 0.57 
0 1(16.67) 17(48.57) 51(42.50) 
1 1(16.67) 7(20.00) 23(19.17) 
>=2 4(66.67) 11(31.43) 46(38.33) 
Regular Period, n (%) 0.36 
No 3(50.00) 9(25.71) 43(35.83) 
Yes 3(50.00) 26(74.29) 77(64.17) 
Average Cycle 
Length, days, median 
(Q1-Q3) 
28.0 
(28.00-29.00) 
28.5 
(28.00-30.00) 
28.7 
(27.00-30.00) 
0.78  
Age of Menarche, 
(years) median(Q1-Q3) 
12 
(11.25-12.75) 
13 
(11.00-13.00) 
12.5 
(11.00-14.00) 
0.75 
Previous STD, n (%) 0.04 
No 3(50.00) 27(77.14) 63(54.31) 
Yes 3(50.00) 8(22.86) 53(45.69) 
Marital Status, n (%) 0.74 
No 2(33.33) 16(45.71) 47(39.17) 
Yes 4(66.67) 19(54.29) 73(60.83) 
Routine Exercise, 
n (%) 
0.05 
No 2(33.33) 16(45.71) 47(39.17) 
Yes 4(66.67) 19(54.29) 73(60.83) 
Alcohol Use, n (%) 0.03 
No 5(83.33) 25(71.43) 60(50.00) 
Yes 1(16.67) 10(28.57) 60(50.00) 
Caffeine Use, n (%) 0.7 
No 0(0.00) 6(18.18) 20(16.81) 
Yes 6(100.00) 27(81.82) 99(83.19) 
Race, n (%) 0.10 
Black 2(33.33) 27(77.14) 83(69.17) 
Other 4(66.67) 8(22.86) 37(30.83) 
AMH (ng/mL),  
median (Q1-Q3) 
3.85 
(3.06-4.65) 
2.17 
(1.47-3.99) 
2.49 
(1.27-4.99) 
0.7 
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Length of Infertility, 
years, median(Q1-Q3)  
1.00 
(0.83-1.17) 
2.00 
(1.00-5.00) 
2.00 
(1.00-4.88) 
  
0.10 
NAT2 Acetylator 
Status, n (%) 
  
0.1 
Rapid 7(100.00) 16(45.71) 76(63.33) 
 
Slow 0(0.00) 8(22.86) 17(14.17) 
 
Pregnant, n (%)    0.21 
No 7(100.00) 21(60.00) 77(64.17) 
 
Yes 0(0.00) 14(40.00) 43(35.83) 
 
Pregnancy Outcome, 
n (%) 
   
 
Miscarriage 0(0.00) 6(45.15) 23(58.97) 0.12 
Live Birth 0(0.00) 7(53.85) 16(41.03) 
  
 
Cotinine mg/dL, 
median (Q1-Q3) 
100 
(27.3-100) 
16.0 
(0.00-100) 
0.00 
(0.00-32.3) 
  
0.52 
Cotinine mg/dL,  
n (%) 
  
 
0  1(16.67) 11(35.48) 60(52.63) 
 
<100  1(16.67) 10(32.26) 27(23.68) <0.001 
100 4(66.67) 10(32.26) 27(23.68) 
  
0.03 
Current, Active 
Smoker, n (%) 
  
0.17 
No 3(42.86) 25(71.43) 90(75.00)  
Yes 4(57.14) 10(28.57) 30(25.00) 
  
 
Self-reported SHS 
Exposure, n (%) 
  
0.10 
Low 1(14.29) 15(42.86) 63(52.50) 
 
High 6(85.71) 20(57.14) 57(47.50)  
 
 
 
 
 
 
 
 
 
199 
S Table 11: Characteristics of Women from Group 2 Stratified by Type of Follow-
up (Medical Records vs Personal) (N=95) 
Medical Record 
only N=35 
Personal only 
N=120 
P-value 
Age, years,  
median (Q1-Q3) 
33.00 
(26.00-34.00) 
33.00 
(28.00-37.00) 
0.23 
BMI, kg/m2, median 
(Q1-Q3) 
28.72 
(25.16-34.30) 
28.54 
(23.62-34.39) 
0.71 
BMI kg/m2, n (%) 0.43 
<25 (Underweight and 
Normal) 
8(22.86) 39(32.50) 
25 - 29.9 (Overweight) 12(34.29) 30(25.00)  
≥ 30 (Obese) 15(42.86) 51(42.50) 
Gravidity, n (%) 0.75 
0 17(48.57) 51(42.50) 
1 7(20.00) 23(19.17) 
>=2 11(31.43) 46(38.33) 
Regular Period, n (%) 0.36 
No 9(25.71) 43(35.83) 
Yes 26(74.29) 77(64.17) 
Average Cycle Length, 
days, median (Q1-Q3) 
28.50 
(28.00-30.00) 
28.50 
(27.00-30.00) 
0.5 
Age of Menarche,  
(years) median(Q1-Q3) 
13.00 
(11.00-13.00) 
12.50 
(11.00-14.00) 
0.6 
Previous STD, n (%) 0.03 
No 27(77.14) 63(54.31) 
Yes 8(22.86) 53(45.69)  
Marital Status, n (%) 0.62 
No 16(45.71) 47(39.17) 
Yes 19(54.29) 73(60.83)  
Routine Exercise, n (%) 0.03 
No 21(61.76) 44(39.29) 
Yes 13(38.24) 68(60.71)  
Alcohol Use, n (%) 0.04 
No 25(71.43) 60(50.00) 
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Yes 10(28.57) 60(50.00)  
Caffeine Use, n (%) 0.8 
No 6(18.18) 20(16.81) 
Yes 27(81.82) 99(83.19)  
Race, n (%) 0.48 
Black 27(77.14) 83(69.17) 
Other 8(22.86) 37(30.83) 
AMH (ng/mL),  
median (Q1-Q3) 
2.17 
(1.47-3.99) 
2.49 
(1.27-4.99) 
0.52  
Length of Infertility, years, 
median(Q1-Q3)  
2.00 
(1.00-4.67) 
1.5 
(0.56-4.00) 
0.3 
Treatment Cycles, n (%) 0.17 
0 16(45.71) 76(63.33) 
1 8(22.86) 17(14.17) 
2 and more 11(31.43) 27(22.50) 
NAT2 Acetylator Status, 
n (%)  
0.94 
Rapid 20(66.67) 65(63.73) 
Slow 10(33.33) 37(36.27) 
Pregnant, n (%) 0.8 
No 21(60.00) 77(64.17) 
Yes 14(40.00) 43(35.83)  
Pregnancy Outcome, n (%) 0.63 
Miscarriage 6(46.15) 23(58.97) 
Live Birth 7(53.85) 16(41.03) 
Cotinine mg/dL, median 
(Q1-Q3) 
16.00 
(0.00-100) 
0.00 
(0.00-100)  
0.08 
Cotinine mg/dL, n (%) 0.23 
0 1(16.67) 71(48.97) 
<100 1(16.67) 37(25.52) 
100 4(66.67) 37(25.52) 
Current, Active Smoker, 
n (%) 
0.84 
No 25(71.43) 90(75.00) 
Yes 10(28.57) 30(25.00) 
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Self-reported SHS Exposure, n (%) 0.42 
Low 15(42.86) 63(54.31) 
High 20(57.14) 57(47.50) 
S Table 12: Characteristics of Women from Group 2 Stratified by Type of Follow-
up (None vs Any) (N=95) 
No Follow-Up 
N=7 
MR and Personal 
Follow-up 
N=155 
P-value 
Age, years,  
median (Q1-Q3) 
29.50 
(26.00-37.50) 
33.00 
(27.00-37.00) 
0.69 
BMI, kg/m2, median 
(Q1-Q3) 
22.8 
(20.39-32.73) 
28.54 
(23.80-34.42) 
0.34 
BMI kg/m2, n (%) 0.15 
<25 (Underweight and 
Normal) 
4(66.67) 47(30.32) 
25 - 29.9 (Overweight) 0(0.00) 42(27.10)  
≥ 30 (Obese) 2(33.33) 66(42.58)  
Gravidity, n (%) 0.25 
0 1(16.67) 68(43.87) 
1 1(16.67) 30(19.35) 
>=2 4(66.67) 57(36.77) 
Regular Period, n (%) 0.42 
No 3(50.00) 52(33.55) 
Yes 3(50.00) 103(66.45) 
Average Cycle Length, 
days, median (Q1-Q3) 
28.00 
(28.00-29.00) 
28.50 
(28.00-30.00) 
0.91  
Age of Menarche,  
(years) median(Q1-Q3) 
12.00 
(11.25-12.75) 
13.00 
(11.0-14.0) 
0.57 
Previous STD, n (%) 0.69 
No 3(50.00) 90(59.6) 
Yes 3(50.00) 61(40.4) 
Marital Status, n (%) 1 
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No 2(33.33) 63(40.65) 
Yes 4(66.67) 92(59.35) 
Routine Exercise, n (%) 1 
No 2(50.00) 65(44.52) 
Yes 2(50.00) 81(55.48) 
Alcohol Use, n (%) 0.23 
No 5(83.33) 85(54.84) 
Yes 1(16.67) 70(45.16) 
Caffeine Use, n (%) 0.59 
No 0(0.00) 26(17.11) 
Yes 6(100.00) 126(82.89) 
Race, n (%) 0.07 
Black 2(33.33) 110(70.97) 
Other 4(66.67) 45(29.03) 
AMH (ng/mL),  
median (Q1-Q3) 
3.85 
(3.06-3.85) 
2.48 
(1.33-4.94) 
0.59  
Length of Infertility, years, 
median(Q1-Q3)  
0.83 
(0.04-1.08) 
1.75 
(0.67-4.00) 
0.04  
NAT2 Acetylator Status, 
n (%)  
0.1 
Rapid 6(100.00) 85(64.39) 
Slow 0(0.00) 47(35.61)  
Pregnant, n (%) 0.05 
No 7(100.00) 98(63.23) 
Yes 0(0.00) 57(36.77) 
Cotinine mg/dL, 
 median (Q1-Q3) 
100 
(27.25-100) 
0.50 
(0.00-100) 
0.05 
Cotinine mg/dL, n (%) 0.1 
0 1(16.67) 71(48.97) 
<100 1(16.67) 37(25.52) 
100 4(66.67) 37(25.52) 
Current, Active Smoker, 
n (%) 
0.09 
No 3(42.86) 115(74.19) 
Yes 4(57.14) 40(25.81) 
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Self-reported SHS 
Exposure, n (%) 
  
0.12 
Low 1(14.29) 78(50.32) 
 
High 6(85.71) 77(49.68) 
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